Document:

EX-10.2

 Exhibit 10.2 

EXECUTION COPY 
 ***Text Omitted and Filed
Separately with the Securities and Exchange Commission 
 Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

Collaboration Agreement 
 This Agreement
is entered into with effect as of the Effective Date (as defined below) 
 by and between 

F. Hoffmann-La Roche Ltd 
 with an office and place
of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) 
 and 

Hoffmann-La Roche Inc. 
 with an office and place
of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”) 

on the one hand 
 and 

Foundation Medicine, Inc. 
 with an office and place of
business at 150 Second Street, Cambridge, Massachusetts 02141 (“FMI”) 
 on the other hand. 

 Table of Contents 

 

									
	 1.
		 Definitions
		 	7	  
			 1.1
		 Affiliate
		 	7	  
			 1.2
		 Agreement
		 	7	  
			 1.3
		 Agreement Term
		 	7	  
			 1.4
		 [...***...] ctDNA [...***...]
		 	7	  
			 1.5
		 Applicable Law
		 	7	  
			 1.6
		 Approved Assay
		 	7	  
			 1.7
		 Background IP
		 	7	  
			 1.8
		 Business Day
		 	8	  
			 1.9
		 Calendar Half
		 	8	  
			 1.10
		 Calendar Quarter
		 	8	  
			 1.11
		 Calendar Year
		 	8	  
			 1.12
		 CDx
		 	8	  
			 1.13
		 CDx Development Program
		 	8	  
			 1.14
		 CLIA
		 	8	  
			 1.15
		 Clinical Study
		 	9	  
			 1.16
		 Commercially Reasonable Efforts
		 	9	  
			 1.17
		 Confidential Information
		 	9	  
			 1.18
		 Control
		 	9	  
			 1.19
		 Cover
		 	10	  
			 1.20
		 ctDNA
		 	10	  
			 1.21
		 ctDNA Assay
		 	10	  
			 1.22
		 ctDNA Platform
		 	10	  
			 1.23
		 ctDNA Platform Development Program
		 	10	  
			 1.24
		 ctDNA Working Group
		 	10	  
			 1.25
		 Data Security Breach
		 	10	  
			 1.26
		 Effective Date
		 	10	  
			 1.27
		 Excepted Activities
		 	11	  
			 1.28
		 Excluded Patent Rights
		 	11	  
			 1.29
		 FDA
		 	11	  
			 1.30
		 FDCA
		 	11	  
			 1.31
		 FMI Background IP Patent Rights
		 	11	  
			 1.32
		 FMI Decisions
		 	11	  
			 1.33
		 FMI Development Costs
		 	11	  
			 1.34
		 FMI Know-How
		 	11	  
			 1.35
		 FMI Foreground Patent Rights
		 	12	  
			 1.36
		 FTE
		 	12	  
			 1.37
		 FTE Rate
		 	12	  
			 1.38
		 Handle
		 	12	  
			 1.39
		 HSR
		 	12	  
			 1.40
		 Immunotherapy Testing Platform Development Program
		 	12	  
			 1.41
		 Immuno-Platform Working Group
		 	12	  
			 1.42
		 Initiation
		 	12	  
			 1.43
		 Insolvency Event
		 	12	  
			 1.44
		 Invention
		 	13	  
			 1.45
		 IUO
		 	13	  
			 1.46
		 JMC
		 	13	  
			 1.47
		 JOC
		 	13	  
			 1.48
		 Joint Know-How
		 	13	  
			 1.49
		 Joint Patent Rights
		 	13	  

  
 ***Confidential Treatment
Requested*** 
 - 2 - 

									
			 1.50
		 JOT
		 	13	  
			 1.51
		 JRDC
		 	13	  
			 1.52
		 Know-How
		 	13	  
			 1.53
		 Molecular Information Platform Program
		 	13	  
			 1.54
		 Molecular Information Platform Working Group
		 	14	  
			 1.55
		 Party
		 	14	  
			 1.56
		 Patent Rights
		 	14	  
			 1.57
		 Performance Specifications
		 	14	  
			 1.58
		 Personal Data
		 	14	  
			 1.59
		 Phase I Study
		 	14	  
			 1.60
		 Phase II Study
		 	14	  
			 1.61
		 Phase III Study
		 	14	  
			 1.62
		 PMA
		 	15	  
			 1.63
		 Quality Standards
		 	15	  
			 1.64
		 R&D Plan
		 	15	  
			 1.65
		 Regulatory Approval
		 	15	  
			 1.66
		 Regulatory Authority
		 	15	  
			 1.67
		 Roche Background IP Patent Rights
		 	15	  
			 1.68
		 Roche Group
		 	15	  
			 1.69
		 Roche Know-How
		 	15	  
			 1.70
		 Roche Foreground Patent Rights
		 	15	  
			 1.71
		 ROW Territory
		 	15	  
			 1.72
		 RUO
		 	15	  
			 1.73
		 Study Data
		 	16	  
			 1.74
		 Sublicensee
		 	16	  
			 1.75
		 Territory
		 	16	  
			 1.76
		 Third Party
		 	16	  
			 1.77
		 US
		 	16	  
			 1.78
		 US$
		 	16	  
			 1.79
		 Work Stream
		 	16	  
			 1.80
		 Additional Definitions
		 	16	  
	 2.
		 Grant of License
		 	18	  
			 2.1
		 Licenses
		 	18	  
			 2.2
		 Sublicense
		 	20	  
			 2.3
		 Right to Subcontract
		 	20	  
	 3.
		 Research and Development Collaboration
		 	20	  
			 3.1
		 Molecular Information Platform Program
		 	20	  
			 3.2
		 Immunotherapy Testing Platform Development Program
		 	23	  
			 3.3
		 ctDNA Platform Development Program
		 	25	  
			 3.4
		 CDx Development Program
		 	27	  
			 3.5
		 Samples, Handling and Disposal
		 	29	  
			 3.6
		 Records; Reports; Audits
		 	30	  
	 4.
		 Diligence
		 	31	  
	 5.
		 Most Favored Customer
		 	31	  
	 6.
		 Governance
		 	31	  
			 6.1
		 Joint Management Committee
		 	31	  
			 6.2
		 JRDC
		 	33	  
			 6.3
		 JOC
		 	34	  
			 6.4
		 Alliance Director
		 	34	  
			 6.5
		 Limitations of Authority
		 	34	  
			 6.6
		 Expenses
		 	35	  
			 6.7
		 Lifetime
		 	35	  

  
 - 3 - 

									
	 7.
		 Regulatory
		 	35	  
	 8.
		 Payment
		 	35	  
			 8.1
		 FTE Funding
		 	35	  
			 8.2
		 Molecular Information Platform Program Fees
		 	35	  
			 8.3
		 Immunotherapy Testing Platform Development Budget and Fees
		 	36	  
			 8.4
		 ctDNA Platform Financial Terms
		 	37	  
			 8.5
		 CDx Development Financial Terms
		 	38	  
			 8.6
		 General Terms
		 	38	  
			 8.7
		 Disclosure of Payments
		 	39	  
	 9.
		 Accounting and reporting
		 	39	  
			 9.1
		 Timing of Payments
		 	39	  
			 9.2
		 Late Payment
		 	39	  
			 9.3
		 Method of Payment
		 	39	  
	 10.
		 Taxes
		 	39	  
	 11.
		 Auditing
		 	40	  
			 11.1
		 Right to Audit
		 	40	  
			 11.2
		 Audit Reports
		 	41	  
			 11.3
		 Over or Underpayment
		 	41	  
			 11.4
		 Duration of Audit Rights
		 	41	  
	 12.
		 Intellectual Property
		 	41	  
			 12.1
		 Ownership of Inventions, data and results
		 	41	  
			 12.2
		 German Statute on Employee’s Inventions
		 	43	  
			 12.3
		 Prosecution and Maintenance of Patent Rights Claiming FMI Inventions
		 	43	  
			 12.4
		 Prosecution and Maintenance of Roche Foreground Patent Rights and Joint Patent Rights
		 	44	  
			 12.5
		 Joint Patent Team
		 	44	  
			 12.6
		 CREATE Act
		 	44	  
			 12.7
		 Infringement
		 	44	  
			 12.8
		 Defense
		 	46	  
			 12.9
		 Common Interest Disclosures
		 	46	  
	 13.
		 Representations and Warranties
		 	47	  
			 13.1
		 Mutual Representations and Warranties
		 	47	  
			 13.2
		 Activities
		 	48	  
			 13.3
		 Safety Data
		 	48	  
			 13.4
		 Third Party Patent Rights
		 	48	  
			 13.5
		 Inventors
		 	48	  
			 13.6
		 Grants
		 	48	  
			 13.7
		 Ownership and Validity of Know-How
		 	48	  
			 13.8
		 Data Protection (Privacy) and Security
		 	48	  
			 13.9
		 No Other Representations
		 	50	  
	 14.
		 Indemnification
		 	50	  
			 14.1
		 Indemnification by Roche
		 	50	  
			 14.2
		 Indemnification by FMI
		 	51	  
			 14.3
		 Procedure
		 	51	  
	 15.
		 Liability
		 	51	  
	 16.
		 Obligation Not to Disclose Confidential Information
		 	51	  
			 16.1
		 Non-Use and Non-Disclosure
		 	51	  
			 16.2
		 Permitted Disclosure
		 	52	  
			 16.3
		 Press Releases
		 	52	  
			 16.4
		 Publications
		 	52	  
			 16.5
		 Commercial Considerations
		 	53	  

  
 - 4 - 

									
	 17.
		 Term and Termination
		 	53	  
			 17.1
		 Commencement and Term
		 	53	  
			 17.2
		 Termination
		 	53	  
			 17.2.1
		 Termination for Breach
		 	53	  
			 17.2.2
		 Insolvency
		 	53	  
			 17.2.3
		 Termination by Roche without Cause
		 	54	  
			 17.2.4
		 Termination by Roche for Frustration of Purpose
		 	54	  
			 17.3
		 Consequences of Termination
		 	54	  
			 17.3.1
		 Termination in General
		 	54	  
			 17.3.2
		 Termination by FMI for Breach by Roche or Roche’s Insolvency; Termination by Roche Without Cause or for Frustration of
Purpose
		 	54	  
			 17.3.3
		 Termination by Roche for Breach by FMI or FMI Insolvency
		 	56	  
			 17.3.4
		 Direct License
		 	57	  
			 17.4
		 Other Obligations
		 	57	  
			 17.5
		 Survival
		 	57	  
	 18.
		 Bankruptcy
		 	57	  
	 19.
		 Miscellaneous
		 	58	  
			 19.1
		 Governing Law
		 	58	  
			 19.2
		 Disputes
		 	58	  
			 19.3
		 Arbitration
		 	58	  
			 19.4
		 Assignment
		 	59	  
			 19.5
		 Debarment and Exclusion
		 	59	  
			 19.6
		 Independent Contractor
		 	60	  
			 19.7
		 Unenforceable Provisions and Severability
		 	60	  
			 19.8
		 Waiver
		 	60	  
			 19.9
		 Appendices
		 	60	  
			 19.10
		 Entire Understanding
		 	61	  
			 19.11
		 Amendments
		 	61	  
			 19.12
		 Invoices
		 	61	  
			 19.13
		 Notice
		 	61	  

  
 - 5 - 

 Collaboration Agreement 

WHEREAS, FMI has or is developing platforms for use in genomic testing, including development of a molecular information platform, an immunotherapy testing
platform, a circulating tumor DNA platform, and a companion diagnostics platform; and 
 WHEREAS, Roche has expertise in the research, development,
manufacture and commercialization of pharmaceutical and diagnostic products, including development of an immunotherapy platform; and 
 WHEREAS,
Roche and FMI want to collaborate on the development of platforms for use in molecular information, immunotherapy, circulating tumor DNA, companion diagnostics, and in vitro diagnostic tests and kits; and 

WHEREAS, Roche Holdings, Inc., an Affiliate of Roche, and FMI are concurrently herewith entering into a Transaction Agreement dated as of the date
hereof (as it may be amended from time to time, the “Transaction Agreement”) which provides, among other things, for Roche to acquire a majority ownership of FMI upon the terms and subject to the conditions set forth in the
Transaction Agreement; and 
 WHEREAS, in connection therewith, and as an inducement to Roche’s and FMI’s willingness to enter into
the Transaction Agreement and to consummate the transactions contemplated thereby, FMI and Roche agree that Roche will work with FMI in the United States to educate relevant persons on next generation sequencing and/or comprehensive genomic
profiling technology (“US Education Collaboration Agreement”), Roche and FMI will collaborate on the commercialization of certain FMI products outside of the United States (“Ex-US Commercialization Agreement”), and
Roche and FMI may collaborate on development and commercialization of decentralized in vitro diagnostic (“IVD”) versions of FMI tests generated by FMI (“IVD Collaboration”), the above mentioned
agreements, including the Transaction Agreement, being referred to collectively as the “Related Agreements”; and 
 WHEREAS, FMI and
Roche intend that assays and other products generated under this Agreement will be commercialized in accordance with the Ex-US Commercialization Agreement and that the governance structure under this Agreement will apply to the US Education
Collaboration Agreement and the Ex-US Commercialization Agreement. 

  
 - 6 - 

 NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 
  

	1.	Definitions 

 As used in this Agreement, the following terms, whether used in the singular or plural,
shall have the following meanings: 
  

	1.1	Affiliate 

 The term “Affiliate” shall mean any individual, corporation, association or other
business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term “control” shall mean the direct or indirect
ownership of more than fifty percent (>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting
securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, Chugai Pharmaceutical Co., Ltd, a Japanese corporation (“Chugai”), shall not be deemed an Affiliate of Roche
unless Roche provides written notice to FMI of its desire to include Chugai as an Affiliate of Roche. Moreover, FMI and its Affiliates existing as of the Effective Date shall not be deemed Affiliates of Roche and its Affiliates existing as of the
Effective Date, and Roche and its Affiliates existing as of the Effective Date shall not be deemed Affiliates of FMI and its Affiliates existing as of the Effective Date. Affiliates coming into existence after the Effective Date shall be classified
by the Parties as either Roche Affiliates or FMI Affiliates for the purposes of this Agreement. 
  

	1.2	Agreement 

 The term “Agreement” shall mean this document including any and all appendices and
amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 
  

	1.3	Agreement Term 

 The term “Agreement Term” shall mean the period of time commencing on the
Effective Date and, unless this Agreement is terminated sooner as provided in Article 17, expiring on the date when all work has been completed or terminated under all R&D Plans. 

 

	1.4	[...***...] ctDNA [...***...] 

 The term “[...***...] ctDNA
[...***...]” shall mean an analytical validated clinical ctDNA Assay [...***...]. 
  

	1.5	Applicable Law 

 The term “Applicable Law” shall mean any law, statute, ordinance, code, rule
or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in each case to the extent that the same
are applicable to the performance by the Parties of their respective obligations under this Agreement. 
  

	1.6	Approved Assay 

 The term “Approved Assay” means any assay or test intended for use in the
diagnosis or evaluation of a disease or condition, excluding any IUO, and with respect to which any necessary Regulatory Approval is received in the relevant country, including PMA approval in the US, if applicable. 

 

	1.7	Background IP 

 The term “Background IP” shall mean all intellectual property rights, including
Patent Rights and Know-How, Controlled by a Party as of the Effective Date and all intellectual property rights Controlled by a Party after the Effective Date but arising from activities other than the activities conducted under this Agreement.
Roche Background IP specifically excludes the Excluded Patent Rights and no licenses are granted to FMI under such Excluded Patent Rights. 

  
 ***Confidential Treatment
Requested*** 
 - 7 - 

	1.8	Business Day 

 The term “Business Day” shall mean 9.00am to 5.00pm local time on a day other
than a Saturday, Sunday or bank or other public or federal holiday in Switzerland, New Jersey or Massachusetts. 
  

	1.9	Calendar Half 

 The term “Calendar Half” shall mean each period of six (6) consecutive
calendar months, ending June 30 and December 31. 
  

	1.10	Calendar Quarter 

 The term “Calendar Quarter” shall mean each period of three
(3) consecutive calendar months, ending March 31, June 30, September 30 and December 31. 
  

	1.11	Calendar Year 

 The term “Calendar Year” shall mean the period of time beginning on
January 1 and ending December 31, except for the first Calendar Year which shall begin on the Effective Date and end on December 31. 
  

	1.12	CDx 

 The term “CDx” shall mean any Products or Services that require Regulatory Approval,
including by any medical device Regulatory Authority, under the device authorities of the Federal Food, Drug, and Cosmetic Act (or equivalent medical device or in vitro diagnostic medical device regime in other countries) for use in
connection with a decision to treat, or the specifics of the actual treatment, of person, with a specific product, as more fully described below: 
  

	 	(i)	identifying a person having a specific disease or condition, or a molecular genotype or phenotype that predisposes a person to such disease or condition, to support a decision to treat such person with such specific
product, whether for prophylactic or therapeutic purposes; 

  

	 	(ii)	defining the prognosis or monitoring the progress of a disease or condition in a person to support a decision to treat, or to continue to treat, such person with such specific product, whether for prophylactic or
therapeutic purposes; 

  

	 	(iii)	supporting the selection of a particular therapeutic or prophylactic regimen, wherein at least one (1) potential therapeutic or prophylactic regimen involves the use of such specific product; and/or

  

	 	(iv)	confirming such specific product’s biological activity and/or optimizing dosing or the scheduled administration of such specific product. 

 

	1.13	CDx Development Program 

 The term “CDx Development Program” shall mean the program for
development by FMI of CDx Assays for select Roche products. 
  

	1.14	CLIA 

 The term “CLIA” shall mean Clinical Laboratory Improvement Amendments as set forth by
the Centers for Medicare & Medicaid Services which regulates all laboratory testing (except research) performed on humans in the U.S. and is certified by the Division of Laboratory Services, within the Survey and Certification Group, under
the Center for Clinical Standards and Quality. 

  
 - 8 - 

	1.15	Clinical Study 

 The term “Clinical Study” shall mean a Phase I Study, Phase II Study, Phase
III Study, as applicable. 
  

	1.16	Commercially Reasonable Efforts 

 The term “Commercially Reasonable Efforts” shall mean, with
respect to the performance of an obligation under this Agreement, such quality and level of effort as is required to carry out such obligation in a sustained manner, consistent with the efforts Roche or FMI, as applicable, devotes to a similar
obligation in connection with an internally developed product or service that is at the same stage of development or commercialization, as applicable, in a similar market, with similar market potential, at a similar stage of product life, taking
into account the existence of other competitive products or services in the market place or under development, the proprietary position of the product or service, the regulatory structure involved, the anticipated profitability of the product or
service and other relevant factors. It is understood that such quality and level if effort may change from time to time based upon changing scientific, business and marketing and return on investment considerations. 

 

	1.17	Confidential Information 

 The term “Confidential Information” shall mean any and all
information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or its Affiliates (“Receiving
Party”). Confidential Information shall not include any information, data or know-how that: 
  

	 	(i)	was generally available to the public at the time of disclosure, or information that becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of
the Receiving Party or its Affiliates, 

  

	 	(ii)	can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party, 

 

	 	(iii)	is obtained by the Receiving Party at any time lawfully from a Third Party under circumstances permitting its use or disclosure, 

  

	 	(iv)	is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through knowledge of Confidential Information, or 

 

	 	(v)	is approved in writing by the Disclosing Party for release by the Receiving Party. 

 The terms of this
Agreement shall be considered Confidential Information of the Parties. 
  

	1.18	Control 

 The term “Control” shall mean (as an adjective or as a verb including conjugations
and variations such as “Controls” “Controlled” or “Controlling”) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights
and/or Know-How as provided herein without violating the terms of any agreement or arrangement between such Party and any other party, where such ability derives from rights other than an assignment or license granted herein and (b) with
respect to proprietary materials, the possession by a Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party.

  
 - 9 - 

	1.19	Cover 

 The term “Cover” shall mean (as an adjective or as a verb including conjugations and
variations such as “Covered,” “Coverage” or “Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given product would infringe a valid claim under the Patent
Rights. As used in the previous sentence, “valid claim” means, with respect to a particular country a claim in an issued and unexpired patent that has not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a
decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed fo appeal and that has not been admitted to be invalid or unenforceable through re-examination, re-issue, disclaimer or
otherwise, or lost in an interference proceeding. 
  

	1.20	ctDNA 

 The term “ctDNA” shall mean circulating tumor DNA. 

 

	1.21	ctDNA Assay 

 The term “ctDNA Assay” shall mean an assay developed on or utilizing FMI’s
ctDNA Platform (including instruments and software) for the detection of genomic alteration in ctDNA, including an RUO, IUO and Approved Assay. 
  

	1.22	ctDNA Platform 

 The term “ctDNA Platform” shall mean Products or Services for testing of
specimens to identify genomic alterations in ctDNA as a blood-based liquid biopsy, including FMI instruments, analytical methods, algorithms, procedures, techniques, software or platforms, intended for use in genomic analysis, and related
technologies and any improvements to the foregoing, in each case Controlled by FMI as of the Effective Date or during the Agreement Term. 
  

	1.23	ctDNA Platform Development Program 

 The term “ctDNA Platform Development Program” shall mean
the program for development of ctDNA analysis platform by FMI for effective genomic profiling from liquid biopsy. 
  

	1.24	ctDNA Working Group 

 The term “ctDNA Working Group” shall mean the group of persons from both
Parties who will handle the day-to-day activities associated with the ctDNA Platform Development Program a set forth herein. 
  

	1.25	Data Security Breach 

 The term “Data Security Breach” means (a) the disclosure or misuse
(by any means) of Personal Data; (b) the inadvertent, unauthorized and/or unlawful processing, access, disclosure, alteration, corruption, transfer, sale or rental, destruction or use of Personal Data; or (c) any other act or omission that
compromises the security, confidentiality, and/or integrity of Personal Data. 
  

	1.26	Effective Date 

 The term “Effective Date” shall mean the latest of (a) the date of the
last signature of this Agreement, or (b) if a HSR filing is made, the second Business Day immediately following the earlier of: (i) the date upon which the waiting period under HSR expires or terminates early or (ii) the date upon
which all requests to the Parties by the Federal Trade Commission or the Justice Department, as the case may be, with regard to the transaction contemplated by this Agreement 

  
 - 10 - 

 
have been satisfactorily met and no objection on the part of the Federal Trade Commission or the Justice Department remains, or (c) the occurrence of the Acceptance Time (as defined in the
Transaction Agreement). 
  

	1.27	Excepted Activities 

 The term “Excepted Activities” shall mean [...***...]. 

 

	1.28	Excluded Patent Rights 

 The term “Excluded Patent Rights” shall mean those Patent Rights
listed in Appendix 1.28. 
  

	1.29	FDA 

 The term “FDA” shall mean the Food and Drug Administration of the United States of
America. 
  

	1.30	FDCA 

 The term “FDCA” shall mean the Food, Drug and Cosmetics Act. 

 

	1.31	FMI Background IP Patent Rights 

 The term “FMI Background IP Patent Rights” means Patent
Rights that Cover Background IP that is Controlled by FMI. 
  

	1.32	FMI Decisions 

 The term “FMI Decisions” shall mean decisions with respect to any of the
following issues that come before the JMC: 
  

	 	(i)	[...***...]. 

  

	 	(ii)	[...***...]. 

  

	 	(iii)	[...***...]. 

  

	 	(iv)	[...***...]. 

  

	1.33	FMI Development Costs 

 The term “FMI Development Costs” means all costs reasonably incurred or
committed to by FMI to perform its obligations and activities hereunder, including without limitation, (i) personnel costs equal to the number of FTE’s used to perform such obligations and activities multiplied by the FTE Rate,
(ii) out-of-pocket costs for consultants, materials and services and (iii) facilities costs reasonably allocated to performance of such obligations and activities, including acquisition, maintenance and operation costs for such facilities.

  

	1.34	FMI Know-How 

 The term “FMI Know-How” shall mean the Know-How that FMI Controls at the
Effective Date and during the Agreement Term. 

  
 ***Confidential Treatment
Requested*** 
 - 11 - 

	1.35	FMI Foreground Patent Rights 

 The term “FMI Foreground Patent Rights” shall mean the Patent
Rights that FMI Controls and that Cover Inventions conceived of and reduced to practice after the Effective Date in the performance of the activities under this Agreement, excluding any Joint Patent Rights and any FMI Background IP Patent Rights.

  

	1.36	FTE 

 The term “FTE” shall mean a full-time equivalent person-year, based upon a total of no
less than one thousand eight hundred (1,800) working hours per year, undertaken in connection with the conduct of research in a Work Stream. In no circumstance can the work of any given person exceed one (1) FTE. 

 

	1.37	FTE Rate 

 The term “FTE Rate” shall mean the amount of [...***...], on a fully burdened
cost basis, which amount shall be subject to increase following the [...***...] anniversary of the Effective Date by an amount equal to the increase in the Consumer Price Index as published by the U.S. Department of Labor, Bureau of Labor
Statistics (the “CPI”) between the Effective Date and such date for a new FTE Rate not to exceed [...***...] per FTE, and which such new FTE Rate shall be subject to subsequent increases upon the date of each renewal or
extension period comprising the Agreement Term by an amount equal to the increase in the CPI as of such date. 
  

	1.38	Handle 

 The term “Handle” shall mean all activities associated with prosecution and
maintenance of a particular patent and patent application(s) derived from such patent, including preparing, filing, prosecuting and maintaining (including interferences, reissue, re-examination, pre- and post-grant proceedings, inter-parties
reviews, derivation proceedings, applications for patent term adjustment and extensions, supplementary protection certificates and oppositions and other similar proceedings). 
  

	1.39	HSR 

 The term “HSR” shall mean the Hart-Scott-Rodino Antitrust Improvements Act. 

 

	1.40	Immunotherapy Testing Platform Development Program 

 The term “Immunotherapy Testing Platform
Development Program” shall mean the program for development of an immunotherapy testing platform. 
  

	1.41	Immuno-Platform Working Group 

 The term “Immuno-Platform Working Group” shall mean the group
of persons from both Parties who will handle the day-to-day activities associated with the Immunotherapy Testing Platform Development Program. 
  

	1.42	Initiation 

 The term “Initiation” shall mean the date that a human is first dosed with the
drug in a Clinical Study approved by the respective Regulatory Authority. 
  

	1.43	Insolvency Event 

 The term “Insolvency Event” shall mean circumstances under which a Party
(i) has a receiver or similar officer appointed over all or a material part of its assets or undertaking; (ii) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation
or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction); (iii) enters into 

  
 ***Confidential Treatment
Requested*** 
 - 12 - 

 
any composition or arrangement with its creditors (other than relating to a solvent restructuring); (iv) ceases to carry on business; (v) is unable to pay its debts as they become due
in the ordinary course of business. 
  

	1.44	Invention 

 The term “Invention” shall mean an invention that is made, i.e. conceived and
reduced to practice, in performance of activities under this Agreement. Under this definition, an Invention may be made by solely by individuals having an obligation to assign rights in such invention to FMI (an “FMI Invention”),
solely by individuals having an obligation to assign rights in such invention to Roche (a “Roche Invention”), or jointly by individuals having an obligation to assign rights in such invention to FMI and individuals having an obligation to
assign rights in such invention to Roche (a “Joint Invention”). 
  

	1.45	IUO 

 The term “IUO” shall mean an assay for investigational use only that meets certain
clinical and manufacturing standards and which is used in clinical studies to gather data for submission to a Regulatory Agency in support of an Approved Assay. 
  

	1.46	JMC 

 The term “JMC” shall mean the joint management committee described in Article 6. 

 

	1.47	JOC 

 The term “JOC” shall mean the joint operating committee as mentioned in Section 6.3 and
described in the Ex-US Commercialization Agreement. 
  

	1.48	Joint Know-How 

 The term “Joint Know-How” shall mean Know-How that is made jointly by the
Parties or their Affiliates or their Sublicensees in performance of activities carried out pursuant to this Agreement. 
  

	1.49	Joint Patent Rights 

 The term “Joint Patent Rights” shall mean all Patent Rights Covering a
Joint Invention. 
  

	1.50	JOT 

 The term “JOT” shall mean a joint operating team described in Section 6.1.7. 

 

	1.51	JRDC 

 The term “JRDC” shall mean the joint research and development committee described in
Section 6.2. 
  

	1.52	Know-How 

 The term “Know-How” shall mean data, knowledge, algorithms, business rules and
information, including manufacturing data, toxicological data, pharmacological data, preclinical data, formulations, specifications, quality control testing data, which are necessary or useful for the discovery, manufacture, development or
commercialization of Products and Services. 
  

	1.53	Molecular Information Platform Program 

 The term “Molecular Information Platform Program”
shall mean the program designed to generate insights for certain of Roche’s clinical development portfolio from FMI’s molecular information platform, comprised of tumor sample genomic analysis, database access, and dedicated FMI clinical
and genomic expertise. 

  
 - 13 - 

	1.54	Molecular Information Platform Working Group 

 The term “Molecular Information Platform Working
Group” shall mean the group of persons from both Parties who will handle the day-to-day activities associated with the Molecular Information Platform Program. 
  

	1.55	Party 

 The term “Party” shall mean FMI or Roche, as the case may be, and “Parties”
shall mean FMI and Roche collectively. 
  

	1.56	Patent Rights 

 The term “Patent Rights” shall mean all rights under any patent or patent
application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division,
continuation or continuation-in-part of any of the foregoing. 
  

	1.57	Performance Specifications 

 The term “Performance Specifications” shall mean a set of minimum
standards and specifications related to FMI’s supply and delivery of Products and Services under this Agreement as set forth in the R&D Plans for each Work Stream or Task Orders, including standards with respect to classes of alterations
detected and sequencing sensitivity and specificity (based on tissue requirements); provided, however, the Performance Specifications for the Molecular Information Platform Program are attached hereto as Exhibit 1.57. 

 

	1.58	Personal Data 

 The term “Personal Data” shall mean any information that can be used to
identify, locate or contact an individual (a “Data Subject”), including but limited to, (a) first name or initial and last name; (b) home or other physical address; (c) telephone number; (d) email address or
online identifier associated with the individual; (e) social security number or other similar identifier; (f) employment financial or health information; or (g) any other information relating to an individual that is combined with any
of the above. 
  

	1.59	Phase I Study 

 The term “Phase I Study” shall mean a human clinical trial in any country that
would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA), as amended from time to time, and the foreign equivalent thereof. 
  

	1.60	Phase II Study 

 The term “Phase II Study” shall mean a human clinical trial, for which the
primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  

	1.61	Phase III Study 

 The term “Phase III Study” shall mean a human clinical trial that is
prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as
described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof. 

  
 - 14 - 

	1.62	PMA 

 The term “PMA” shall mean a premarket approval application as defined under section 515
of the FDCA. 
  

	1.63	Quality Standards 

 The term “Quality Standards” shall mean CLIA or QSR requirements, each as
applicable, and other Applicable Laws. If requested by Roche, the JRDC will establish which such quality standards specifically apply to Products and Services within a given Work Stream. 

 

	1.64	R&D Plan 

 The term “R&D Plan” shall mean a plan of research and development for each
Work Stream other than the Molecular Information Platform Program. The initial R&D Plans are attached as Appendix 1.64 and outline the work expected to be performed by FMI for the relevant Work Stream. Such plans may be updated from time to time
as provided in this Agreement. 
  

	1.65	Regulatory Approval 

 The term “Regulatory Approval” shall mean any approvals, licenses,
registrations, authorizations, or certifications by Regulatory Authority or any CE markings, necessary for the manufacture, sale or putting into service of a product in a regulatory jurisdiction in the Territory. 

 

	1.66	Regulatory Authority 

 The term “Regulatory Authority” shall mean any national, supranational
(e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country
involved in the granting of Regulatory Approval for a product or service. 
  

	1.67	Roche Background IP Patent Rights 

 The term “Roche Background IP Patent Rights” means Patent
Rights that Cover Background IP that is Controlled by Roche. 
  

	1.68	Roche Group 

 The term “Roche Group” shall mean collectively Roche, its Affiliates and its
Sublicensees, excluding FMI and FMI Affiliates. 
  

	1.69	Roche Know-How 

 The term “Roche Know-How” shall mean all Know-How that Roche Controls during
the Agreement Term. 
  

	1.70	Roche Foreground Patent Rights 

 The term “Roche Foreground Patent Rights” shall mean the
Patent Rights that Roche Controls (other than through licenses granted under this Agreement) and that Cover Inventions conceived of and reduced to practice after the Effective Date in the performance of the activities under this Agreement, excluding
any Joint Patent Rights and the Excluded Patent Rights. 
  

	1.71	ROW Territory 

 The term “ROW Territory” shall mean [...***...]. 

 

	1.72	RUO 

 The term “RUO” shall mean an assay intended or approved for research use only. 

  
 ***Confidential Treatment
Requested*** 
 - 15 - 

	1.73	Study Data 

 The term “Study Data” shall mean all data related to any Data Subject collected by
or transferred to the Roche Group or business partners, in connection with any services that FMI may provide to Roche. 
  

	1.74	Sublicensee 

 The term “Sublicensee” shall mean an entity to which Roche or FMI, as applicable,
has licensed rights (through one or multiple tiers), other than through a Compulsory Sublicense, pursuant to this Agreement. 
  

	1.75	Territory 

 The term “Territory” shall mean [...***...]. 

 

	1.76	Third Party 

 The term “Third Party” shall mean a person or entity other than (i) FMI or
any of its Affiliates or (ii) a member of the Roche Group. 
  

	1.77	US 

 The term “US” shall mean the United States of America and its territories and possessions.

  

	1.78	US$ 

 The term “US$” shall mean US dollars. 

 

	1.79	Work Stream 

 The term “Work Stream” shall mean each of the Molecular Information Platform
Program, Immunotherapy Testing Platform Development Program, the ctDNA Platform Development Program, and the CDx Development Program. 
  

	1.80	Additional Definitions 

 Each of the following definitions is set forth in the Section of this Agreement
indicated below: 
  

			
	 Definition
	  	 Section

	 AAA
	  	19.3
	 Accounting Period
	  	9.1
	 Advanced Genomic Analyses
	  	3.1.4
	 Alliance Director
	  	6.2
	 Approved Markers
	  	3.4.1
	 Assessment
	  	10
	 Bankruptcy Code
	  	18
	 Binding Orders
	  	3.1.5
	 Biomarker IP
	  	2.1.2
	 Breaching Party
	  	17.2.1
	 CDx Assays
	  	3.4.1
	 CDx Platform Working Group
	  	3.4.2
	 Chairperson
	  	6.1.1
	 Competent Authority Procedures
	  	10
	 ctDNA Milestone Date
	  	8.4
	 Create Act
	  	12.6
	 Database Renewal Term
	  	3.1.9
	 Database Queries
	  	3.1.8

  
 ***Confidential Treatment
Requested*** 
 - 16 - 

			
	 Definition
	  	 Section

	 Data Subject
	  	1.57
	 Decision Period
	  	12.5
	 Disclosing Party
	  	1.17
	 Ex-US Collaboration Agreement
	  	Whereas Clause
	 First ctDNA Milestone Date
	  	8.4
	 FMI CDx IP
	  	12.1.5
	 FMI-Derived Advanced Genomic Analysis Results
	  	3.1.8
	 FMI Improvement IP
	  	12.1.2
	 FMI Invention
	  	1.44
	 Immuno-Biomarker Discovery Platform
	  	3.2.1
	 Immuno-Clinical Study Assays
	  	0
	 Immunotherapy Exclusivity Period
	  	3.2.8
	 Immunotherapy Testing Platform Development Budget
	  	8.3.1
	 Genomic Analyses
	  	3.1.4
	 Indemnified Party
	  	14.3
	 Indemnifying Party
	  	14.3
	 Initial Roche ctDNA Assay
	  	8.4
	 Initiating Party
	  	12.5
	 Investigational Markers
	  	3.4.1
	 IVD Collaboration
	  	Whereas Clause
	 Joint Invention
	  	1.44
	 Materially Modified
	  	8.3.2(i)
	 Members
	  	6.1.1
	 Molecular Information Database
	  	3.1.8
	 Molecular Information Database Access
	  	3.1.8
	 Non-Breaching Party
	  	17.2.1
	 Payment Currency
	  	9.3
	 Peremptory Notice Period
	  	17.2.1
	 Products and Services
	  	7
	 Profiling Renewal Term
	  	3.1.9
	 Profiling Term
	  	3.1.9
	 Publishing Notice
	  	16.4
	 Publishing Party
	  	16.4
	 Receiving Party
	  	1.17
	 Related Agreements
	  	Whereas Clause
	 Reserved Capacity
	  	3.1.4
	 Reserved Capacity Fees
	  	8.2.1.1
	 Roche CDx Development IP
	  	12.1.5
	 Roche ctDNA Sample Results
	  	12.1.4
	 Roche Immunotherapy Sample Results
	  	12.1.3
	 Roche Improvement IP
	  	12.1.2
	 Roche Invention
	  	1.44
	 Roche-Owned Advanced Genomic Analysis Results
	  	12.1.2
	 Roche’s Jurisdiction
	  	10
	 Sample Profiling
	  	3.1.4

  
 - 17 - 

			
	 Definition
	  	 Section

	 Sample Results
	  	3.1.6
	 Second ctDNA Milestone Date
	  	8.4
	 Settlement
	  	12.5
	 Signature Identification
	  	3.2.1
	 Suit Notice
	  	12.5
	 Task Orders
	  	3.1.3
	 TPP
	  	6.1.5.2
	 Transaction Agreement
	  	Whereas Clause
	 US Education Collaboration Agreement
	  	Whereas Clause

  

	2.	Grant of License 

  

	2.1	Licenses 

  

	 	2.1.1	Research and Development Cross License 

 Each Party grants to the other Party during the time that a Work Stream
is in effect, a non-exclusive right and license under Know-How and Patent Rights, including the Background IP, Controlled by such Party and that are necessary or useful solely to enable the other Party to perform the activities contemplated under
this Agreement; [...***...]. 
  

	 	2.1.2	Molecular Information Platform Licenses 

 Roche hereby grants to FMI a non-exclusive, royalty-free, worldwide
and perpetual license, sublicensable to FMI’s Affiliates, under any intellectual property rights arising directly from the Sample Results, or the correlation of the Sample Results to patient data (“Biomarker IP”) (i) to
the extent such Biomarker IP becomes publicly known, for internal research purposes, (ii) to the extent such Biomarker IP becomes publicly known, to develop, make, have made, use, offer for sale, sell, import, and commercialize FMI’s
Products and Services relating to genomic analysis, and (iii) [...***...]. 
 Roche hereby grants to FMI a non-exclusive, royalty-free, worldwide and
perpetual license, sublicensable to Affiliates, to use the Roche-Owned Advanced Genomic Analysis Results to develop, make, have made, use, offer for sale, sell, import and commercialize FMI’s products and services relating to genomic analysis.

 FMI hereby grants to Roche a non-exclusive, royalty-free, worldwide and perpetual license, sublicensable to Roche’s Affiliates under any FMI
Improvements for Roche’s internal research purposes and to develop, make, have made, use, offer for sale, sell, import and commercialize Roche’s products and services other than diagnostic products and services. 

 

	 	2.1.3	Immunotherapy Testing Platform Licenses 

 Effective after the Immunotherapy Exclusivity Period, Roche hereby
grants to FMI a non-exclusive, royalty-free, worldwide, perpetual, and sublicensable to Affiliates, license to any intellectual property arising from the Immunotherapy Testing Platform Development Program Controlled by Roche (excluding Roche
Immunotherapy Sample Results) to the extent necessary 

  
 ***Confidential Treatment
Requested*** 
 - 18 - 

 
for FMI to develop, make, have made, use, offer for sale, sell, import and commercialize the Immuno-Biomarker Discovery Platform, Signature Identification services, Clinical Study assays, CDx
assays, or any other FMI testing or services (including that are part of the Genomic Analysis Platform). 
 FMI hereby grants to Roche a non-exclusive,
royalty-free, worldwide, perpetual, and sublicensable license to any intellectual property arising from the Immunotherapy Testing Platform Program Controlled by FMI for internal research purposes and to the extent necessary for Roche to research,
develop, make, have made, use, offer for sale, sell, import and commercialize Roche products other than diagnostic products. 
 If FMI is unable or
unwilling to develop and commercialize an Immuno Clinical Study assay or CDx assay resulting from the Immunotherapy Testing Platform Development Program in a given country within the Territory as specified in an R&D Plan for any reason other
than a breach of this Agreement by Roche, and on the timeline agreed to in such R&D Plan, then, effective on the end of the timeline specified in such R&D Plan, FMI hereby grants to Roche a non-exclusive, royalty-free, perpetual, and
sublicensable license under any intellectual property invented by FMI arising from the Immunotherapy Testing Platform Program or the Immunotherapy Testing Platform Development that is necessary for Roche to develop and commercialize such tests in
such country in the Territory. 
  

	 	2.1.4	ctDNA Licenses 

 FMI hereby grants to Roche (i) an exclusive, royalty-free, sublicensable, worldwide and
perpetual license to any intellectual property rights arising from the ctDNA Development Platform Program that are necessary for Roche to develop, make, have made, use, offer for sale, sell, import and commercialize Roche products other than
diagnostic products (including the use, formulation, methods of treatment, clinical data or other data, information or results relating to the Roche therapeutic product) solely for use in connection with such activities and such Roche products and
(ii) a non-exclusive, royalty-free, worldwide and perpetual license, with the right to grant sublicenses solely to Roche Affiliates, to any intellectual property rights arising from the ctDNA Development Platform Program, for internal research
purposes. 
 Roche hereby grants to FMI a non-exclusive, royalty-free, worldwide, perpetual, and sublicensable license to any IP Controlled by Roche and
developed under the ctDNA Platform Development Program (excluding Roche Immunotherapy Sample Results) to the extent necessary for FMI to research, develop, make, have made, use, offer for sale, sell, import and commercialize the ctDNA Assays. 

 

	 	2.1.5	CDx Development Program 

 FMI hereby grants to Roche a non-exclusive license under the FMI CDx IP for internal
research purposes, and to the extent necessary to research, develop, make, have made, use, offer for sale, sell, import and commercialize Roche products other than diagnostic products. 

If FMI is unwilling or unable to develop and commercialize a CDx Assay for a given country in the Territory as specified in the R&D Plan, and on the
timeline set forth in the relevant R&D Plan, for any reason other than a breach of this Agreement by Roche, then FMI hereby grants to Roche a non-exclusive, royalty-free, sublicensable, and perpetual license under any intellectual property
invented by FMI arising from the CDx Development Program that is necessary for Roche to develop and commercialize a CDx Assay equivalent in such country in the Territory. 

  
 - 19 - 

	2.2	Sublicense 

 Except as otherwise provided herein, where the right to sublicense is granted under this
Agreement, the licensee shall have the right to sublicense, and subcontract (subject to Section 2.3), through multiple tiers. Each sublicense granted hereunder to a Third Party shall be pursuant to a written agreement. Each sublicense granted
hereunder by a Party shall include restrictions on the disclosure of the other Party’s Confidential Information that are substantially similar to the protections provided herein. Each Party shall be liable for any action or failure to act by a
sublicensee under a sublicense granted by such Party to the extent such action or failure to act on the part of such Party would constitute a breach of this Agreement by such Party. 

 

	2.3	Right to Subcontract 

 Each Party shall have the right to subcontract the work performed under this
Agreement in accordance with the applicable R&D Plan. Each such subcontract with a Third Party shall be pursuant to a written agreement. Each such subcontract by a Party shall include restrictions on the disclosure of the other Party’s
Confidential Information that are substantially similar to the protections provided herein. Each Party shall be liable for any action or failure to act by a subcontractor under a subcontract entered into by such Party to the extent such action or
failure to act on the part of such Party would constitute a breach of this Agreement by such Party. 
  

	3.	Research and Development Collaboration 

  

	3.1	Molecular Information Platform Program 

  

	 	3.1.1	Scope 

 Roche and FMI shall conduct the Molecular Information Platform Program pursuant to this Agreement under
the direction of the Molecular Information Platform Working Group. 
  

	 	3.1.2	Molecular Information Platform Working Group 

 The Parties shall establish the Molecular Information Platform
Working Group within sixty (60) days after the Effective Date to operationalize the Molecular Information Platform Program. The Molecular Information Platform Working Group’s activities will be overseen by JRDC. 

 

	 	3.1.3	Task Orders 

 The Parties will conduct the Molecular Information Platform Program in accordance with agreed upon
task orders (“Task Orders”) and in compliance with Performance Specifications and Quality Standards. Each Task Order will be substantially in the form set forth in Appendix 3.1.3. To the extent any terms set forth in a Task Order
conflict with the terms set forth in this Agreement, the terms of this Agreement shall control. 
  

	 	3.1.4	Sample Profiling and Reserved Capacity 

 FMI shall provide, and shall reserve capacity to provide, Roche with
comprehensive profiling, analysis and reporting (“Sample Profiling”) of at least [...***...] during the first [...***...] immediately following the Effective date, and at least [...***...] samples during the next
[...***...] 

  
 ***Confidential Treatment
Requested*** 
 - 20 - 

 
(“Reserved Capacity”) using FMI’s platform for molecular genomic profiling of cancer samples (the “Genomic Analysis Platform”). The initial laboratory and
computational biology activities performed on the Samples as part of Sample Profiling are “Genomic Analyses”. FMI will provide Sample Profiling in accordance with the Reserved Capacity during the Profiling Term and Profiling Renewal
Term, using the then-current versions of the tests included in its Genomic Analysis Platform. The Sampling Profiles shall be provided in a specified format to be mutually agreed by the Parties. The JMC will discuss and decide upon the Reserved
Capacity commitment for Profiling Renewal Terms, provided that any Reserved Capacity amount in excess of [...***...] that would require FMI to increase its existing capacity will require FMI approval. 

Sample Profiling will include advanced genomic analyses, i.e. advanced laboratory and computational biology activities in the field of cancer genomic
sequencing and analysis performed on Samples, including [...***...] (collectively, “Advanced Genomic Analyses”). Sample Profiling includes Genomic Analyses and Advanced Genomic Analyses. 

FMI may adopt modifications to the Performance Specifications without Roche’s consent, so long as such modifications do not result in a material
diminution in the analytical performance of the Genomic Analysis Platform as measured by the metrics set forth in Appendix 1.57 (which such material diminution would require the prior written consent of Roche). In the event [...***...], and
such change results in a material diminution in the analytical performance of the Genomic Analysis Platform as measured by the metrics set forth in Appendix 1.57, Roche may, at its election, and upon written notice to FMI, terminate each
Party’s obligations under Reserved Capacity, including Roche’s obligations under Section 8.2.1.1 to pay Reserved Capacity Fees and opt out of the price per Sample fees for Sample Profiling otherwise specified in Section 8.2.1.2,
in each case, from the effect of such sequencing platform change. If Roche elects to terminate the Parties’ obligations under Reserved Capacity and opts out of the per Sample pricing for Sample Profiling specified in Section 8.2.1.2,
Sample Profiling shall then be performed, and fees for such Sample Profiling shall then be charged, on a per Sample basis at FMI’s standard rates or on pricing terms to be mutually agreed in writing by the Parties (or as otherwise mutually
agreed in writing by the Parties). 
  

	 	3.1.5	Forecasting and Binding Orders 

 Not later than the first Business Day of [...***...] during the Profiling
Term and Profiling Renewal Terms, Roche will provide FMI with a rolling forecast of its estimated requirements for Sample Profiling for the following [...***...], the rolling forecast for the [...***...] of which shall be deemed to be a
binding order for sample volume (including specifications for the number of samples to be run using each of FMI’s different tests) (“Binding Orders”). Binding Orders will not impact FMI’s commitment to provide services for
at least the Reserved Capacity amount, and Roche’s financial commitment to pay the Reserved Capacity Fee. FMI shall use Commercially Reasonable Efforts to fulfill requests for Sample Profiling exceeding the Reserved Capacity based on forecasts
provided by Roche (each a “Forecast”) in advance of [...***...] as specified below. 
  

	 	3.1.6	Samples, Sample Results, Web-Portal 

 Roche will provide samples to FMI for Sample Profiling as provided for in
Section 3.5. The results of the Sample Profiling (“Sample Results”) shall be provided by FMI to Roche in a timeframe to be agreed upon by the Parties. A sample report is attached as Appendix 3.1.6. 

  
 ***Confidential Treatment
Requested*** 
 - 21 - 

 FMI will set up and utilize a basic web-portal for Roche to access Sample Results and patient reports for Roche
Clinical Studies. This web-portal shall be similar to the portal that FMI provides to its other major pharmaceutical customers. 
  

	 	3.1.7	Clinical Reports 

 FMI will provide Roche with clinical (e.g., FoundationOne® or FoundationOne® Heme)
reports from Sample Profiling on reasonable request, to be specified in applicable Task Orders, to enable Roche to provide comprehensive information to physicians and patients. 

 

	 	3.1.8	Database Insights 

 FMI will provide molecular information insights (“Database Insights”)
arising from FMI’s database of aggregated clinical genomic analysis results, which include genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements) detected by the Genomic Analysis Platform
across FMI’s clinical testing experience in all disease ontologies (the “Molecular Information Database”), in response to queries supplied by Roche (“Database Queries”) or generated by FMI in response to
discussions between the Parties about areas of interest for Roche (e.g., [...***...]), utilizing a team of [...***...] FMI FTEs with requisite training and experience to generate Database Insights (“Molecular Information Database
Access”). 
 Database Insights and results of Advanced Genomic Analyses performed against the Molecular Information Database (which, for clarity,
does not include Roche’s Sample Results) (“FMI-Derived Advanced Genomic Analysis Results”) shall be deemed FMI Confidential Information. Roche and its Affiliates may use the Database Query Results and FMI-Derived Advanced
Genomic Analysis Results for all purposes, except that Roche may not disclose the Database Query Results to Third Parties, other than as necessary for development, approval or commercialization of a therapeutic or diagnostic product owned or
controlled by Roche, or as otherwise consistent with the terms of confidentiality contained in the Definitive Agreement. 
  

	 	3.1.9	Molecular Information Database Access 

 As set forth in Section 3.1.8, FMI will provide Roche mediated (indirect
through dedicated FMI FTEs) access to the Molecular Information Database to pose Database Queries and will provide the resulting Database Insights to Roche in a format to be mutually agreed by the Parties. FMI will also provide Roche with direct
access to the Molecular Information Database for Roche to perform Database Queries and generate Database Insights, when such service is made available to Third Parties by FMI in the ordinary course of business. 

 

	 	3.1.10	Duration and Extension 

 The term for Sample Profiling set forth in Section 3.1.4 shall commence on the
Effective Date and continue for five (5) years thereafter (the “Profiling Term”). The Profiling Term may be extended at Roche’s option, upon [...***...] written notice to FMI as specified in Section 19.13, for
additional three (3) year periods, during any period of time in which Roche is a majority shareholder of FMI (each a “Profiling Renewal Term”). 

The term for Database Insights under Section 3.1.8 shall commence on the Effective Date and continue for five (5) years thereafter (the “Database
Insights Term”). The Database Insights 

  
 ***Confidential Treatment
Requested*** 
 - 22 - 

 
Term may be extended at Roche’s option, upon [...***...] notice to FMI as specified in Section 19.13, for additional three (3) year periods, during any period of time in
which Roche is a majority shareholder of FMI (each a “Database Renewal Term”). 
 During any Profiling Renewal Term and/or Database Renewal
Term, if FMI increases the fees it charges to Third Parties for Sample Profiling and/or Database Insights, then FMI will notify Roche of such adjustment(s), and the Parties shall agree upon the fees to be charged to Roche during the Profiling
Renewal Term and/or Database Renewal Term, subject to Article 5, for such Profiling Renewal Term and/or Database Renewal Term prior to its commencement. 

If FMI is unable to provide Roche with the Reserved Capacity, or to provide Roche with deliverables meeting Performance Specifications for the Sample
Profiling or the Database Queries or fails to comply with Quality Standards, then Roche will have the right to terminate the Sample Profiling and/or Database Insights, as applicable, as set forth in Section 17.3.3, subject to the notice and cure
provisions therein. 
  

	3.2	Immunotherapy Testing Platform Development Program 

  

	 	3.2.1	Scope 

 Roche and FMI shall conduct the Immunotherapy Testing Platform Development Program pursuant to a
mutually agreed R&D Plan under the direction of the Immuno-Platform Working Group. The purpose of the Immunotherapy Testing Platform Development Program is to develop an immunotherapy testing platform meeting the specifications set forth by the
Immuno-Platform Working Group for profiling of cancer immunotherapy patients (the “Immuno-Biomarker Discovery Platform”). The Parties hope to further deploy the platform for use in Clinical Study sample profiling to identify
possible signatures for immunotherapy response (“Signature Identification”). Roche may also, at its option, request that FMI develop CLIA immunotherapy testing Clinical Study assays for use in selecting or differentiating patients
in Roche Clinical Studies in immuno-oncology (“Immuno-Clinical Study Assays”). 
  

	 	3.2.2	Immuno-Platform Working Group 

 The Parties shall establish the Immuno-Platform Working Group within sixty
(60) days after the Effective Date to operationalize the Immunotherapy Testing Platform Development. The Immuno-Platform Working Group’s activities will be overseen by JRDC. 

The Immuno-Platform Working Group shall serve as a forum for discussion and sharing updates and information between the Parties, but shall have no
decision-making authority. The Immuno-Platform Working Group shall: 
  

	(i)	serve as a forum for discussing the development of the Immuno-Biomarker Discovery Platform and related Products and Services, as well as Immuno-Clinical Study Assays, if applicable; 

 

	(ii)	serve as a forum for coordinating the Parties’ efforts to carry out the R&D Plan; 

  

	(iii)	periodically monitor progress of activities under the R&D Plan and discuss any obstacles or delays with regard to achieving the timelines set forth therein; 

  
 ***Confidential Treatment
Requested*** 
 - 23 - 

	(iv)	discuss the overall strategy, including the submission plans, for obtaining and maintaining Regulatory Approval of any of the Products and Services developed in the Immunotherapy Testing Platform Development Program;
and 

  

	(v)	such other responsibilities as may be assigned to the Immuno-Platform Working Group in or pursuant to this Agreement or as may be mutually agreed by the Parties in writing. 

 

	 	3.2.3	R&D Plan 

 The Parties will conduct the Immunotherapy Testing Platform Development Program in accordance
with an R&D Plan and in compliance with Performance Specifications and Quality Standards. Unless decided otherwise by the JMC, the R&D Plan will be updated [...***...] by the Immuno-Platform Working Group, reviewed and recommended for
approval by the JRDC and approved by the JMC. The R&D Plan will set forth (i) the scope of the Immunotherapy Testing Platform Development Program and the FTE resources that will be dedicated to the activities contemplated within the scope
of the Immunotherapy Testing Platform Development Program, including the responsibilities of each Party (ii) an overall timeline and specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRDC as
research progresses, and (iii) budgets for such activities. The Parties shall update the R&D Plan no later than [...***...] before the first anniversary of the Effective Date. The JRDC shall review the R&D Plan on an ongoing basis
and may amend the R&D Plan. Any such changes shall be reflected in written amendments to the R&D Plan. 
  

	 	3.2.4	Responsibilities of the Parties 

 FMI will work with Roche in accordance with the R&D Plan to develop the
Immuno-Biomarker Discovery Platform, perform Signature Identification, and, as requested by Roche, develop Immuno Clinical Study Assays. Except for the contracts listed on Appendix 3.2.4, the Parties will meet and discuss existing contracts for
activities that are Excepted Activities, and enact a plan for winding-down such contracts, where appropriate. 
 Roche will work with FMI in accordance with
the R&D Plan established by the Immuno-Platform Working Group, including by providing relevant samples and associated data, immuno-oncology expertise, and bioinformatics support, in each case to the extent agreed to in the R&D Plan. 

 

	 	3.2.5	Budget 

 A budget for the anticipated work for the Immunotherapy Testing Platform Development forms a part of
the R&D Plan. Any changes to this budget shall be reviewed by the JRDC and then submitted to the JMC for approval. 
  

	 	3.2.6	Duration 

 The initial term of the Immunotherapy Testing Platform Development Program will be five
(5) years beginning on the Effective Date. 
  

	 	3.2.7	Extension 

 Roche shall have the right to extend the Immunotherapy Testing Platform Development Program, upon
[...***...] written notice to FMI as specified in Section 19.13, for up to six (6)

  
 ***Confidential Treatment
Requested*** 
 - 24 - 

 
additional one (1) year periods, during any period of time in which Roche is a majority shareholder of FMI (each a “Signature Identification Renewal Term”), provided, for
clarity, that during any Signature Identification Renewal Term, FMI’s obligations under Section 16.1 shall continue to apply to any signature identified under this Agreement but that exclusivity under Section 3.2.8 shall not apply to
the Immuno-Biomarker Discovery Platform. 
  

	 	3.2.8	Exclusivity 

 Except for Excepted Activities, for the lesser of (i) [...***...] after the Effective
Date or (ii) [...***...] (the “Immunotherapy Exclusivity Period”), FMI will work exclusively with Roche with respect to [...***...]. Except with regard to Excepted Activities, FMI will not (i) work directly or
indirectly with any Third Party in the field of [...***...], (ii) use for the benefit of any Third Party the [...***...] or (iii) transfer to or otherwise enable any Third Party to make use of any data, technology or results
from the Immunotherapy Testing Platform Development Program for [...***...]. 
 Following the Immunotherapy Exclusivity Period, FMI shall have the
right to work with Third Parties in the field of cancer immunotherapy, and to otherwise commercialize the Immuno-Biomarker Discovery Platform, subject to the Related Agreements. 

 

	 	3.2.9	Excepted Activities 

 For any Excepted Activities, FMI shall provide copies of proposed publications Roche for
review in accordance with Section 16.4. 
  

	 	[...***...]	

 For the first [...***...] following commercial launch by FMI of any Immuno Clinical Study Assay(s)
created during or derived from the Immunotherapy Testing Platform Development, Roche and its Affiliates will be entitled to [...***...], for the purchase of any such Immuno Clinical Study Assay(s). 

 

	3.3	ctDNA Platform Development Program 

  

	 	3.3.1	Scope 

 Roche and FMI shall conduct the ctDNA Platform Development Program, pursuant to a mutually agreed
R&D Plan under the direction of the ctDNA Working Group. The purpose of the ctDNA Platform Development Program is to develop ctDNA Assays meeting the specifications set forth in the R&D Plan. 

 

	 	3.3.2	Working Group 

 The Parties shall establish the ctDNA Working Group within sixty (60) days after the
Effective Date to operationalize the ctDNA Platform Development. The ctDNA Working Group’s activities will be overseen by JRDC. 

  
 ***Confidential Treatment
Requested*** 
 - 25 - 

 The ctDNA Working Group shall serve as a forum for discussion and sharing updates and information between the
Parties, but shall have no decision-making authority. The ctDNA Working Group shall: 
  

	 	(i)	serve as a forum for discussing the development of the ctDNA Platform and ctDNA Products; 

  

	 	(ii)	serve as a forum for coordinating the Parties’ efforts to carry out the R&D Plan; 

  

	 	(iii)	periodically monitor progress of activities under the R&D Plan and discuss any obstacles or delays with regard to achieving the timelines set forth therein; 

 

	 	(iv)	discuss the overall strategy, including the submission plans, for obtaining and maintaining Regulatory Approval of any of the ctDNA Products; and 

 

	 	(v)	such other responsibilities as may be assigned to the ctDNA Working Group in or pursuant to this Agreement or as may be mutually agreed by the Parties in writing. 

 

	 	3.3.3	R&D Plan 

 FMI will develop the ctDNA Assays, leveraging ongoing efforts, in accordance with the R&D
Plan and in compliance with Performance Specifications and Quality Standards. Unless decided otherwise by the JMC, the R&D Plan will be updated [...***...] by the ctDNA Working Group, reviewed and recommended for approval by the JRDC and
approved by the JMC. The R&D Plan will set forth (i) the scope of the ctDNA Platform Development Program and the FTE resources that will be dedicated to the activities contemplated within the scope of the ctDNA Platform Development Program,
including the responsibilities of each Party (ii) an overall timeline and specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRDC as research progresses, and (iii) budgets for such
activities. The Parties shall update the R&D Plan no later than [...***...] before the first anniversary of the Effective Date. The JRDC shall review the R&D Plan on an ongoing basis and may amend the R&D Plan subject to approval
of the JMC. Any such changes shall be reflected in written amendments to the R&D Plan. 
  

	 	3.3.4	Responsibilities of the Parties 

 FMI shall, subject to all terms and conditions of this Agreement, use
Commercially Reasonable Efforts to Develop the Initial Roche ctDNA Assay and the ALK ctDNA Clinical Trial Assay in accordance with the R&D Plan. FMI will work with Roche in accordance with the R&D Plan to develop ctDNA Assays. 

Roche will work with FMI in accordance with the R&D Plan, including by providing relevant Samples and associated data, in each case to the extent agreed
to in the R&D Plan. 
 Roche assumes no liability for use of the Genomic Analyses obtained from Samples provided under this Agreement, except as and to
the extent arising out of a breach by Roche of this Agreement. 

  
 - 26 - 

	 	3.3.5	Budget 

 FMI will have sole control over, and responsibility for, the budget and funding for the anticipated
work for the ctDNA Platform Development under the R&D Plan. 
  

	 	3.3.6	Duration 

 The initial term of the ctDNA Platform Development Program will be twelve (12) months. 

 

	 	3.3.7	Extension 

 The initial term of the ctDNA Platform Development Program may be extended by the mutual agreement
of the Parties. 
  

	 	[...***...]	

 For the [...***...] following commercial launch by FMI of any ctDNA Assay(s) created during or derived
from the ctDNA Platform Development, Roche and its Affiliates will be entitled to [...***...], for the purchase of any such ctDNA Assay(s). 
  

	 	3.3.9	Commercialization 

 Subject to the Related Agreements, FMI shall have the right to commercialize the ctDNA
Assays. The ctDNA Assays may be made commercially available to any customer, except that FMI shall not disclose to an Third Party the specific content of any ctDNA Assay developed specifically for Roche for use as a Clinical Study assay. 

 

	3.4	CDx Development Program 

  

	 	3.4.1	Scope 

 Roche and FMI shall conduct the CDx Development Program pursuant to a mutually agreed R&D Plan. The
activities conducted in connection with the CDx Development Program will be overseen by the JRDC. The purpose of the CDx Development Program is to develop certain companion diagnostic tests or assays (the “CDx Assays”) for use in
connection with certain Roche products. Such CDx Assays may include those developed at Roche’s request in connection with markers that have not yet been approved by the FDA for the particular tumor type/indication for which Roche is developing
the relevant therapeutic (“Investigational Markers”) and those developed by mutual agreement of the Parties in connection with markers that are included in one or more assays approved by the FDA for the particular tumor
type/indication to indicate use of a Roche therapeutic (“Approved Markers”). 
  

	 	3.4.2	Working Group 

 For each CDx Assay under development, the Parties shall establish a working group (the
“CDx Platform Working Group”), to operationalize the CDx Development. The Parties shall establish the first CDx Platform Working Group within sixty (60) days after the Effective Date. Each CDx Platform Working Group’s
activities will be overseen by JRDC. 

  
 ***Confidential Treatment
Requested*** 
 - 27 - 

 The CDx Platform Working Group shall serve as a forum for discussion and sharing updates and information between
the Parties, but shall have no decision-making authority. The CDx Platform Working Group shall: 
  

	(i)	serve as a forum for discussing the development of CDx Assays and related Products and Services; 

  

	(ii)	serve as a forum for coordinating the Parties’ efforts to carry out the R&D Plan; 

  

	(iii)	periodically monitor progress of activities under the R&D Plan and discuss any obstacles or delays with regard to achieving the timelines set forth therein; 

 

	(iv)	discuss the overall strategy, including the submission plans, for obtaining and maintaining Regulatory Approval of any of the Products and Services developed in the CDx Development Program; and 

 

	(v)	such other responsibilities as may be assigned to the CDx Platform Working Group in or pursuant to this Agreement or as may be mutually agreed by the Parties in writing. 

 

	 	3.4.3	R&D Plan 

 The Parties will conduct the CDx Development Program in accordance with the R&D Plan and in
compliance with Performance Specifications and Quality Standards. Unless decided otherwise by the JMC, the R&D Plan will be updated [...***...] by the CDx Platform Working Group, reviewed and recommended for approval by the JRDC and
approved by the JMC. The R&D Plan will set forth (i) the scope of the CDx Development Program and the resources that will be dedicated to the activities contemplated within the CDx Development Program, including the responsibilities of each
Party (ii) specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRDC as research progresses, and (iii) budgets for such activities. The Parties shall prepare a plan for activities to be
conducted no later than [...***...] before the first anniversary of the Effective Date. The JMC shall review the R&D Plan on an ongoing basis and may amend the R&D Plan. Any such changes shall be reflected in written amendments to the
R&D Plan. 
  

	 	3.4.4	Responsibilities of the Parties 

 FMI will provide CDx development and testing services, including, as required
by the R&D Plan, providing FDA QSR laboratory capacity to support such testing. The CDx services will be based on individual CDx R&D Plans for specific Roche assets that will be agreed upon, signed by the Parties and thereby made a part of
this Agreement as Appendices 3.4.4(a), 3.4.4(b) and so on. All CDx services will be performed with appropriate systems and documentation to support eventual FDA approval of a PMA or 510(k) or, if agreed by the Parties, approval from the relevant
regulatory authorities for an ROW Territory in which FMI will deliver a CDx Assay for Roche therapeutics. 
 FMI will be responsible for performing the
development work for the CDx Assays according to the individual CDx R&D Plans. Unless otherwise expressly agreed between the Parties, FMI will be responsible for seeking regulatory approval (including PMAs, 510(k)s or equivalent) for the CDx
Assays. FMI will provide Roche with cross-reference letters, and shall otherwise coordinate regulatory submissions and related information, with Roche. 

  
 - 28 - 

 Roche is responsible for supplying FMI with the information and materials necessary for each CDx Assay to be
developed under the CDx Development Program in accordance with the R&D Plan. Roche will be solely responsible for seeking regulatory approval for the associated Roche asset. Roche will provide FMI with cross-reference letters, and shall
otherwise coordinate regulatory submissions and related information with FMI. 
  

	 	3.4.5	Budget 

 Roche and FMI shall agree on a budget for each CDx Assay. The initial budget forms a part of the
initial R&D Plan. 
  

	 	3.4.6	Duration 

 The term of the CDx Development Program shall be five (5) years. 

 

	 	3.4.7	Extension 

 Roche shall have the right to extend the term of the CDx Development Program, upon [...***...]
prior written notice to FMI as specified in Section 19.13, for additional three (3) year periods, during any period of time in which Roche is a majority shareholder of FMI. 

 

	 	3.4.8	Continuing Obligations 

 If work under an individual CDx R&D Plan is initiated during the initial term of
the CDx Development Program or an extension thereof, then such work shall be completed as set forth in the applicable individual CDx R&D Plan after the initial term or extension, as applicable, in accordance with the terms set forth therein and
herein (including with respect to funding obligations). 
  

	 	3.4.9	Commercialization 

 Subject to the Related Agreements, FMI shall have the right to commercialize the CDx Assays.

  

	3.5	Samples, Handling and Disposal 

  

	 	3.5.1	Samples 

 Roche will provide samples to FMI that meet the FMI specimen requirements attached hereto as Appendix
3.5.1 and in accordance with the applicable R&D Plan. FMI shall not transfer the Samples or other materials obtained or received in connection with this Agreement, or any derivatives thereof, to any Third Party without Roche’s prior written
approval. FMI shall use the Samples and material obtained or received in connection with this Agreement solely for the performance of activities permitted under this Agreement in FMI’s laboratories under suitable containment conditions in
accordance with all Applicable Law. FMI shall not analyze the Samples other than as expressly provided for in this Agreement. FMI may use such Samples in accordance with the applicable R&D Plan without any obligation of compensation to the
subjects from whom such Samples were obtained or any other Third Party for the intellectual property associated with, or any use of, such Samples. 

  
 ***Confidential Treatment
Requested*** 
 - 29 - 

	 	3.5.2	Sample Handling and Disposal 

 All Samples provided to FMI by or on behalf of Roche shall have been collected or
shall be collected, handled, and transferred in compliance with Applicable Law and any applicable policies of any institutional review board, privacy board, or ethics committee with jurisdiction over the collection, handling, and transfer of such
material or information. Upon termination of the Agreement or the Work Stream requiring the use of the Samples, or upon completion of those activities requiring use of the Samples, FMI shall promptly return to Roche unused or remaining Samples, or,
at FMI’s option, securely dispose of all unused or remaining Samples and provide Roche with a written notice of such disposal. 
 Roche has
authorization and all consents required for FMI to use the Samples in accordance with the R&D Plans and the Agreement. FMI shall use, store and handle all Samples in accordance with the R&D Plans and all Applicable Laws. In the event of
withdrawal of a subject’s consent, Roche will promptly notify FMI and FMI will destroy the corresponding unused Samples (as documented by written confirmation) or return such Samples to Roche for destruction. 

 

	3.6	Records; Reports; Audits 

  

	 	3.6.1	Progress Reports 

 At least [...***...] during the time a Work Stream remains in effect, unless otherwise
agreed by the Parties, FMI shall have the obligation to prepare and provide to the JRDC a summary presentation on the progress of the work performed by FMI in the course of each Work Stream during the preceding [...***...]. Promptly upon
expiry of such Work Stream, other than the Molecular Information Platform Program, FMI shall provide a final written report summarizing its activities under such Work Stream and the results thereof. 

 

	 	3.6.2	Research Records 

 Each Party shall maintain records of each Work Stream (or cause such records to be
maintained), except Roche shall not have such obligation for the Molecular Information Platform Program, in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in
the performance of such Work Stream. All laboratory notebooks shall be maintained for no less than the term of any Patent Rights issuing therefrom. 
 In
addition, during the Agreement and for [...***...] thereafter, FMI shall maintain all data provided to FMI by Roche, the Genomic Results, the FMI Advanced Genomic Analysis Results, Database Insights Database Query Results, and documentation
necessary to demonstrate FMI’s compliance with the terms of this Agreement, including computerized records and files, in a secure area reasonably protected from fire, theft and destruction; provided, however, that with respect to raw
genomic data, FMI shall only be required to retain the original, unprocessed BAM file generated from its sequencing process and no other raw genomic data or intermediate BAM files created in processing to generate the Results. 

 

	 	3.6.3	Regulatory Inspections and Audit 

 Roche shall be entitled, upon reasonable notice and during FMI’s regular
business hours, to visit FMI’s facility (and those facilities of its subcontractors), including FMI’s CLIA-compliant 

  
 ***Confidential Treatment
Requested*** 
 - 30 - 

 
facilities, to audit for quality assurance purposes its facilities, documentation and procedures used in conducting its activities pursuant to this Agreement. Such audits may be conducted up to
[...***...] and Roche shall use reasonable effort not to disrupt ongoing operations during such audits. FMI shall provide Roche with prompt notice of any governmental or regulatory review, audit or inspection of any of its facilities involved
in the development of the Molecular Information Platform, Immunotherapy Testing Platform, ctDNA Platform, or CDx Assays, and all Products and Services resulting therefrom, and FMI’s CLIA-compliant facilities. FMI shall provide Roche with
(a) the results of any such review, audit or inspection (including a copy of the relevant sections of the report) to the extent such results pertain to any activities under this Agreement; and (b) the opportunity to provide assistance to
FMI in responding to any such review, audit or inspection. 
  

	4.	Diligence 

 Roche and FMI shall use Commercially Reasonable Efforts to perform their respective
activities contemplated by this Agreement. 
  

	5.	Most Favored Customer 

 FMI agrees that the pricing terms for Products and Services provided by FMI to
Roche herein, and services provided under the Molecular Information Platform Program, are, and will be, at least as favorable as the pricing terms granted by FMI to any existing customer or collaborator for such (or substantially similar) products
or services. If FMI enters into any subsequent agreement with another customer or collaborator which provides for pricing terms for substantially the same product or services at substantially the same (or a lesser) scale, which pricing terms are
more favorable than those contained herein, then FMI shall notify Roche and Roche will have the right to modify this agreement to provide Roche with those more favorable pricing terms. [...***...]. 

 

	6.	Governance 

  

	6.1	Joint Management Committee 

 Within sixty (60) days after the Effective Date, the Parties shall
establish a JMC to ensure the smooth operation of the arrangements and activities envisaged under this Agreement. 
  

	 	6.1.1	Members 

 The JMC shall be composed of six (6) persons (“Members”). Roche and FMI each
shall be entitled to appoint three (3) Members with appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement. A Party that replaces a
Member shall notify the other Party at least ten (10) days prior to the next scheduled meeting of the JMC. Both Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Both Parties may invite a
reasonable number of additional experts and/or advisors to attend part or the whole JMC meeting with prior notification to the JMC. Members may be represented at any meeting by another person designated by the absent Member. One JMC representative
from a Party shall chair (“Chairperson”) the JMC on a rotating annual calendar year basis, with the initial chairperson to be from Roche. The JMC will be made up of senior representatives from FMI and Roche, including alliance
directors. The JMC may create and/or dissolve joint teams tasked with oversight of specific programs or projects, subject to overall governance by the JMC. The role of the alliance directors will be to facilitate communication and collaboration
between the Parties. 

  
 ***Confidential Treatment
Requested*** 
 - 31 - 

	 	6.1.2	Responsibilities of the JMC 

 The JMC shall have the responsibility and authority to: 

 

	a)	approve the R&D Plans; 

  

	b)	establish, disband and set expectations and mandates for JRDC, JOC, JPT and JOTs, if applicable; 

  

	c)	oversee the JRDC, JOC, JPT and JOTs, if applicable; 

  

	d)	provide financial oversight for the Immunotherapy Testing Platform Development Program and the CDx Development Program; and 

  

	e)	attempt to resolve any disputes escalated from the JRDC or JOC. 

 The JMC shall have no responsibility and
authority other than that expressly set forth in this section. 
  

	 	6.1.3	Meetings 

 The Chairperson or his/her delegate is responsible for sending invitations and agendas for all JMC
meetings to all Members at least ten (10) days before the next scheduled meeting of the JMC. The venue for the meetings shall be agreed by the JMC. The JMC shall hold meetings at least twice per calendar year, either in person or by
tele-/video-conference, and in any case as frequently as the Members of the JMC may agree shall be necessary, but not more than four times a year. The Alliance Director of each Party may attend the JMC meetings as a permanent participant. 

 

	 	6.1.4	Minutes 

 The Chairperson is responsible for designating a Member to record in reasonable detail and circulate
draft minutes of JMC meetings to all members of the JMC for comment and review within twenty (20) days after the relevant meeting. The Members of the JMC shall have ten (10) days to provide comments. The Party preparing the minutes shall
incorporate timely received comments and distribute finalized minutes to all Members of the JMC within thirty-five (35) days of the relevant meeting. The Chairperson approves the final version of the minutes before its distribution. 

 

	 	6.1.5	Decisions 

  

	 	6.1.5.1	Decision Making Authority 

 The JMC shall decide matters within its responsibilities set forth in Section 6.1.2.

  

	 	6.1.5.2	ctDNA Platform 

 FMI will have final decision-making rights at the JMC with respect to the ctDNA Platform
Development, provided that FMI may not change the timelines agree in Section 8.4, and any change to the Roche specifications (“TPP”) for a ctDNA Assay specifically requested by Roche as part of the R&D Plan will require
Roche’s prior approval. 

  
 - 32 - 

	 	6.1.5.3	Consensus; Good Faith 

 The Members of the JMC shall act in good faith to cooperate with one another and seek
agreement with respect to issues to be decided by the JMC. The Parties shall endeavor to make decisions by consensus with each Party having one (1) vote. 
  

	 	6.1.5.4	Failure to Reach Consensus 

 If the JMC is unable to decide a matter by consensus, then the escalation procedure
in Section 6.1.5.5 shall be applied. 
  

	 	6.1.5.5	Escalation 

 If the JMC is unable to decide a matter by consensus, then such matter shall be referred to the
Chief Executive Officer of FMI or equivalent position or his/her nominee and the Chief Executive Officer of Roche or equivalent position or his/her nominee for resolution, who together shall use reasonable and good faith efforts to reach a decision
by consensus within [...***...] after the date such matter is referred to them. If the Parties still fail to reach a decision within such [...***...]. Any such decision shall constitute a decision of the JMC. Notwithstanding the
foregoing, neither Party may exercise deciding authority (i) to impose resource or financial burdens on the other Party for a Work Stream beyond the scope set forth in an agreed upon R&D Plan for such Work Stream or Reserved Capacity under
the Molecular Information Platform Program, or (ii) that would violate or amend the terms of this Agreement. The JMC will exist for the Agreement Term. 
  

	 	6.1.6	Information Exchange 

 FMI and Roche shall exchange the information in relation to its activities under this
Agreement through the JMC and FMI and Roche may ask reasonable questions in relation to the above information and offer advice in relation thereto and Roche shall give due consideration to FMI’s input. The JMC may determine other routes of
information exchange. 
  

	 	6.1.7	Subcommittees and Joint Operational Teams 

 The JMC has the right to establish sub-committees or JOTs. The JRDC
shall be established within thirty (30) days after the JMC is established. The JOC shall be established as soon as the JMC deems it necessary. 
  

	6.2	JRDC 

 The JRDC shall oversee the implementation of the Work Streams and to more generally identify
opportunities for value creation in research and development activities between the Parties. The JDRC shall be composed of an equal number of persons from each Party, each person having appropriate seniority and functional expertise. Each Party may
replace any a person and appoint another person to fill the vacancy arising from each such replacement. The JRDC will strive to reach consensus on any matters within the committee’s authority with each Party having one (1) vote. Unresolved
dispute at the JRDC will be escalated to the JMC. 
  

	 	6.2.1	Responsibilities of the JRDC 

 The JRDC shall have the responsibility and authority to: 

 

	a)	recommend the R&D Plans for approval by the JMC; 

  

	b)	review and recommend for approval any revisions to the R&D Plans; 

  
 ***Confidential Treatment
Requested*** 
 - 33 - 

	c)	review and oversee the execution of the R&D Plans; 

  

	d)	establish timelines and criteria for decision points; 

  

	e)	determine whether criteria have been met, including whether the criteria as to whether milestones or events have been achieved; 

  

	f)	review the efforts of the Parties and allocate those resources for the R&D Plans (including their budgets); 

  

	g)	identify appropriate resources necessary to conduct the R&D Plans; 

  

	h)	oversee the progress of the Work Streams; 

  

	j)	monitor the development costs and manage reimbursement for FMI activities under this Agreement; 

  

	k)	determine for Products and Services Performance Specifications and identify Quality Standards applicable to respective Work Streams; and 

 

	l)	attempt to resolve any disputes. 

 The JRDC shall have no responsibility and authority other than that
expressly set forth in this section. 
  

	6.3	JOC 

 The JOC shall plan and oversee the commercial, co-marketing, educational, and/or promotion
activities between the Parties and to serve as a forum for communicating generally about FMI’s products and strategies for global commercialization, as such activities are further described in the US Education Collaboration Agreement and the
Ex-US Commercialization Agreement. The JOC shall be composed of an equal number of persons from each Party, each person having appropriate seniority and functional expertise. A description of the roles, responsibilities, and workings of the JOC are
described in the Ex-US Commercialization Agreement. Through the JOC, Roche may share with FMI knowledge and experience related to countries and markets outside the United States, and will support the design and implementation of a global expansion
plan for FMI products. The JOC will strive to reach consensus on any matters within the committee’s authority, with each Party having one (1) vote. Unresolved disputes at the JOC will be escalated to the JMC. 

 

	6.4	Alliance Director 

 Each Party shall appoint one person to be the point of contact within each Party with
responsibility for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall be permanent participants of the JMC meetings (but not members of the JMC) and may
attend JDRC, JOC and JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JMC to reach consensus and avert escalation of such issues or potential
disputes. 
  

	6.5	Limitations of Authority 

 No committee, working group or individual shall have the authority to amend or
waive any terms of this Agreement. 

  
 - 34 - 

	6.6	Expenses 

 Each Party shall be responsible for its own expenses including travel and accommodation costs
incurred in connection with the JMC. 
  

	6.7	Lifetime 

 The JMC shall exist during the Agreement Term. 

 

	7.	Regulatory 

 Subject to the Related Agreements, FMI, [...***...], shall use Commercially Reasonable
Efforts to pursue all regulatory affairs related to its products and services developed under this Agreement (collectively, “Products and Services”) in the Territory including the preparation, filing and maintenance of applications
for regulatory approval, as well as any or all governmental approvals required to develop, have developed, make, have made, use, have used, manufacture, have manufactured, import, have imported, sell and have sold such Products and Services. Subject
to the Related Agreements, FMI shall be responsible for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with regulatory agencies, for all Products and Services in all countries in the Territory. Subject to
the Related Agreements, FMI or its Affiliates shall own and file in their discretion all regulatory filings and Regulatory Approvals for all Products and Services in all countries of the Territory. FMI shall supply Roche with a copy of all material
communications related to Products and Services to or from the Regulatory Authorities. Upon request of Roche, FMI shall supply Roche with a copy of all such communications to or from the Regulatory Authorities. 

Subject to the Ex-US Commercialization Agreement, FMI, [...***...], shall report to appropriate Redulatory Authorities in accordance with local
requirements all adverse events related to use of the Products and Services in the Territory. 
  

	8.	Payment 

  

	8.1	FTE Funding 

 Roche will be responsible for funding the FTEs in accordance with the R&D Plans and
budgets at the FTE Rate for performance of the research and other activities for which FMI is responsible under the R&D Plans and for the database queries. Each individual included in the funded FTEs shall possess a bachelor’s degree or
higher in a relevant scientific discipline and shall be experienced in the type of research or other activities to be performed by such individual under this agreement. 
  

	8.2	Molecular Information Platform Program Fees 

  

	 	8.2.1	Sample Profiling Fees 

  

	 	8.2.1.1	Reserved Capacity Fees 

 In consideration for the Reserved Capacity and provision of the Sample Results
associated with the Reserved Capacity, and subject to any reduction resulting from the application of Article 5, Roche shall pay to FMI an amount equal to [...***...] for [...***...] of the Profiling Term [...***...] for the
[...***...] of the Profiling Term (“Reserved Capacity Fees”). The Reserved Capacity Fees are paid as follows: 
 [...***...]
equal installments of [...***...] payable within [...***...] of receipt by Roche of an invoice from FMI, beginning with receipt by Roche of a first invoice from FMI issued following the Effective Date and followed by [...***...]
additional invoices at [...***...] intervals thereafter. 

  
 ***Confidential Treatment
Requested*** 
 - 35 - 

 [...***...] equal installments of [...***...] payable within [...***...] of receipt by Roche of
an invoice from FMI, beginning [...***...] of the Effective Date and followed by [...***...] additional invoices at [...***...] intervals thereafter. 

For renewal terms, the agreed upon Reserved Capacity Fee shall be paid within [...***...] of receipt by Roche of an invoice from FMI at
[...***...] intervals. 
 The Reserved Capacity Fee payments shall be [...***...] against Roche’s Binding Order for such period, the amount
of the Reserved Capacity Fee being [...***...]. Actual Sample Profiling costs, based on delivery of Sample Results during the [...***...] to which the Reserved Capacity Fee applies, shall be [...***...]. If actual Sample Profiling
exceeds the amount of Sample Profiling paid by the Reserved Capacity Fees, then [...***...]. Roche shall pay FMI for [...***...]. If a Binding Order causes Roche to [...***...]. Fees for Binding Orders shall [...***...]. 

 

	 	8.2.1.2	Per Sample Profiling Fees 

 The per Sample Profiling fees (notwithstanding the Reserved Capacity Fee) shall be
as follows: 
 [...***...]. 
  

	 	8.2.2	Molecular Information Database Access and Database Queries Fees 

 For Molecular Information Database Access and
performance of Database Queries by FMI, Roche will pay FMI a total of [...***...] of the Database Term, (the “Database Access Fee”), which is comprised of funding for [...***...] FTEs, each at the FTE Rate, for
performance of such Database Queries and delivery of Database Insights, and a Database Access Fee of [...***...]. Roche shall pay to FMI the Database Access Fee [...***...] installments of [...***...], each payable every
[...***...] of the Database term and within [...***...] after receipt by Roche of an invoice from FMI. 
  

	8.3	Immunotherapy Testing Platform Development Budget and Fees 

  

	 	8.3.1	R&D Plan Budget 

 Roche shall be solely responsible for Roche’s costs under the Immunotherapy Testing
Platform Development Budget. 
 Roche will pay FMI [...***...] of FMI Development Cost as agreed in the Immunotherapy Testing Platform Budget for
development of the Immuno-Biomarker Discovery Platform. 
 Roche will pay [...***...] of FMI Development Cost as agreed in the Immunotherapy Testing
Platform Budget for Signature Identification. 

  
 ***Confidential Treatment
Requested*** 
 - 36 - 

 Such reimbursement of FMI Development Cost shall be paid [...***...] in arrears. Each [...***...],
FMI shall invoice Roche for its share of FMI Development Cost incurred in the previous [...***...]. Invoices shall be payable within [...***...] after receipt by Roche of an invoice from FMI. 

 

	 	8.3.2	Payments for Achieving Certain Immunotherapy Testing Platform Development Events 

 In addition to payment of the
Immunotherapy Testing Platform Development Budget as specified above, Roche shall pay FMI: 
  

	 	(i)	[...***...] on Initiation of the first Roche Clinical Study utilizing a Clinical Study assay, [...***...]. 

  

	 	(ii)	[...***...] on Initiation of the first Roche Clinical Study utilizing a Clinical Study assay, [...***...]. 

  

	 	(iii)	[...***...] on Initiation of the first Roche Clinical Study utilizing a Clinical Study assay, [...***...]. 

  

	 	8.3.3	Immuno Clinical Study Assays requested by Roche 

 Roche will pay [...***...] of FMI’s Development
Costs for development of Immuno Clinical Study Assays as may be requested by Roche, subject to an agreed upon budget for such development as provided for in Section 3.2.5. 
  

	 	8.3.4	Immunotherapy CDx Assays 

 If the Parties chose to develop an Immunotherapy CDx Assay, they the Parties shall
agree to Roche paying certain costs and milestones for such Immunotherapy CDx assay. 
  

	8.4	ctDNA Platform Financial Terms 

 FMI will be responsible for all FMI Development Cost for the ctDNA
Platform Development. As part of the agreed upon ctDNA R&D Plan, FMI will provide sample testing performed under such ctDNA R&D Plan at no cost to Roche (other than Roche’s cost in supplying FMI the Samples specified in the ctDNA
R&D Plan). 
 Roche will pay FMI [...***...] if FMI successfully [...***...] set forth in the R&D Plan (“Initial Roche ctDNA
Assay”) within [...***...] from [...***...] (the “First ctDNA Milestone Date”). Payment by Roche shall be made within [...***...] after achieving the First ctDNA Milestone Date and the receipt by Roche of
an invoice from FMI. 
 In addition, Roche will pay FMI [...***...] if FMI successfully [...***...] as agreed to in the R&D Plan; provided
that [...***...] (the “Second ctDNA Milestone Date”). Payment by Roche shall be made within [...***...] after achieving the Second ctDNA Milestone Date and the receipt by Roche of an invoice from FMI. 

The Parties may develop additional ctDNA Assays for use as Clinical Study assays, subject to an agreed financial structure for such work under the R&D
Plan. Such additional development work will be conducted, if at all, pursuant to an amendment to this Agreement or a separate written agreement between the Parties. 

  
 ***Confidential Treatment
Requested*** 
 - 37 - 

	8.5	CDx Development Financial Terms 

  

	 	8.5.1	CDx Development Costs 

 Roche shall pay FMI [...***...] of FMI Development Cost for CDx Development of
Investigational markers in compliance with the investigational CDx budget that forms part of the R&D Plan. 
 FMI shall pay [...***...] of the FMI
Development Cost for Approved Markers. 
 Such reimbursement of FMI Development Cost shall be paid [...***...] in arrears. Each [...***...], FMI
shall invoice Roche for its share of the FMI Development Cost incurred in the [...***...]. Invoices shall be payable within [...***...] after receipt by Roche of an invoice from FMI. 

 

	 	8.5.2	PMA Event Payments 

 For each PMA approval corresponding to a Roche product, Roche shall pay FMI
[...***...], within [...***...] after the occurrence of such event and receipt by Roche of an invoice from FMI. 
  

	 	8.5.3	Commercial Success Event Payments 

 Roche shall pay FMI the following milestone payments upon achievement of CDx
Assay report volumes by tissue type within the first [...***...] after [...***...] of the associated CDx Assay as specified below: 
  

	 	(i)	CDx Assays Including Investigational/Approved Marker(s) for [...***...]: 

  

	 	 	[...***...]. 

  

	 	(ii)	CDx Assays Including Investigational/Approved Marker(s) for [...***...]: 

  

	 	 	[...***...]. 

 Upon achievement of each of the CDx Assay volumes under this Section 8.5.3, FMI shall
timely notify Roche and payment shall be made by Roche within [...***...] after achieving the applicable event and the receipt by Roche of an invoice from FMI. 

In the event the Parties wish to develop another CDx Assay other than those specified above for [...***...] and [...***...] pursuant to a CDx
R&D Plan, the Parties shall mutually agree to [...***...] milestones and payments for achieving them. 
  

	8.6	General Terms 

 All rates and costs set forth herein shall remain firm for the Agreement Term and the
services to be performed under each Work Stream, unless otherwise agreed to in writing, shall be at the FTE Rate. FMI has an affirmative obligation to use Commercially Reasonable Efforts to negotiate favorable terms for all FMI Development Cost that
will be passed through FMI to Roche. FMI shall extend to Roche the benefit of any and all discounts and savings provided to FMI in connection with FMI Development Cost that will be passed through to Roche. Roche shall [...***...], any amounts
in excess of the agreed upon budget. 

  
 ***Confidential Treatment
Requested*** 
 - 38 - 

	8.7	Disclosure of Payments 

 FMI acknowledges that Roche may be obligated to disclose this financial
arrangement, including all fees, payments and transfers of value, as may be advisable or required under Applicable Law, including the US Sunshine Act. 
  

	9.	Accounting and reporting 

  

	9.1	Timing of Payments 

 Payments shall be made during the time periods set forth in this Agreement. If not
stated explicitly, payments shall be made by Roche within [...***...] after Roche receives an invoice from FMI. 
  

	9.2	Late Payment 

 Any payment under this Agreement that is not paid on or before the date such payment is
due shall bear interest, to the extent permitted by Applicable Law, at [...***...] points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such
payment is overdue. 
  

	9.3	Method of Payment 

 All amounts payable hereunder shall be paid in US dollars (the “Payment
Currency”) to account(s) designated by FMI. 
  

	10.	Taxes 

 FMI shall pay all sales, turnover, income, revenue, value added, and other taxes levied on
account of any payments accruing or made to FMI under this Agreement. 
 If provision is made in law or regulation of any country for withholding of taxes
of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to FMI, then Roche or its relevant Affiliates shall promptly pay such tax, levy or charge for and on behalf of FMI to the proper
governmental authority, and shall promptly furnish FMI with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due FMI or be promptly reimbursed by FMI if no further
payments are due FMI. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount
required to be so withheld or deducted. 

  
 ***Confidential Treatment
Requested*** 
 - 39 - 

 It is understood between the Parties that the agreed upon and/or applied remunerations and other payments under
this Agreement for all transactions between (a) FMI and (b) Roche are based on arm’s length and good faith considerations. Should such remunerations for products and services or other payments nevertheless be challenged by any
Governmental Authority including any tax authority in the US, or in Switzerland or other jurisdiction of Roche or its relevant Affiliates (“Roche’s Jurisdiction”): 

 

	 	(a)	FMI and Roche or its relevant Affiliates shall fully co-operate with each other with the objective to convince the challenging authority that such remunerations for products and services and other payments are
appropriate, including providing each other with copies of third party agreements if necessary to utilize as comparables to support the arm’s length nature of transactions between FMI and Roche. In the event that the challenging authority
is not convinced, the Parties shall request that the tax authorities in the US and in Roche’s Jurisdiction initiate government-to-government procedures pursuant to the applicable bi-lateral convention for the avoidance of double taxation or
similar treaty or convention (if any) between the US and Roche’s Jurisdiction (“Competent Authority Procedures”). 

  

	 	(b)	In the event that the US tax authorities determine that such remunerations for products and services or other payments are not appropriate and levy an assessment on FMI, and such assessment results in a refund (or
similar payment or credit) by or from the tax authorities in Roche’s Jurisdiction to Roche or its relevant Affiliate, then Roche shall pay (or shall ensure that Roche shall pay) the amount of such refund to FMI. In the event that the tax
authorities in Roche’s Jurisdiction determine that such remunerations for products and services or other payments are not appropriate and levy an assessment on Roche, and such assessment results in a refund (or similar payment or credit) by or
from the US tax authorities to FMI then FMI shall pay (or shall ensure that FMI shall pay) the amount of such refund to Roche. Each Party shall use its reasonable efforts to obtain such refund (or similar payment or credit). 

 

	 	(c)	In the event of such an assessment by either tax authority (an “Assessment”), the Parties agree to making adjustments to the relevant remunerations for products and services or other payments to levels
agreed to by the tax authorities in both the US and Roche’s Jurisdiction as the result of Competent Authority Procedures. 

  

	11.	Auditing 

  

	11.1	Right to Audit 

 Each Party shall keep, and shall require its Affiliates and Sublicensees to keep, full,
true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all payments payable under this Agreement, including, for Roche, the right to audit materials necessary to ensure compliance with the
most favored customer provisions of Article 5. Such books of accounts shall be kept at their principal place of business. At the expense of the auditing Party, the auditing Party shall have the right to engage an internationally recognized,
independent public accountant reasonably accept able to the other Party to perform, on behalf of such Party an audit of such books and records of the audited Party and its Affiliates, its licensees and Sublicensees, that are deemed necessary for the
period or periods requested by the auditing Party and the correctness of any financial report or payments made under this Agreement, including with respect to benefits and terms complying with the most favored

  
 - 40 - 

 
customer provisions of Article 5. For avoidance of doubt, all audits under this Section shall be conducted solely by an independent public accountant as described in the foregoing sentence.

 Upon timely request and at least [...***...] prior written notice from the auditing Party, such audit shall be conducted in the countries
specifically requested by the auditing Party, during regular business hours in such a manner as to not unnecessarily interfere with the audited Party’s normal business activities, and shall be limited to results in the [...***...] prior
to audit notification. 
 Such audit shall not be performed more frequently than [...***...] nor more frequently than [...***...] with respect
to records covering, or impacting in accordance with Article 5, any specific period of time. 
 All information, data documents and abstracts herein
referred to shall be used only for the purpose of verifying payment obligations, shall be treated as the audited Party’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than
[...***...] after completion of an audit hereof, if an audit has been requested; nor more than [...***...] from the end of the [...***...] to which each shall pertain; nor more than [...***...] after the date of termination
of this Agreement. 
  

	11.2	Audit Reports 

 The auditors shall only state factual findings in the audit reports and shall not
interpret the agreement. The auditors shall share all draft audit reports with the auditing Party before the draft report is shared with the audited Party and before the final document is issued. The final audit report shall be shared with the
auditing Party at the same time it is shared with the audited Party. 
  

	11.3	Over or Underpayment 

 If the audit reveals an overpayment by Roche, FMI shall reimburse Roche for the
amount of the overpayment within [...***...]. If the audit reveals an underpayment by Roche, Roche shall make up such underpayment with the next payment or, if no further payments are owed by Roche, Roche shall reimburse FMI for the amount of
the underpayment within [...***...]. The audited Party shall pay for the audit costs if the underpayment of the audited Party exceeds [...***...] of the aggregate amount of royalty payments owed with regard to the period subject of the
audit. Section 9.2 shall apply to this Section 11.3. 
  

	11.4	Duration of Audit Rights 

 The failure of a Party to request verification of any calculation within the
period during which corresponding records must be maintained under this Article 11 will be deemed to be acceptance of the payments and reports. 
  

	12.	Intellectual Property 

  

	12.1	Ownership of Inventions, data and results 

  

	 	12.1.1	In General 

 Except as specifically set forth herein, FMI shall own all FMI Inventions, Roche shall own all
Roche Inventions, and FMI and Roche shall jointly own all Joint Inventions. FMI and Roche each shall require all of its employees to assign all inventions related to Products and Services made by them to Roche and FMI, as the case may be. 

  
 ***Confidential Treatment
Requested*** 
 - 41 - 

 The determination of ownership of Inventions shall be determined in accordance with US inventorship laws as if
such Inventions were made in the US. 
 Except as otherwise expressly set forth herein, each Party shall retain full ownership and control of, and all
rights in, its Background IP and any improvements or modifications thereto (“Roche Improvement IP” and “FMI Improvement IP” respectively). Roche Improvement IP shall mean any improvements or modifications to
Roche’s Background IP discovered, conceived or reduced to practice after the Effective Date in the performance of activities under this Agreement. FMI Improvement IP shall mean any improvements or modifications to FMI’s Background IP
discovered, conceived or reduced to practice after the Effective Date in the performance of activities under this Agreement. All materials, information, data and writings provided to FMI by or on behalf of Roche, in any form whatsoever, which were
Controlled by Roche prior to being provided to FMI, shall remain the property of Roche; FMI shall acquire no right, title or interest in such materials, information, data and writings as the result of its activities under this Agreement. 

Except as specifically set forth herein, this Agreement shall not be construed, by implication, necessity or otherwise as (i) giving any of the Parties
any license, right, title, interest in or ownership to the Confidential Information; (ii) granting any license or right under any intellectual property rights; or (iii) representing any commitment by either Party to enter into any
additional agreement. 
  

	 	12.1.2	For the Molecular Information Platform Program 

 Subject to the license granted to FMI under Section 2.1.2,
Roche shall exclusively own all right title and interest to any information, results, and intellectual property from any Clinical Study undertaken or supported by Roche, including, without limitation, the Sample Results and information and results
from any Sample Profiling. FMI shall assign to Roche its rights to any intellectual property in or arising from the Sample Results (except for FMI Improvements). 

Except as otherwise set forth herein, FMI shall exclusively own all right, title, and interest to any improvements or modifications to the FMI Genomic
Analysis Platform that arise in connection with the performance of the work under the Molecular Information Platform Program. 
 Roche shall exclusively own
all information, results, and intellectual property from Advanced Genomic Analyses performed on Roche samples (“Roche-Owned Advanced Genomic Analysis Results”), and any inventions arising from the Roche-Owned Advanced Genomic
Analysis Results, and FMI will assign all rights to any such inventions to Roche (except for FMI Improvements). 
  

	 	12.1.3	For the Immunotherapy Testing Platform Program 

 Subject to the license granted to FMI under Section 2.1.3,
Roche shall exclusively own all data, results, and intellectual property therein arising from profiling samples provided by Roche to FMI for testing in the Immunotherapy Testing Platform Development (except for FMI Improvements) (“Roche
Immunotherapy Sample Results”), and FMI shall assign to Roche all such intellectual property. FMI shall not disclose Roche Immunotherapy Sample Results to third parties or use such results in work with Third Parties. 

  
 - 42 - 

 Roche shall exclusively own, and FMI shall assign to Roche, all intellectual property arising from the
Immunotherapy Testing Platform Development that Covers methods of treatment, stratifying patients, or identifying patients that would benefit from a particular treatment, and all other methods useful in connection with the therapeutic treatment of a
patient. 
 To the extent third-party intellectual property must be licensed for the Immunotherapy Testing Platform Development, Roche and FMI shall jointly
decide on an appropriate in-licensing strategy and negotiate a fair cost sharing between the Parties in good faith; provided however, that FMI shall retain the right to take such a license at its own cost on such terms as it shall determine if the
Parties cannot reach a timely agreement on how to proceed. 
  

	 	12.1.4	For the ctDNA Program 

 Subject to the license granted to FMI under Section 2.1.4, Roche shall exclusively
own all data, results, and intellectual property arising from the profiling of Roche samples in the ctDNA Platform Development Program (“Roche ctDNA Sample Results”). FMI shall not disclose Roche ctDNA Sample Results to third
parties or use such results in work with third parties. 
  

	 	12.1.5	For the CDx Development Program 

 Subject to the license granted to Roche under Section 2.1.5, FMI shall
exclusively own all intellectual property arising from the CDx Development that Covers the CDx Assays (“FMI CDx IP”). 
 Roche shall
exclusively own all data, results, and intellectual property arising from analysis of its samples in the relevant CDx Development as well as all intellectual property arising from the CDx Development Program to the extent that it is reasonably
related to or Covers the relevant Roche product including the use, formulation, and methods of treatment for the relevant Roche product (“Roche CDx Development IP”). 

To the extent third-party intellectual property must be licensed for the Investigational CDx Development or commercialization of the Investigational CDx
Assays, Roche and FMI shall jointly decide on an appropriate in-licensing strategy and negotiate a fair cost sharing between the Parties in good faith. 
  

	12.2	German Statute on Employee’s Inventions 

 In accordance with the German Statute on Employees’
Inventions, each Party agrees to claim the unlimited use of any Invention conceived, reduced to practice, developed, made or created in the performance of, or as a result of, any Research Program by employees of any German Affiliates or any other
persons acting on behalf of such German Affiliates. For the avoidance of doubt, each Party is responsible for fulfilling the obligations towards their employees under the German Statute of Employee’s Inventions. 

 

	12.3	Prosecution and Maintenance of Patent Rights Claiming FMI Inventions 

 FMI shall, at its own expense and
discretion, (i) control and Handle all FMI Foreground Patent Rights, (ii) consult with Roche as to the Handling of such FMI Foreground Patent Rights, and (iii) furnish to Roche copies of all material documents relevant to any such
Handling. FMI shall furnish such documents and consult with Roche in sufficient time before any action by FMI is due to allow Roche to provide comments thereon, which comments FMI must consider. At FMI’s

  
 - 43 - 

 
expense and reasonable request, Roche shall cooperate, in all reasonable ways with the Handling of all FMI Foreground Patent Rights. If FMI elects not to Handle any FMI Foreground Patent Rights
under this Section 12.3, then FMI shall provide at least [...***...] prior written notice to Roche. Thereafter, Roche shall have the right, but not the obligation to Handle any such notified FMI Foreground Patent Rights, at its sole
expense and its sole discretion. Notwithstanding the foregoing, and for clarity, FMI shall have no obligations to Roche under this Section 12.3 in regard to FMI Foreground Patent Rights relating to the Genomic Analysis Platform or the Molecular
Information Database (including, without limitation, methods, procedures, and algorithms related to or embodied in each) that do not incorporate or rely on the continued use of Roche Confidential Information. 

 

	12.4	Prosecution and Maintenance of Roche Foreground Patent Rights and Joint Patent Rights 

 Roche shall, at
its own expense and discretion, control and Handle (including abandon) all Roche Foreground Patent Rights and Joint Patent Rights. If Roche elects not to Handle any Patent Rights under this Section 12.4, then Roche shall provide at least
[...***...] prior written notice to FMI. Thereafter, FMI shall have the right, but not the obligation to Handle any such notified Patent Rights, at its sole expense and its sole discretion. 

 

	12.5	Joint Patent Team 

 Where the Parties need to consult with each other on the Handling of Patent Rights,
the Parties shall establish a joint patent team (“JPT”) and shall adopt procedures for interacting on patent matters. The JPT shall be subject to the oversight of the JMC. The JPT shall also serve as a forum for promptly notifying
the other Party when an Invention is made by a Party. 
  

	12.6	CREATE Act 

 It is the intention of the Parties that this Agreement is a “joint research
agreement” as that phrase is defined in Public Law 108-53 (“Create Act”) and applied in 35 USC §103(c)(3). If either Party intends to overcome a rejection of a claimed invention within the FMI Foreground Patent Rights or
Roche Foreground Patent Rights pursuant to the provisions of the Create Act, then the Parties, through the JPT, shall work together in good faith to agree in writing how any rejection should be overcome. 

 

	12.7	Infringement 

 Each Party shall promptly provide written notice to the other Party during the Agreement
Term of any (i) known infringement or suspected infringement by a Third Party of any FMI Background Patent Rights, FMI Foreground Patent Rights, Roche Background Patent Rights, Roche Foreground Patent Rights or Joint Patent Rights, or
(ii) known or suspected unauthorized use or misappropriation by a Third Party of any FMI Background Know-How, FMI Know-How, Roche Background Know-How, Roche Know-How or Joint Know-How, and shall provide the other Party with all evidence in its
possession supporting such infringement or unauthorized use or misappropriation. 
 Within [...***...] after a Party provides or receives such written
notice (“Decision Period”), the Party Handling enforcement of such Patent Right as set forth in this Section 2.7, in its sole discretion, shall decide whether or not to initiate such suit or action in the Territory and shall
notify the other Party in writing of its decision in writing (“Suit Notice”). 

  
 ***Confidential Treatment
Requested*** 
 - 44 - 

 For any FMI Background Patent Right or sole FMI Patent Right, FMI in its sole discretion shall decide whether or
not to initiate such suit or action in the Territory. FMI shall have full discretion as to how it wishes to handle such suit and may reach Settlement under any terms and conditions it desires and retain all damages, settlement fees or other
consideration received in connection therewith. Only if a Settlement could adversely affect Roche shall the written consent of Roche be required, which consent shall not be unreasonably withheld. The term “adversely affect” in the previous
sentence shall include, among other things, [...***...]. 
 For any sole Roche Background Patent Right or Roche Patent Right, Roche, in its sole
discretion, shall decide whether or not to initiate such suit or action in the Territory. Roche shall have full discretion as to how it wishes to handle such suit and may reach Settlement under any terms and conditions it desires and retain all
damages, settlement fees or other consideration received in connection therewith. Only if a Settlement could adversely affect FMI shall the written consent of FMI be required, which consent shall not be unreasonably withheld. 

If for a Joint Patent Right, Roche decides to bring a suit or take action, once Roche provides Suit Notice, Roche may immediately commence such suit or take
such action. In the event that Roche (i) does not in writing advise FMI within the Decision Period that Roche will commence suit or take action, or (ii) fails to commence suit or take action within a reasonable time after providing Suit
Notice, FMI shall thereafter have the right to commence suit or take action in the Territory and shall provide written notice Roche of any such suit commenced or action taken by FMI. 

Upon written request, the Party bringing suit or taking action (“Initiating Party”) shall keep the other Party informed of the status of any
such suit or action and shall provide the other Party with copies, to the extent the Initiating Party is lawfully permitted to do so, of all material documents or communications filed in such suit or action. The Initiating Party shall have the sole
and exclusive right to select counsel for any such suit or action. 
 The Initiating Party shall, except as provided below, pay all expenses of the suit or
action, including the Initiating Party’s attorneys’ fees and court costs. Any damages, settlement fees or other consideration received as a result of such suit or action shall be allocated as follows: 

 

	(a)	First, to reimburse the Initiating Party for its costs and, if any remains, to the other Party for any advisory counsel fees and costs; and 

 

	(b)	Second, the balance, if any, shall be allocated [...***...]. 

 If the Initiating Party believes it is
reasonably necessary or desirable to obtain an effective remedy, upon written request the other Party agrees to be joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation
is required as the result of its being a named party to the suit or action. At the Initiating Party’s written request, the other Party shall offer reasonable assistance to the Initiating Party in connection therewith at no charge to the
Initiating Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other Party in rendering such assistance. The other Party shall have the right to participate and be represented in any such suit or action by its own
counsel at its own expense. 
 The Initiating Party may settle, consent judgment or otherwise voluntarily dispose of the suit or action
(“Settlement”) without the written consent of the other Party but only if such Settlement can be achieved without adversely affecting the other Party (including any of its Patent Rights). If a Settlement could adversely affect the
other Party, then the written consent of the other Party would be required, which consent shall not be unreasonably withheld. 

  
 ***Confidential Treatment
Requested*** 
 - 45 - 

	12.8	Defense 

 If an action for infringement is commenced against either Party, its licensees or its
sublicensees related to such Party’s conduct of a Work Stream within the scope of an R&D Plan then such Party shall defend such action at its own expense, and the other Party shall assist and cooperate with such Party, at its own expense,
to the extent necessary in the defense of such suit. The defending Party shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion, so long as such settlement or adverse judgment does not adversely
affect the rights of the other Party and its Affiliates (including any patent rights Controlled by any of them). The defending Party shall assume full responsibility for the payment of any award for damages, or any amount due pursuant to any
settlement entered into by it with such Third Party. 
 If the manufacture, use, importation, offer for sale or sale of any Products and Services results in
any claim, suit or proceeding alleging patent infringement or trade secret misappropriation against FMI or a member of the Roche Group, then such Party shall promptly notify the other Party hereto. The Parties shall cooperate with each other in
connection with any such claim, suit or proceeding and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding. 

If a Third Party asserts that Patent Rights owned by or licensed to it are infringed by the development, manufacture, use, importation, offer for sale or sale
of products arising out of this Agreement by a member of the Roche Group, or that its trade secrets were misappropriated in connection with such activity, then Roche shall have the exclusive right and responsibility to resolve any such claim,
whether by obtaining a license from such Third Party, by defending against such Third Party’s claims or otherwise, and shall be solely responsible for the defense of any such action, any and all costs incurred in connection with such action
(including, without limitation, attorneys’ and expert fees) and all liabilities incurred in connection therewith. Notwithstanding the above, Roche shall not enter into any settlement of any such claim without the prior written consent of FMI if
such settlement would require FMI to be subject to an injunction or to make any monetary payment to Roche or any Third Party, or admit any wrongful conduct by FMI or its Affiliates, or would limit or restrict the claims of or admit any invalidity
and/or unenforceability of any of the Patent Rights Controlled by FMI, or have any impact on activities outside the Field. 
  

	12.9	Common Interest Disclosures 

 With regard to any information or opinions disclosed pursuant to this
Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property
rights may affect the conduct of the Work Streams and/or Products and Services, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual
property rights relating to the conduct of the Work Streams and/or Products and Services. Accordingly, the Parties agree that all such information and materials obtained by FMI and Roche from each other will be used solely for purposes of the
Parties’ common legal interests with respect to the conduct of the Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or

  
 - 46 - 

 
immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared
information and materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the
conduct of one Party be deemed to apply against any other Party. 
  

	13.	Representations and Warranties 

  

	13.1	Mutual Representations and Warranties 

 FMI and Roche each represent and warrant that: 

(a) it has all requisite power and authority to enter into and perform its obligations under this Agreement; 

(b) it has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement or that would preclude its personnel from
complying with the provisions hereof; 
 (c) all of its employees, officers and consultants have executed agreements requiring assignment to it of all
Inventions made by such individuals during the course of and as a result of their participation in activities under this Agreement; 
 (d) the execution,
delivery and performance of this Agreement by it and all instruments and documents to be delivered by it hereunder: (i) are within its corporate power; (ii) have been duly authorized by all necessary or proper corporate action;
(iii) are not in contravention of any provision of any of its formation or governing documents; (iv) to its knowledge, will not violate any law or regulation or any order or decree of any court of governmental instrumentality;
(v) will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which it is a party or by which it or any of its property is bound, which violation would have an adverse effect on its financial
condition or on its ability to perform its obligations hereunder; and (vi) do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or
obtained previously (other than approvals required under the HSR Act, Regulatory Approvals required for the sale of Products and filings with Regulatory Authorities required in connection with Products); 

(e) there are no claims or investigations (other than with respect to the Parties’ HSR filings), pending or threatened against it or any of its
Affiliates, at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect its ability to perform its obligations hereunder; and 

(f) neither it nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of
this Agreement or that would impede the fulfillment of its obligations hereunder. 

  
 - 47 - 

	13.2	Activities 

 Each Party will perform all activities under this Agreement (i) in a professional
manner, (ii) in conformance with the level or care and skill ordinarily exercised by other professional institutions in similar circumstances, and (iii) in compliance with Applicable Law. 

 

	13.3	Safety Data 

 FMI represents and warrants that FMI has disclosed to Roche and will immediately continue
to disclose to Roche any relevant safety data relevant to the Work Streams and assays being developed thereunder. 
  

	13.4	Third Party Patent Rights 

 FMI represents and warrants that FMI has no knowledge of the existence of any
patent or patent application owned by or licensed to any Third Party that could prevent in the Territory the activities contemplated under this Agreement. 
  

	13.5	Inventors 

 FMI represents and warrants that FMI has obtained the assignment of, or a license under, the
FMI Background Patent Rights necessary to grant the licenses granted hereunder. FMI shall obtain the assignment of, or a license under, the FMI Foreground Patent Rights necessary to grant the licenses granted hereunder. 

 

	13.6	Grants 

 FMI represents and warrants that, to the best of FMI’s knowledge and belief, FMI has the
lawful right to grant Roche and its Affiliates the rights and licenses described in this Agreement. 
  

	13.7	Ownership and Validity of Know-How 

 FMI represents and warrants that FMI’s Know-How is legitimately
in the possession of FMI and has not been misappropriated from any Third Party. FMI has taken reasonable measures to protect the confidentiality of its Know-How. 
  

	13.8	Data Protection (Privacy) and Security. 

  

	 	13.8.1	Study Data Collection 

 FMI shall collect and process Study Data in accordance with the provisions of this
Agreement and in compliance with Applicable Law with respect to the processing of Study Data, including but not limited to applicable international, US federal, state and local data protection and data security laws. 

 

	 	13.8.2	Data Protection 

 To ensure the privacy and security of the health or medical data, including Study Data or
other Personal Data related to this Agreement that FMI shall create, acquire, receive, maintain, or transmit as a result of entering into the Agreement, FMI shall implement adequate and reasonable safeguards to prevent the use or disclosure of such
information other than as provided for in the Agreement, and to protect the confidentiality, integrity, and availability of such information. In addition, FMI shall protect all such data, in accordance with applicable international Data Protection
laws and US federal and state laws and regulations. 

  
 - 48 - 

	 	13.8.3	Privacy 

 FMI understands and agrees that the confidentiality, privacy and security requirements contained in
this Agreement also apply to any permitted sub-contractors, temporary employees or other third-parties who receive any health or medical data, including Study Data, or other Personal Data, as a result of this Agreement. FMI will ensure that all of
these parties enter substantially similar confidentiality, privacy and security agreements with Institution. Copies of such Agreements shall be provided to Roche within seven (7) business days upon written request of Roche. 

 

	 	13.8.4	Training 

 FMI shall also ensure that its own employees, as well as any permitted subcontractors, temporary
employees or other Third Parties who assist FMI in performing activities under the Agreement, and who have access to any health or medical data, including Study Data or other Personal Data, as a result of this Agreement receive appropriate privacy
and security training, which shall be updated periodically in accordance with applicable laws, regulations, and industry standard, or as otherwise reasonably requested by Roche. 

 

	 	13.8.5	Processing of Study Data 

 FMI, its Affiliates and agents shall not collect or process health or medical data,
including Study Data or any other Personal Data related to this Agreement, in a manner that involves the transfer of such Personal Data from one jurisdiction to any other jurisdiction (the EEA constituting a single jurisdiction for this purpose),
without prior written consent of Roche. 
  

	 	13.8.6	Compliance 

 FMI undertakes to comply with its obligations (if any) under applicable legislation to notify any
supervisory authority of its collection and processing activities under this Agreement and further agrees to take all such steps as Roche may reasonably require from time to time in order to enable Roche to comply with any notification obligation
applicable to Roche. 
  

	 	13.8.7	Data Collection 

 FMI will ensure that it does not collect any health or medical data, including Study Data,
relating to individuals other than the categories of data specified in the protocol identified in the applicable Task Order and will collect and process Study Data for the sole purpose of the study identified in the applicable Task Order and not
further process such data in any other manner. 
  

	 	13.8.8	Disclosure 

 FMI will not disclose health or medical data, including Study Data or any other Personal Data
related to this Agreement to any Third Party outside of the requirements of this Agreement without the prior permission in writing of Roche, except where such disclosure is required by any applicable law, regulation or supervisory authority, in
which case the Institution will, wherever possible, notify Roche prior to complying with any such request for disclosure and shall comply with all reasonable directions of Roche with respect to such disclosure. 

  
 - 49 - 

	 	13.8.9	Document Retention 

 FMI will have appropriate procedures in place for the destruction or purging of any medical
or health data, including Study Data and any other Personal Data, related to this Agreement when the retention time that applies to the data has been reached. 
  

	 	13.8.10	Procedures 

 FMI shall ensure that it has appropriate procedures in place to fulfill applicable International
Data Protection laws and US federal and state or other legal requirements, should an individual request access to or changes to the health or medical data, including Study Data or any Personal Data related to this Agreement, maintained by
Institution. Institution will notify Roche promptly (and in any event within [...***...] after receipt) of any communication received from a Data Subject relating to the Data Subject a right to access, modify or correct Study Data and to
comply with all instructions of Roche in responding to such communications. 
  

	 	13.8.11	Survival 

 FMI’s obligations to maintain privacy and security over medical or health data, including Study
Data and other Personal Data received pursuant to this Agreement, will survive the termination or expiration of this Agreement. 
  

	 	13.8.12	Security Breach 

 At any time during the processing of Persona Data, FMI shall notify Roche immediately (but no
later than [...***...] from the date) of any Data Security Breach involving Roche data. FMI shall assist and cooperate with Roche concerning any disclosures to affected parties, government or regulatory agencies and with any other remedial
measures requested by Roche or mandated by Applicable Law. 
  

	13.9	No Other Representations 

 EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT AND THE RELATED AGREEMENTS
BEING ENTERED INTO BY THE PARTIES AT THIS TIME, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OF PRODUCTS. IN NO EVENT SHALL EITHER FMI OR ROCHE BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY. 

 

	14.	Indemnification 

  

	14.1	Indemnification by Roche 

 Roche shall indemnify, hold harmless and defend FMI and its directors,
officers, employees and agents from and against any and all losses, expenses, cost of defense (including without 

  
 ***Confidential Treatment
Requested*** 
 - 50 - 

 
limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts FMI becomes legally obligated to pay because of any claim or claims
against it to the extent that such claim or claims arise out of Roche’s and its Affiliates’ actions or inactions in connection with activities under this Agreement, except to the extent such losses, expenses, costs and amounts are due to
the gross negligence or willful misconduct or failure to act of FMI. 
  

	14.2	Indemnification by FMI 

 FMI shall indemnify, hold harmless and defend Roche and its directors, officers,
employees and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Roche becomes legally
obligated to pay because of any claim or claims against it to the extent that such claim or claims arise out of FMI’s and FMI’s Affiliates’ actions or inactions in connection with activities under this Agreement, except to the extent
that such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of Roche. 
  

	14.3	Procedure 

 In the event of a claim by a Third Party against a Party entitled to indemnification under
this Agreement (“Indemnified Party”), the Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and solely manage and
control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its
choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such
settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 
  

	15.	Liability 

 THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND
WARRANTIES NOT EXPRESSLY SET FORTH HEREIN. FMI AND ROCHE DISCLAIM ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER
THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. 

 

	16.	Obligation Not to Disclose Confidential Information 

  

	16.1	Non-Use and Non-Disclosure 

 During the Agreement Term and for [...***...] thereafter, a Receiving
Party shall (i) treat Confidential Information provided by Disclosing Party as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information

  
 ***Confidential Treatment
Requested*** 
 - 51 - 

 
to Third Parties, without the Disclosing Party’s prior written consent, and (iii) not use such Confidential Information other than for fulfilling its obligations or exercising its
rights under this Agreement. If any Confidential Information is required to be disclosed by the Receiving Party or its Affiliates to comply with a court or administrative order, the Receiving Party or its Affiliates, prior to making such disclosure,
shall furnish as much notice as is reasonable under the circumstances to the Disclosing Party to enable it to resist such disclosure. 
  

	16.2	Permitted Disclosure 

 Notwithstanding the obligation of non-use and non-disclosure set forth in
Section 16.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations. 

 

	16.3	Press Releases 

 Following the Effective Date, the Parties will issue a joint press release announcing
the existence and selected key terms of this Agreement, in a form substantially similar to the template attached as Appendix 16.3. 
 Each Party shall
provide the other with a copy of any draft press release related to the activities contemplated by this Agreement at least ten (10) Business Days prior to its intended publication for such other Party’s review. The reviewing Party may
provide the releasing Party with suggested modification to the draft press release. The releasing Party shall consider, and shall not unreasonably disregard, the reviewing Party’s suggestions in issuing its press release. Notwithstanding the
foregoing, each Party must comply with its obligations under Section 16.1 and 16.5. 
  

	16.4	Publications 

 During the Agreement Term, the following restrictions shall apply with respect to
disclosure by any Party of Confidential Information in any publication or presentation. A Party (“Publishing Party”) shall provide the other Party with a copy of any proposed publication or presentation at least [...***...]
prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential Information disclosed by the other Party to the
Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies (“Publishing Notice”) the Publishing Party in
writing, within [...***...] after receipt of the copy of the proposed publication or presentation, that such publication or presentation in its reasonable judgment (i) contains an invention, solely or jointly conceived and/or reduced to
practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (ii) could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other
Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely
preparation and filing of a patent application(s) on such invention, and in no event less than [...***...] from the date of the Publishing Notice. 

  
 ***Confidential Treatment
Requested*** 
 - 52 - 

	16.5	Commercial Considerations 

 Nothing in this Agreement shall prevent a Party or its Affiliates from
disclosing Confidential Information of the other Party to (i) governmental agencies to the extent required or desirable to secure government approval for the development, manufacture or sale of a product in the Territory and (ii) Third
Parties acting on behalf of a Party, to the extent reasonably necessary to conduct the activities contemplated by this Agreement provided that such Third Parties are bound by confidentiality obligations with respect to such information that are no
less stringent than those included in this Agreement. 
  

	17.	Term and Termination 

  

	17.1	Commencement and Term 

 This Agreement shall commence upon the Effective Date and continue for the
Agreement Term. 
  

	17.2	Termination 

  

	 	17.2.1	Termination for Breach 

 A Party (“Non-Breaching Party”) shall have the right to
terminate this Agreement on a Work Stream-by-Work Stream basis, or, for Roche, on an Approved Marker or Investigational Marker basis in the case of the CDx Development Program, in the event the other Party (“Breaching Party”) is in
material breach of any of its material obligations under the applicable Work Stream (or obligations pertaining to an Approved Marker or Investigational Marker program). Failure of FMI to comply materially with Performance Specifications or Quality
Standards shall be considered a material breach by FMI. For avoidance of doubt, a Non-Breaching Party shall only be permitted to terminate the Work Stream (or Approved Marker or Investigational Marker program) to which a material breach of a
material obligation relates. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach. Except in the event of a breach that, by its nature, is not amenable to cure, in which case termination
may be made effective immediately, the Breaching Party shall have a period of [...***...] after such written notice is provided (“Peremptory Notice Period”) to cure such breach or, absent withdrawal of the Non-Breaching
Party’s request for termination, the relevant Work Stream (or Approved Marker or Investigational Marker program) shall terminate; provided that, if the Breaching Party has a bona fide dispute as to whether such breach: (i) occurred,
(ii) pertains to a material obligation, or (iii) has been cured, the Breaching Party will so notify the Non-Breaching Party, the relevant Work Stream (or Approved Marker or Investigational Marker program) shall not terminate and the
expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section 19.2. If such dispute is resolved by finding that the Non-Breaching Party is entitled to terminate the relevant Work Stream (or
Approved Marker or Investigational Marker program), the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the
Non-Breaching Party’s request for termination, the relevant Work Stream (or Approved Marker or Investigational Marker program) shall terminate in accordance with the notice from the Non-Breaching Party as of the expiration of the Peremptory
Notice Period. 
  

	 	17.2.2	Insolvency 

 A Party shall have the right to terminate this Agreement, if the other Party incurs an
Insolvency Event; provided, however, in the case of any involuntary bankruptcy proceeding, such right to 

  
 ***Confidential Treatment
Requested*** 
 - 53 - 

 
terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed within [...***...] after the
filing thereof. 
  

	 	17.2.3	Termination by Roche without Cause 

 Roche shall have the right to terminate the Agreement in its
entirety, or on a Work Stream-by-Work Stream basis, except for the ctDNA Work Stream, upon [...***...] prior written notice, without cause. With regard to the CDx Development Program, Roche shall also have the right to terminate, without
cause, the development of an Approved Marker and/or an Investigational Marker for inclusion in a CDx Assay, upon [...***...] prior written notice; provided however that this right shall expire with respect to each Approved Marker for inclusion
in a particular CDx Assay at such time as FMI has completed analytical validation for such Approved Marker. With regard to the Molecular Information Platform Program, Roche shall have the right to terminate without cause either or both of the Sample
Profiling or Molecular Information Database Access activities individually. 
  

	 	17.2.4	Termination by Roche for Frustration of Purpose 

 Roche shall have the right to terminate the ctDNA
Platform Development Program upon [...***...] prior written notice for frustration of purpose in the event that the Clinical Study for which the ctDNA Assay is being developed is canceled. 

 

	17.3	Consequences of Termination 

  

	 	17.3.1	Termination in General 

 Upon any termination of the Agreement, a Work Stream (or Approved Marker or
Investigational Marker program), or this Agreement under Section 17.2.2, (i) FMI shall promptly return to Roche unused or remaining Samples that were provided for use in a terminated Work Stream (or related to the relevant Approved Marker
or Investigational Marker), or, at Roche’s option, securely dispose of all such unused or remaining Samples and provide Roche with a written notice of such disposal, (ii) each Party shall wind-down their activities under the Agreement in a
manner that is intended to be expeditious and to mitigate losses arising from non-cancellable expenses and financial commitments to Third Parties, (iii) upon any termination by Roche under Section 17.2.3, or by FMI under
Section 17.2.1 or Section 17.2.2, that includes the Immunotherapy Testing Platform Development Work Stream, the obligations in Section 3.2.8 shall terminate, (iv) each Party shall continue to Control its own intellectual
property, including Patent Rights and Know-How, and Handle its own Patent Rights, and (v) Joint Patent Rights, if any, shall be handled by Roche subject to the provisions of Section 12.4 and 12.6, and each Party shall have the right to
fully exploit such Joint Patent Rights. 
 17.3.2 Termination by FMI for Breach by Roche or Roche’s Insolvency; Termination by
Roche Without Cause or for Frustration of Purpose 
 Upon any termination by FMI for breach by Roche under Section 17.2.1, for Roche’s Insolvency
under Section 17.2.2, by Roche without cause under Section 17.2.3, or by Roche for frustration of purpose under Section 17.2.4: 
  

	 	(i)	The rights and licenses granted by FMI to Roche hereunder shall terminate for the terminated Agreement, or Work Stream, or portion of the Work Stream (as applicable, the “Terminated Matter”), on the
effective date of termination; 

  
 ***Confidential Treatment
Requested*** 
 - 54 - 

	 	(ii)	All licenses granted by Roche to FMI hereunder pertaining to the Terminated Matter become fully paid up, perpetual and irrevocable; 

  

	 	(iii)	Roche shall retain all licenses granted by FMI to Roche pertaining to intellectual property arising from work on the Terminated Matter prior to termination, provided, however, FMI shall be under no obligation to Handle
any patent or patent application arising from Terminated Matters and may freely abandon (without offering Roche the right to Handle) or license (but, for clarity, not exclusively license or assign without Roche’s consent if Roche retains
license rights) such patent or patent application. 

  

	 	(iv)	Within [...***...] after the effective date of termination and receipt by Roche of an invoice from FMI, Roche shall pay to FMI the following amounts: 

 

	 	a.	In the event of termination of the Molecular Information Platform Program Work Stream, Roche shall pay FMI all [...***...] that would be owed over the remainder of the Agreement Term, or any [...***...],
plus any applicable incremental per Sample Profiling Fees for Sample Profiling performed by FMI during the year in which termination occurs that are [...***...]; 

 

	 	b.	In the event of termination of the Immunotherapy Testing Platform Development Work Stream, (1) for avoidance of doubt, Roche shall pay FMI Roche’s share of any FMI Development Costs incurred in connection with
the Immunotherapy Testing Platform Development Work Stream as of the effective date of termination that were not previously paid by Roche; (2) (A) if the effective date of termination occurs prior to FMI’s completion of the
Immuno-Biomarker Discovery Platform, then Roche will pay FMI for the entirety of the FMI Development Costs FMI incurred in connection with FMI’s performance of the Immunotherapy Testing Platform Development Work Stream, excluding any portion
that was previously paid by Roche, or (B) if the effective date of termination occurs after FMI’s commencement of Signature Identification services, then Roche will pay FMI for the entirety of the FMI Development Costs FMI incurred prior
to the effective date of termination in connection with any ongoing performance of Signature Identification work by FMI, excluding any portion of such FMI Development Costs that was previously paid by Roche or that is payable by Roche under the
foregoing clause (1); and (3) Roche shall pay FMI in accordance with Section 8.3.2 with respect to signatures developed by FMI prior to the effective date of termination. 

 

	 	c.	In the event of termination of the ctDNA Platform Development Program Work Stream, Roche shall have no contractual payment obligation under this Section 17.3.2; provided, however, that Roche shall be obligated to
honor payment obligations triggered prior to the effective date of termination; 

  

	 	d.	 In the event of termination of the CDx Development Program Work Stream: for avoidance of doubt, Roche shall pay any FMI Development Costs in
connection with the development of an Investigational Marker as specified by Section 8.5.1 incurred as of the effective date of termination that were not previously paid by Roche and any non-cancellable commitments reasonably incurred by FMI in

  
 ***Confidential Treatment
Requested*** 
 - 55 - 

	 	
anticipation of receiving PMA with regard to any Investigational Marker to the extent not re-allocable to FMI’s other business activities, including without limitation, all accrued amounts
under any individual CDx R&D Plan entered into by the Parties as described in Section 3.4.8 above; (ii) if the effective date of such termination is after FMI has completed analytical validation of any Investigational Marker for
inclusion in a CDx Assay, then Roche shall remain obligated to pay a fee for each such terminated Investigational Marker equal to [...***...] upon PMA approval; and (iii) the milestone payments specified under Section 8.5.3 shall
apply with respect to CDx Assays containing any Approved Marker and/or Investigational Marker; and 

  

	 	e.	In the event of termination of the Agreement in its entirety under 17.2.2, Roche shall pay to FMI all amounts under the foregoing subsections (a) through (d) (inclusive) as applicable, if such fees become
payable. 

  

	 	(v)	FMI shall retain all rights and remedies available to it under law and equity in connection with breach by Roche under Section 17.2.1 or other termination under Section 17.2.2, Section 17.2.3, or 17.2.4,
provided, however, that in the case of termination of the Molecular Information Platform Program under Section 17.2.1 or Section 17.2.3 above, FMI’s exclusive remedy (other than for breach of confidentiality under Section 16.1)
shall be the accelerated payments specified under Section 17.3.2(iv)a. 

 For avoidance of doubt, in the event FMI terminates the
Agreement in its entirety due to Roche’s Insolvency, all Work Streams and other activities under the Agreement will be deemed to be terminated and all of the applicable effects of termination in this Section 17.3.2 shall apply. 

 

	 	17.3.3	Termination by Roche for Breach by FMI or FMI Insolvency 

 Upon any termination by Roche for breach by
FMI under Section 17.2.1 or FMI’s Insolvency, under Section 17.2.2: 
  

	 	(i)	The rights and licenses granted by Roche to FMI under Section 2.1 shall terminate for each terminated Work Stream, on the effective date of termination, except that the rights granted to FMI under
Section 2.1.2 shall survive such termination; 

  

	 	(ii)	All licenses granted by FMI to Roche hereunder pertaining to a terminated Work Stream become fully paid up, perpetual and irrevocable; 

 

	 	(iii)	The [...***...] under Section 3.2.10 shall survive termination of the Immunotherapy Testing Platform Development Work Stream; 

 

	 	(iv)	The [...***...] under Section 3.3.9 shall survive termination of the ctDNA Platform Development Program Work Stream; 

  

	 	(v)	Within [...***...] after the effective date of termination and receipt by Roche of an accounting from FMI, FMI shall pay to Roche any unused Reserved Capacity Fees and Database Access Fees previously paid pursuant
to Section 8.2.1.1 or any other unused and pre-paid amounts; 

  
 ***Confidential Treatment
Requested*** 
 - 56 - 

	 	(vi)	FMI shall transfer to Roche all FMI Know-How, other than FMI Know-How pertaining to the Molecular Information Platform Program, necessary for Roche to practice the Terminated Matter, solely for the purposes or
practicing the Terminated Matter, including any necessary algorithms; and 

  

	 	(vii)	Roche shall retain all rights and remedies available to it under law and equity in connection with such breach by FMI. 

For avoidance of doubt, in the event Roche terminates the Agreement in its entirety due to FMI’s Insolvency, all Work Streams and other activities under
the Agreement will be deemed to be terminated and all of the applicable effects of termination in this Section 17.3.3 shall apply. 
  

	 	17.3.4	Direct License 

 Irrespective of anything to the contrary in this Agreement, any existing, permitted
sublicense granted by a Party under this Agreement (and any further sublicenses thereunder) shall, upon a termination of the license granted hereunder that pertains to such sublicense, shall terminate; provided that if the licensee Party so requests
in writing, the licensor Party shall negotiate with the relevant sublicensee towards the grant of a direct license of rights, provided that such sublicensee is not then in breach of its sublicense agreement with the licensee Party. 

 

	17.4	Other Obligations 

 Termination of this Agreement by a Party, for any reason, shall not release Roche
from any obligation to make payments to FMI that are due and payable prior to the effective date of termination. Termination of this Agreement by a Party, for any reason, will release Roche from any obligation to any payments to FMI that would
otherwise become due or payable on or after the effective date of termination. 
  

	17.5	Survival 

 In addition to any provisions that expressly survive in accordance with Article 17.3, Article
1 (Definitions, to the extent necessary to interpret the Agreement), Section 3.5.2 (Sample Handling and Disposal, to the extent applicable), Section 10 (Taxes), Section 12.1 (Ownership of Inventions), Section 12.9 (Common Interest
Disclosures), Section 13.8.11 (Survival of Privacy and Security Obligations), Article 14 (Indemnification), Article 16 (Obligation Not to Disclose Confidential Information), Section 17.3 (Consequences of Termination), Section 17.5 (Surival), Section
19.1 (Governing Law), and Section 19.3 (Arbitration) shall survive any expiration or termination of this Agreement for any reason. Notwithstanding the foregoing, any provision of this Agreement that is intended by its very nature to survive
expiration or termination of this Agreement shall also survive. 
  

	18.	Bankruptcy 

 All licenses (and to the extent applicable rights) granted under or pursuant to this
Agreement by FMI to Roche are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under
Section 101(35A) of the Bankruptcy Code. Unless Roche elects to terminate this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and
elections under the Bankruptcy Code, subject to the continued performance of its obligations under this Agreement. 

  
 - 57 - 

	19.	Miscellaneous 

  

	19.1	Governing Law 

 This Agreement shall be governed by and construed in accordance with the laws of New
York, US, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

 

	19.2	Disputes 

 Unless otherwise set forth in this Agreement, in the event of any dispute in connection with
this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows:

  

			
	For FMI:		CEO
	For Roche:		Head of Roche Partnering

  

	19.3	Arbitration 

 Should the Parties fail to agree within [...***...] after such dispute has first
arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association (“AAA”) as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators.
The place of arbitration shall be New York, New York, US. The language to be used shall be English. 
  

	 	19.3.1	Arbitrators 

 Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the
request for arbitration within [...***...] of being requested to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within [...***...] of being requested to do so, the other
Party shall request the AAA to make such appointment. 
 The arbitrators nominated by the Parties shall, within [...***...] from the appointment of
the arbitrator nominated in the answer to the request for arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the Arbitral Tribunal. Should such procedure not result in an
appointment within the [...***...] time limit, either Party shall be free to request the AAA to appoint the third arbitrator. 
 Where there is more
than one claimant and/or more than one respondent, the multiple claimants or respondents shall jointly appoint one arbitrator. 
 Any Party-appointed
arbitrator or the third arbitrator resigns or ceases to be able to act, a replacement shall be appointed in accordance with the arrangements provided for in this clause. 

The language of the arbitration shall be English. Documents submitted in the arbitration (the originals of which are not in English) shall be submitted
together with an English translation. 
  

	 	19.3.2	Decisions; Timing of Decisions 

 The arbitrators shall render a written opinion setting forth findings of fact
and conclusions of law with the reason therefor stated, within no later than [...***...] from the date on which the arbitrators were appointed to the dispute. A transcript of the evidence adduced at the arbitration hearing shall be made and,
upon request, shall be made available to each Party. 

  
 ***Confidential Treatment
Requested*** 
 - 58 - 

 The time periods set forth in the AAA Arbitration Rules shall be followed; provided however that the arbitrators
may modify such time periods as reasonably necessary to render a written opinion in accordance with this Section 19.3.2. 
 The Arbitrator is empowered
to award any remedy allowed by law, including money damages, prejudgment interest and attorneys’ fees, and to grant final, complete, interim, or interlocutory relief, including injunctive relief. 

This arbitration agreement does not preclude either Party seeking conservatory or interim measures from any court of competent jurisdiction including, without
limitation, the courts having jurisdiction by reason of either Party’s domicile. Conservatory or interim measures sought by either Party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim
measures. Conservatory or interim measures sought by either Party before the Arbitral Tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim measures. 

In the event that any issue shall arise which is not clearly provided for in this Section 19.3, the matter shall be resolved in accordance with the AAA
Arbitration Rules. 
 Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard
each Party’s Confidential Information. Except as required by law, neither Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written
consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise
required by Applicable Law. 
 Notwithstanding anything to the contrary in this Agreement, any and all issues regarding the scope, construction, validity
and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent Rights in question. 

Notwithstanding anything to the contrary in this Agreement, any and all issues regarding a breach or alleged breach of a Party’s obligations under
Article 16 (Obligation Not to Disclose Confidential Information) shall be determined in a court of competent jurisdiction under the laws of New York, with express exclusion of its conflict of laws principles. 

 

	19.4	Assignment 

 Neither Party shall have the right to assign the present Agreement or any part thereof to
any Third Party other than Affiliates without the prior written approval of the other Party. 
  

	19.5	Debarment and Exclusion 

  

	 	19.5.1	Past Activities 

 Each Party represents and warrants that it has never been debarred under 21 U.S.C. §335a,
disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care 

  
 - 59 - 

 
Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared
ineligible from any other similar Federal or state agency or program. In the event a Party receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes, such Party shall
immediately notify the other Party in writing and such other Party shall have the right, but not the obligation, to terminate this Agreement, effective, at such other Party’s option, immediately or at a specified future date. 

 

	 	19.5.2	Future Activities 

 Each Party agrees that, to the best of its knowledge, none of its employees or agents
conducting activities on its behalf under the Agreement is currently or will be during the term of this Agreement, debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care
Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or
program. In the event a Party learns that any such employee or agent becomes so debarred, sanctioned, suspended, excluded or declared ineligible or is the subject of proceedings that may result in such debarment, sanction, suspension, exclusion or
ineligibility, it will promptly so notify the other Party and will no longer allow such employee or agent to conduct activities under this Agreement. 
  

	19.6	Independent Contractor 

 No employee or representative of either Party shall have any authority to bind
or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and not-
withstanding any other provision of this Agreement to the contrary, FMI legal relationship to Roche under this Agreement shall be that of independent contractor. 
  

	19.7	Unenforceable Provisions and Severability 

 If any of the provisions of this Agreement are held to be
void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement
will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 

 

	19.8	Waiver 

 The failure by either Party to require strict performance and/or observance of any obligation,
term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any
obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
  

	19.9	Appendices 

 All Appendices to this Agreement shall form an integral part to this Agreement. 

  
 - 60 - 

	19.10	Entire Understanding 

 This Agreement contains the entire understanding between the Parties hereto with
respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral. 
  

	19.11	Amendments 

 No amendments of the terms and conditions of this Agreement shall be binding upon either
Party hereto unless in writing and signed by both Parties. 
  

	19.12	Invoices 

 All invoices that are required or permitted hereunder shall be in writing and sent by FMI to
Roche at the following address or other address as Roche may later provide: 
 F. Hoffmann-La Roche Ltd 

Kreditorenbuchhaltung 
 4070 Basel

 Switzerland 
  

	19.13	Notice 

 All notices that are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: 
  

			
	if to FMI, to:		 Foundation Medicine, Inc.
 150 Second Street

Cambridge, Massachusetts 02141
 Attn: Legal Department

Facsimile No.: +1 617 418 2201

		
	if to Roche, to:		 F. Hoffmann-La Roche Ltd
 Grenzacherstrasse
124
 4070 Basel
 Switzerland

Attn: Legal Department
 Facsimile No.: +41 61 688 13
96

		
	and:		 Hoffmann-La Roche Inc.
 150 Clove Road

Suite 8
 Little Falls, New Jersey 07424

US
 Attn. Corporate Secretary

Facsimile No.: +1 973 890-8433

  
 - 61 - 

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in
writing in accordance herewith. 
 [Signature Page Follows] 

  
 - 62 - 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

			
	Foundation Medicine, Inc.
	
	 /s/ Steven J. Kafka

		
	Name:		Steven J. Kafka
		
	Title:		Chief Operating Officer

  

									
	F. Hoffmann-La Roche Ltd						
			
	 /s/ Jason Coloma
				 /s/ Stefan Arnold

					
	Name:		Jason Coloma 				Name:		Stefan Arnold
					
	Title:		Global Head of Venture & Innovation, Roche Partnering				Title:		Head Legal Pharma

  

			
	Hoffmann-La Roche Inc.
	
	 /s/ John P. Parise

		
	Name:		John P. Parise
		
	Title:		Authorized Signatory

  

 Appendix 1.28 

Excluded Patent Rights 

[...***...]. 

  
 ***Confidential Treatment
Requested*** 
 A-1 

 Appendix 1.57 

[...***...] 

  
 ***Confidential Treatment
Requested*** 
 A-2 

 Appendix 1.64 

[...***...] 

  
 ***Confidential Treatment
Requested*** 
 A-3 

 Appendix 3.1.3 

Form of Task Order 
 TASK ORDER
FOR MOLECULAR INFORMATION PLATFORM AGREEMENT 
 This [Insert number of Task Order] Task Order is effective as of the last date below (“Task
Order # Effective Date. 
 TASK: [Insert Task Name] 

FMI Reference Number: [Insert FMI Reference Number] 
  

			
	Roche Contact:		[Insert Roche Contact]

 This Task is divided into the following six sections: 

 

	 	A.	Task Activities – Description of the Task Activities to be performed. 

  

	 	B.	Schedule – Task start date, projected end date and checkpoint dates (if any). 

  

	 	C.	Dependencies – Obligations, technology requirements. 

  

	 	D.	Deliverables – Identifiable work product resulting from the Task. 

  

	 	E.	Fee – Fixed price or time & materials rates and payment schedules. 

  

	 	F.	Special Terms – Terms applicable to this specific effort not addressed by this Agreement. 

  

	A.	Task Activities 

 [Describe Task Activities to be provided] 

 

	B.	Schedule 

 [Describe schedule for Task Activities to be provided and specify
the duration of the Task Activities] 
  

	C.	Dependencies 

 [Describe dependencies as relating to the Task Activities]

  

	D.	Deliverables 

 [Describe deliverables as relating to the Task Activities]

  

	E.	Fee 

 [Describe payment schedule and form of payment for the Task Activities]

  

	F.	Special Terms 

 [Describe any special terms for the Task Activities] 

Signatures of Project Managers 

  

									
	FMI				ROCHE
					
	By:		  
				By:		  

					
	Name:		  
				Name:		  

					
	Title:		  
				Title:		  

					
	Date:		  
				Date:		  

  
 A-5 

 Appendix 3.1.6 

[...***...] 

  
 ***Confidential Treatment
Requested*** 
 A-6 

 Appendix 3.2.4 

Excluded Contracts 

[...***...] 

  
 ***Confidential Treatment
Requested*** 
 A-7 

 Appendix 3.5.1 

FMI Specimen Requirements 
  

 

  
 

 

  
 

 

 Appendix 16.3 

Form of Press Release 

  
 A-9EX-10.3

 Exhibit 10.3 

EXECUTION COPY 
 ***Text Omitted and Filed
Separately with the Securities and Exchange Commission 
 Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

Ex-US Commercialization Agreement 
 This
Agreement is entered into with effect as of the Effective Date (as defined below) 
 by and between 

F. Hoffmann-La Roche Ltd 
 with an office and place of
business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”) 
 on the one hand 

and 
 Foundation Medicine, Inc. 

with an office and place of business at 150 Second Street, Cambridge, Massachusetts 02141 (“FMI”) 

on the other hand. 

  

 Table of Contents 

 

							
	 1.           
	 	 Definitions
	  	 	1	  
		 	 1.1        [...***...] Region
	  	 	1	  
		 	 1.2        Affiliate
	  	 	2	  
		 	 1.3        Agreement
	  	 	2	  
		 	 1.4        Agreement Term
	  	 	2	  
		 	 1.5        Allocable Overhead Expenses
	  	 	2	  
		 	 1.6        Applicable Law
	  	 	2	  
		 	 1.7        Business Day
	  	 	2	  
		 	 1.8        Calendar Quarter
	  	 	3	  
		 	 1.9        Calendar Year
	  	 	3	  
		 	 1.10      Commercially Launch(ed)
	  	 	3	  
		 	 1.11      Commercially Reasonable Efforts
	  	 	3	  
		 	 1.12      Confidential Information
	  	 	3	  
		 	 1.13      Control
	  	 	3	  
		 	 1.14      Cost of Services
	  	 	4	  
		 	 1.15      Cover
	  	 	4	  
		 	 1.16      Effective Date
	  	 	4	  
		 	 1.17      EMA
	  	 	4	  
		 	 1.18      EU
	  	 	4	  
		 	 1.19      Existing Third Party Rights
	  	 	5	  
		 	 1.20      FMI Know-How
	  	 	5	  
		 	 1.21      FMI Patent Rights
	  	 	5	  
		 	 1.22      FMI Territory
	  	 	5	  
		 	 1.23      FMI Trademarks
	  	 	5	  
		 	 1.24      FTE
	  	 	5	  
		 	 1.25      Gross Margin
	  	 	5	  
		 	 1.26      HSR
	  	 	5	  
		 	 1.27      IFRS
	  	 	5	  
		 	 1.28      Insolvency Event
	  	 	5	  
		 	 1.29      JMC
	  	 	6	  
		 	 1.30      JOC
	  	 	6	  
		 	 1.31      Know-How
	  	 	6	  
		 	 1.32      Net Sales
	  	 	6	  
		 	 1.33      Non-Europe Region
	  	 	6	  
		 	 1.34      [...***...] Region
	  	 	6	  
		 	 1.35      Party
	  	 	6	  
		 	 1.36      Patent Rights
	  	 	6	  
		 	 1.37      Post Approval Plan
	  	 	6	  
		 	 1.38      Product
	  	 	6	  
		 	 1.39      Quality Standards
	  	 	7	  
		 	 1.40      Region
	  	 	7	  
		 	 1.41      Regulatory Approval
	  	 	7	  
		 	 1.42      Regulatory Authority
	  	 	7	  
		 	 1.43      Roche Group
	  	 	7	  
		 	 1.44      Sales
	  	 	7	  
		 	 1.45      Sublicensee
	  	 	7	  
		 	 1.46      Tactical Plan
	  	 	7	  
		 	 1.47      Territory
	  	 	8	  

  
 ***Confidential Treatment
Requested*** 
 - ii - 

							
			 1.48      Third Party
		 	8	  
			 1.49      US
		 	8	  
			 1.50      US$
		 	8	  
			 1.51      Additional Definitions
		 	8	  
	 2.           
		 Licensesand Exclusivity
		 	9	  
			 2.1        Licenses
		 	9	  
			 2.2        Exclusive Right to Commercialize Products
		 	10	  
	 3.           
		 Right    to Include Future Products
		 	11	  
	 4.           
		 Governance
		 	11	  
			 4.1        Joint Management Committee
		 	11	  
			 4.2        Joint Operational Committee
		 	11	  
			 4.3        Members
		 	12	  
			 4.4        Responsibilities of the JOC
		 	12	  
			 4.5        Meetings
		 	13	  
			 4.6        Minutes
		 	13	  
			 4.7        Decisions
		 	13	  
			 4.8        Information Exchange
		 	14	  
			 4.9        Joint Operational Teams
		 	14	  
			 4.10      Alliance Director
		 	14	  
			 4.11      Limitations of Authority
		 	14	  
			 4.12      Expenses
		 	14	  
			 4.13      Lifetime
		 	14	  
	 5.           
		 Supply 
		 	14	  
	 6.           
		 Regulatory
		 	15	  
			 6.1        Responsibility
		 	15	  
			 6.2        Clinical Trials
		 	15	  
			 6.3        Reporting Adverse Events
		 	16	  
			 6.4        Reimbursement
		 	16	  
	 7.           
		 Commercialization
		 	16	  
			 7.1        Business Planning Period
		 	16	  
			 7.2        Reduction in Scope of Territory
		 	16	  
			 7.3        Sales
		 	17	  
			 7.4        Territory, Initial Launch and Launch Delay Fee
		 	17	  
			 7.5        Responsibility
		 	17	  
			 7.6        Branding and Pricing
		 	20	  
			 7.7        Product Promotional Materials
		 	20	  
	 8.           
		 Payment
		 	21	  
			 8.1        General
		 	21	  
			 8.2        Costs of Services
		 	21	  
			 8.3        Royalty Payments and Sales Milestones
		 	22	  
			 8.4        Disclosure of Payments
		 	23	  
	 9.           
		 Accountingand Reporting
		 	23	  
			 9.1        Timing of Payments
		 	23	  
			 9.2        Late Payment
		 	23	  
			 9.3        Method of Payment
		 	23	  
			 9.4        Currency Conversion
		 	24	  
			 9.5        Reporting
		 	24	  
	 10.        
		 Taxes   
		 	24	  
	 11.        
		 Auditing
		 	24	  

  
 - iii - 

							
			 11.1      Right to Audit
		 	24	  
			 11.2      Audit Reports
		 	25	  
			 11.3      Over-or Underpayment
		 	25	  
			 11.4      Duration of Audit Rights
		 	25	  
	 12.        
		Intellectual Property		 	25	  
			 12.1      Ownership of Inventions
		 	25	  
			 12.2      Trademarks and Labeling
		 	25	  
			 12.3      Prosecution of Patent Rights
		 	26	  
			 12.4      Patent Coordination Team
		 	26	  
			 12.5      Infringement
		 	26	  
			 12.6      Defense
		 	26	  
			 12.7      Common Interest Disclosures
		 	27	  
	 13.        
		 Representationsand Warranties
		 	27	  
			 13.1      FMI Representations and Warranties
		 	27	  
			 13.2      Mutual Representations of the Parties
		 	28	  
	 14.        
		 Indemnification
		 	29	  
	 15.        
		 Liability
		 	29	  
			 15.1      Disclaimer
		 	29	  
	 16.        
		 ObligationNot to Disclose Confidential Information
		 	30	  
			 16.1      Non-Use and Non-Disclosure
		 	30	  
			 16.2      Permitted Disclosure
		 	30	  
			 16.3      Press Releases
		 	30	  
			 16.4      Publications
		 	30	  
			 16.5      Commercial Considerations
		 	31	  
	 17.        
		 Term    and Termination
		 	31	  
			 17.1      Commencement and Term
		 	31	  
			 17.2      Termination
		 	31	  
			 17.3      Consequences of Termination and Expiration
		 	32	  
			 17.4      Survival
		 	36	  
	 18.        
		 Bankruptcy
		 	36	  
	 19.        
		 Miscellaneous
		 	36	  
			 19.1      Governing Law
		 	36	  
			 19.2      Disputes
		 	36	  
			 19.3      Arbitration
		 	37	  
			 19.4      Assignment
		 	38	  
			 19.5      Compliance with Applicable Law
		 	38	  
			 19.6      Debarment
		 	38	  
			 19.7      Independent Contractor
		 	39	  
			 19.8      Unenforceable Provisions and Severability
		 	39	  
			 19.9      Waiver
		 	39	  
			 19.10    Appendices
		 	39	  
			 19.11    Entire Understanding
		 	39	  
			 19.12    Amendments
		 	40	  
			 19.13    Invoices
		 	40	  
			 19.14    Notice
		 	40	  
			 19.15    Subcontractors
		 	40	  
			 19.16    Force Majeure
		 	41	  

  
 - iv - 

 Ex-US Commercialization Agreement 

WHEREAS, FMI has certain products that it currently commercializes, FoundationOne® and FoundationOne® Heme, and would like to commercialize, either by itself or through a collaborator, additional products in the future; and 

WHEREAS, Roche has expertise in the commercialization of pharmaceutical and diagnostic products; and 

WHEREAS, Roche and FMI want to collaborate on the commercialization of certain FMI products outside of the US; and 

WHEREAS, Roche and FMI are concurrently herewith entering into that certain transaction agreement dated as of the date hereof (as it may be amended from time
to time, the “Transaction Agreement”) which provides, among other things, for Roche to acquire a majority ownership of FMI upon the terms and subject to the conditions set forth in the Transaction Agreement, and a related investor
rights agreement, “Investor Rights Agreement”); and 
 WHEREAS, in connection therewith, and as an inducement to Roche’s and
FMI’s willingness to enter into the Transaction Agreement and to consummate the transactions contemplated thereby, the Parties hereto agree that , Roche will work with FMI in the United States to educate relevant persons on next generation
sequencing and/or comprehensive genomic profiling technology pursuant to the US educaton collaboration agreement dated as of the date hereof (as it may be amended from time-to-time, the “US Education Collaboration Agreement”), Roche
will collaborate with FMI on the development of genomic testing platforms (“Collaboration Agreement”), and Roche and FMI wll evaluate a collaboration on certain diagnostics, including certain decentralized IVD diagnostics generated
by FMI pursuant to the IVD collaboration termsheet dated as of the date hereof (as it may be amended from time-to time, the “IVD Collaboration”, together with the US Education Collaboration Agreement and the IVD Collaboration, the
“Related Agreements” ); and 
 WHEREAS, FMI and Roche intend that assays and other products generated under the Collaboration Agreement
will be commercialized in accordance with this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this
Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 

 

	1.	Definitions 

 As used in this Agreement, the following terms, whether used in the singular or plural,
shall have the following meanings: 
  

	 	1.1	[...***...] Region 

 The term “[...***...] Region” shall mean [...***...].

  
 ***Confidential Treatment
Requested*** 

	 	1.2	Affiliate 

 The term “Affiliate” shall mean any individual, corporation, association or other
business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term “control” shall mean the direct or indirect
ownership of more than fifty percent (>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting
securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, Chugai Pharmaceutical Co., Ltd, a Japanese corporation (“Chugai”), shall not be deemed an Affiliate of Roche unless
Roche provides written notice to FMI of its desire to include Chugai as an Affiliate of Roche. Moreover, FMI and its Affiliates existing as of the Effective Date shall not be deemed Affiliates of Roche and its Affiliates existing as of the Effective
Date, and Roche and its Affiliates existing as of the Effective Date shall not be deemed Affiliates of FMI and its Affiliates existing as of the Effective Date. Affiliates coming into existence after the Effective Date shall be classified by the
Parties as either Roche Affiliates or FMI Affiliates for the purposes of this Agreement. 
  

	 	1.3	Agreement 

 The term “Agreement” shall mean this document including any and all appendices and
amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 
  

	 	1.4	Agreement Term 

 The term “Agreement Term” shall mean the period of time commencing on the
Effective Date and, unless this Agreement is terminated sooner as provided in Article 17, expiring five (5) years from the Effective Date (“Initial Term”) unless extended by Roche in writing at least [...***...] prior to
the expiration of the Initial Term (or any Renewal Term) (i) in its entirety, (ii) on a country-by-country, Region by Region and/or Product-by-Product basis, or (iii) by mutual agreement of the Parties, in each case for additional two (2) year
periods (each a “Renewal Term”) during any period of time in which the Aggregate Ownership Percentage (as defined in the Investor Rights Agreement) of Roche and its Affiliates is at least 50.1% (it being understood that this
requirement is subject to Section 4.04 of the Investor Rights Agreement). 
  

	 	1.5	Allocable Overhead Expenses 

 The term “Allocable Overhead Expenses” shall mean costs incurred
by a Party for its account which are attributable to the Party’s [...***...]. Allocable Overhead Expenses shall not include [...***...]. 
  

	 	1.6	Applicable Law 

 The term “Applicable Law” shall mean any law, statute, ordinance, code, rule
or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in each case to the extent that the same
is applicable to the performance by the Parties of their respective obligations under this Agreement. 
  

	 	1.7	Business Day 

 The term “Business Day” shall mean 9:00 a.m. to 5:00 p.m. local time on a day
other than a Saturday, Sunday or bank or other public or federal holiday in Switzerland, New Jersey or Massachusetts. 

  
 ***Confidential Treatment
Requested*** 
 - 2 - 

	 	1.8	Calendar Quarter 

 The term “Calendar Quarter” shall mean each period of three
(3) consecutive calendar months, ending March 31, June 30, September 30, and December 31. 
  

	 	1.9	Calendar Year 

 The term “Calendar Year” shall mean the period of time beginning on
January 1 and ending December 31, except for the first year which shall begin on the Effective Date and end on December 31. 
  

	 	1.10	Commercially Launch(ed) 

 The term “Commercially Launch(ed)” shall mean a commercial launch of
a particular Product, which shall at a minimum require at least commercial scale sales, marketing and promotional activities using Commercially Reasonable Efforts. 
  

	 	1.11	Commercially Reasonable Efforts 

 The term “Commercially Reasonable Efforts” shall mean such
level of efforts required to carry out such obligation in a sustained manner consistent with the efforts that Roche or FMI, as applicable, devotes at the same stage of development or commercialization, as applicable, for its own products with
similar market potential, at a similar stage of their product life taking into account the existence of other competitive products in the market place or under development, the proprietary position of the product, the regulatory structure involved,
the anticipated profitability of the product and other relevant factors. It is understood that such product potential may change from time to time based upon changing scientific, business and marketing and return on investment considerations. 

 

	 	1.12	Confidential Information 

 The term “Confidential Information” shall mean any and all
information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or its Affiliates (“Receiving
Party”). Confidential Information shall not include any information, data or know-how that: 
  

	 	(i)	was generally available to the public at the time of disclosure, or becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving
Party or its Affiliates, 

  

	 	(ii)	can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party, 

 

	 	(iii)	is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure, 

  

	 	(iv)	is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through knowledge of Confidential Information, or 

 

	 	(vi)	is approved in writing by the Disclosing Party for release by the Receiving Party. 

 The terms of this
Agreement shall be considered Confidential Information of the Parties. 
  

	 	1.13	Control 

 The term “Control” shall mean (as an adjective or as a verb including conjugations
and variations such as “Controls” “Controlled” or “Controlling”) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent

  
 - 3 - 

 
Rights and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a
Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 

 

	 	1.14	Cost of Services 

 The term “Cost of Services” means, as applicable to a Product, FMI’s
costs incurred in connection with sample preparation, sequencing, data analysis, medical curation and report generation (collectively, “Service Activities” for such Product), equal to (a) [...***...] and
(b) [...***...]. The Cost of Services shall be calculated in accordance with GAAP, or IFRS, as applicable and as consistently applied by FMI in preparing its audited consolidated financial statements. FMI shall be solely responsible for
all capital costs incurred in connection with providing the Service Activities for Products for use in the Territory, including without limitation building out capacity for such Products, provided that depreciation for any equipment used to provide
the Service Activities will be included in the Cost of Services to the extent allocable to a Product in a manner consistent with FMI’s internal and external accounting principles as consistently applied. Except as provided for in
Section 8.2, Cost of Services will not include any transfer pricing mark-up. For clarity, any given deduction utilized in calculating Cost of Services (including the components thereof) shall be taken only once. 

 

	 	1.15	Cover 

 The term “Cover” shall mean (as an adjective or as a verb including conjugations and
variations such as “Covered,” “Coverage” or “Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given compound, formulation or product would infringe a
valid claim in the absence of a license under the Patent Rights to which such valid claim pertains. The determination of whether a compound, formulation, process or product is covered by a particular valid claim shall be made on a country-by-country
basis. As used in the previous sentence, “valid claim” means, with respect to a particular country a claim in an issued and unexpired patent that has not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a
decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and that has not been admitted to be invalid or unenforceable through re-examination, re-issue, disclaimer or
otherwise, or lost in an interference proceeding. 
  

	 	1.16	Effective Date 

 The term “Effective Date” shall mean the effective date of the Collaboration
Agreement. 
  

	 	1.17	EMA 

 The term “EMA” shall mean the European Medicines Agency or any successor agency with
responsibilities comparable to those of the European Medicines Agency. 
  

	 	1.18	EU 

 The term “EU” shall mean the European Union and all its then-current member countries.

  
 ***Confidential Treatment
Requested*** 
 - 4 - 

	 	1.19	Existing Third Party Rights 

 The term “Existing Third Party Rights” shall mean any Third Party
rights granted by FMI to such Third Party relating to the Products in the Territory under an agreement with FMI existing as of the Effective Date. The Existing Third Party Rights are listed in Appendix 1.19. 

 

	 	1.20	FMI Know-How 

 The term “FMI Know-How” shall mean the Know-How that FMI Controls at the
Effective Date and during the Agreement Term. 
  

	 	1.21	FMI Patent Rights 

 The term “FMI Patent Rights” shall mean the Patent Rights that FMI Controls
Covering a Product or its use. 
  

	 	1.22	FMI Territory 

 The term “FMI Territory” shall mean (i) the US, (ii) any countries
that have been excluded during or after the Business Planning Period, and (iii) any countries that have been removed from the Territory pursuant to the terms of this Agreement. 

 

	 	1.23	FMI Trademarks 

 The term “FMI Trademarks” shall mean all trademarks Controlled by FMI which
are necessary or useful for use in connection with the commercialization of Products. 
  

	 	1.24	FTE 

 The term “FTE” shall mean a full-time equivalent person-year, based upon a total of no
less than one thousand eight hundred (1,800) working hours per year, undertaken in connection with the conduct of research in the Research Program. In no circumstance can the work of any given person exceed one (1) FTE. 

 

	 	1.25	Gross Margin 

 The term “Gross Margin” shall mean Net Sales minus Cost of Services. 

 

	 	1.26	HSR 

 The term “HSR” shall mean the Hart-Scott-Rodino Antitrust Improvements Act. 

 

	 	1.27	IFRS 

 The term “IFRS” shall mean International Financial Reporting Standards. 

 

	 	1.28	Insolvency Event 

 The term “Insolvency Event” shall mean circumstances under which a Party
(i) has a receiver or similar officer appointed over all or a material part of its assets or undertaking; (ii) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation
or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction); (iii) enters into any composition or arrangement with its creditors (other than relating to
a solvent restructuring); (iv) ceases to carry on business; (v) is unable to pay its debts as they become due in the ordinary course of business. 

  
 - 5 - 

	 	1.29	JMC 

 The term “JMC” shall mean the joint management committee described in Article 6 of the
Collaboration Agreement. If the Collaboration Agreement terminates before this Agreement, then the provisions of the Collaboration Agreement to the necessary to interpret or implement this Agreement shall be incorporated by reference into this
Agreement. 
  

	 	1.30	JOC 

 The term “JOC” shall mean the joint operating committee as mentioned in the Collaboration
Agreement and the US Education Collaboration Agreement, and described in Section 4.2. 
  

	 	1.31	Know-How 

 The term “Know-How” shall mean data, knowledge and information, including chemical
manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development or
commercialization of Products. 
  

	 	1.32	Net Sales 

 The term “Net Sales” shall mean, for a Product in a particular period, the amount
calculated by subtracting from the Sales of such Product for such period: (i) [...***...]. 
  

	 	1.33	Non-Europe Region 

 The “Non-Europe Region” shall mean all countries in the Territory excluding
the [...***...] Region and the [...***...] Region. 
  

	 	1.34	[...***...] Region 

 The term “[...***...] Region” shall mean [...***...].

  

	 	1.35	Party 

 The term “Party” shall mean FMI or Roche, as the case may be, and “Parties”
shall mean FMI and Roche collectively. 
  

	 	1.36	Patent Rights 

 The term “Patent Rights” shall mean all rights under any patent or patent
application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division,
continuation or continuation-in-part of any of the foregoing. 
  

	 	1.37	Post Approval Plan 

 The term “Post Approval Plan” shall mean the plan for regulatory
(including the strategy with respect to Regulatory Approvals and reimbursement approvals for Products) and clinical activities associated with a Product in the Territory. 
  

	 	1.38	Product 

 The term “Product” shall mean (i) FoundationOne® and FoundationOne®
Heme, and any updated and successor versions to FoundationOne® and FoundationOne® Heme, including any updated and successor versions with updated gene lists or that provide clinical outcome data (collectively, “Initial
Products”), (ii) any clinical diagnostic testing commercial products developed under the Immunotherapy Testing Platform Development Program (as defined in the 

  
 ***Confidential Treatment
Requested*** 
 - 6 - 

 
Collaboration Agreement, the ctDNA Platform Development Program (as defined in the Collaboration Agreement), or the CDx Development Program (as defined in the Collaboration Agreement) (clause
(ii) collectively, “Collaboration Products”) subject to the terms of Section 8.3.5 , and (iii) any other products that the Parties mutually agree to include under this Agreement. The term “Product” shall include
associated Service Activities provided in connection with Sales, [...***...]. For clarity, (a) in vitro diagnostic kit products, (b) companion diagnostic assay products developed by FMI for Third Parties, and (c) any
standalone data or molecular information products (i.e. other than clinical diagnostic testing commercial products), are excluded from the definition of a Product. 
  

	 	1.39	Quality Standards 

 The term “Quality Standards” shall mean (i) FMI’s standard
specifications in accordance with Section 2.3, with respect to the Products and performance of Service Activities, which shall include technical specifications on such Product and standards for the validation of such Product, and (ii) CLIA or
QSR requirements, each as applicable to a Product, and other standards required by Applicable Laws in the Territory. 
  

	 	1.40	Region 

 The term “Region” shall mean the [...***...] Region, the [...***...]
Region, and the Non-Europe Region. 
  

	 	1.41	Regulatory Approval 

 The term “Regulatory Approval” shall mean any approvals, licenses,
registrations or authorizations by any Regulatory Authority, necessary to manufacture, sell, market or import or have imported any Product in the Territory. 
  

	 	1.42	Regulatory Authority 

 The term “Regulatory Authority” shall mean any national, supranational
(e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the EMA, in any country
involved in the granting of Regulatory Approval for the Product. 
  

	 	1.43	Roche Group 

 The term “Roche Group” shall mean collectively Roche and its Affiliates and
Sublicensees. 
  

	 	1.44	Sales 

 The term “Sales” shall mean, for a Product in a particular period, the sum of
(i) and (ii): [...***...]. 
  

	 	1.45	Sublicensee 

 The term “Sublicensee” shall mean a permitted entity to which Roche has licensed
rights in accordance with Section 2.1.2 of this Agreement. 
  

	 	1.46	Tactical Plan 

 The term “Tactical Plan” shall mean the plan describing the tactics and
logistics for marketing, promotion and sale of a Product in a specific country or Region, which shall address matters such as (i) annual minimum amounts of Product to be sold in such country or Region, (ii) details regarding the marketing
support for the Products, and (iii) other activities to be conducted by either Party. 

  
 ***Confidential Treatment
Requested*** 
 - 7 - 

	 	1.47	Territory 

 The term “Territory” shall mean all countries of the world, excluding the FMI
Territory. 
  

	 	1.48	Third Party 

 The term “Third Party” shall mean a person or entity other than (i) FMI or
any of its Affiliates or (ii) a member of the Roche Group. 
  

	 	1.49	US 

 The term “US” shall mean the United States of America and its territories and possessions.

  

	 	1.50	US$ 

 The term “US$” shall mean US dollars. 

 

	 	1.51	Additional Definitions 

 Each of the following definitions is set forth in the Section of this Agreement
indicated below: 
  

			
	 Definition
	  	 Section

	Accounting Period	  	9.1
	Alliance Director	  	4.10
	Arbitration Offer	  	8.3.5
	Arbitration Commencement Date	  	8.3.5
	Average Delivery Time Metric	  	7.5.2.4
	Bankruptcy Code	  	18
	Breaching Party	  	17.2.1
	Business Planning Period	  	7.1
	Chairperson	  	4.2
	Collaboration Agreement	  	Whereas clause
	Collaboration Product	  	1.38
	Consensus Matters	  	4.7.3
	Decision Period	  	12.4
	Dependent Obligation	  	7.5.1.4
	Disclosing Party	  	1.12
	Expert	  	8.3.5
	Extended Period	  	7.4
	Global Cost	  	8.2.1
	Global Test Fixed Fee	  	8.2.1
	Indemnified Party	  	14.3
	Indemnifying Party	  	14.3
	Initial Discussion Period	  	8.3.5
	Initial Term	  	1.4
	Initial Product	  	1.38
	Initiating Party	  	12.4
	Investor Rights Agreement	  	Whereas clause
	IVD Collaboration	  	Whereas clause

  
 - 8 - 

			
	 Definition
	  	 Section

	JOT	  	4.9
	Local Cost	  	8.2.2
	Local Test Fixed Fee	  	8.2.2
	Members	  	4.2
	[...***...]	  	7.6
	Minimum Revenue Requirements	  	1.1.1.1
	Minimum Transfer Payment	  	17.3.4.3
	NGS	  	7.4
	Non-Breaching Party	  	17.2.1
	Panel	  	8.3.5
	Payment Currency	  	9.3
	Peremptory Notice Period	  	17.2.1
	Precedent Obligation	  	7.5.1.4
	Product Trademark	  	12.2
	Publishing Notice	  	16.4
	Publishing Party	  	16.4
	Qualified Sample	  	7.5.2.4
	Quarterly Average Delivery Time Failure	  	7.5.2.4
	Rebuttal	  	8.3.5
	Receiving Party	  	1.12
	Related Agreements	  	Whereas clause
	Renewal Term	  	1.4
	Roche Transfer Activities	  	17.3.4.3
	ROFN Negotiation Period	  	3
	Royalty Term	  	8.3.1
	Samples	  	17.3.4.3
	Selected Agreement	  	8.3.5
	Settlement	  	12.4
	Service Activities	  	1.14
	Suit Notice	  	12.4
	Supporting Memorandum	  	8.3.5
	Third Party Test Fee	  	8.2.2
	Transaction Agreement	  	Whereas clause
	Universal CDx Product	  	2.2
	US Education Collaboration Agreement	  	Whereas clause

  

	2.	Licenses and Exclusivity 

  

	 	2.1	Licenses 

  

	2.1.1	Patents and Know-How 

 Subject to the terms and conditions of this Agreement, FMI hereby grants to Roche a right
and license, including the right to sublicense solely as permitted in Section 2.1.2, under FMI’s interest in the FMI Patent Rights and FMI Know-How to use, have used, import, have imported, export,

  
 ***Confidential Treatment
Requested*** 
 - 9 - 

 
have exported, market, have marketed, distribute, have distributed, sell and have sold Products in the Territory. Subject to Section 2.2, the foregoing license shall be co-exclusive (with FMI)
during the Business Planning Period and exclusive (even as to FMI) following the Business Planning Period. 
  

	2.1.2	Sublicenses 

 The licenses granted by FMI to Roche in Section 2.1.1 and 2.1.3 may be sublicensed by Roche
to any Affiliate of Roche for so long as such Affiliate remains an Affiliate. Any such sublicense automatically terminates if such Affiliate Sublicensee ceases to be an Affiliate of Roche. In addition, the licenses granted by FMI to Roche in
Section 2.1.1 and 2.1.3 (and any sublicense by Roche to an Affiliate of Roche) may be sublicensed (through one or more tiers) by Roche (and its Affiliates) to a Third Party (i) without the prior written consent of FMI in countries where
Roche customarily utilizes such Third Party to conduct commercialization activities on behalf of Roche or its Affiliates or (ii) otherwise with the prior written consent of FMI, not to be unreasonably withheld. Roche shall be liable for any act
or omission of any such Sublicensee that is a breach of any of Roche’s obligations under this Agreement as though the same were a breach by Roche, and FMI shall have the right to proceed directly against Roche without any obligation to first
proceed against such Sublicensee. 
  

	2.1.3	Trademarks 

 Subject to the terms and conditions of this Agreement, FMI hereby grants to Roche a right and
license, including the right to sublicense solely as permitted in Section 2.1.2, under FMI’s interest in the FMI Trademarks to use, have used, import, have imported, export, have exported, market, have marketed, distribute, have distributed,
sell and have sold Products in the Territory. Subject to Section 2.2, the foregoing license shall be co-exclusive (with FMI) during the Business Planning Period and exclusive (even as to FMI) following the Business Planning Period. Such trademark
licenses shall be non-transferable, except that FMI shall have the right to sublicense such rights to its licensees in the FMI Territory, and Roche shall have the right to sublicense such rights to its permitted Sublicensees in the Territory. 

 

	 	2.2	Exclusive Right to Commercialize Products 

 During the Business Planning Period, FMI will continue to be
responsible for and will book all sales of Products in the Territory. 
 After the Business Planning Period, Roche and its Sublicensees shall have the
exclusive right (even as to FMI) to market, distribute and sell Products in the Territory, subject to activities designated for FMI to conduct under a Tactical Plan approved by the JOC. To the extent applicable, the foregoing right shall be subject
to the rights granted under the Existing Third Party Rights. If FMI receives any order from a prospective purchaser located in a country in the Territory, FMI shall promptly refer that order to Roche, and Roche shall process such order for such
purchaser in the Territory in accordance with the terms of this Agreement. If Roche receives any order from a prospective purchaser located in the FMI Territory, then Roche shall promptly refer that order to FMI. The Parties will discuss an
appropriate transition plan for the Existing Third Party Rights. However, after the Business Planning Period, at Roche’s request, and to the extent possible under the Existing Third Party Rights without incurring any termination fee, penalty or
similar fee, FMI will terminate any or all of the Existing Third Party Rights. Notwithstanding the above, if there is any termination fee, penalty or similar fee, Roche shall have the right to pay such termination fee, penalty or similar fee to
terminate any or all of the Existing 

  
 - 10 - 

 
Third Party Rights. Moreover, Roche shall have the right, in coordination with FMI, to engage in negotiations with the Third Parties to which the Existing Third Party Rights pertain, with the
intent of allowing Roche to intervene to terminate such Existing Third Party Rights. 
 Unless otherwise agreed expressly by the Parties, for any companion
diagnostic assay Product that is also for use in indicating a therapeutic or referencing a clinical trial of a Third Party (“Universal CDx Product”), such Third Party shall have the right to recommend use of such Universal CDx
Product in the Territory to the extent allowable under Applicable Law, including using or referencing such Universal CDx Product name, logo and trade dress in such Third Party therapeutics label, package insert, or in its promotional and regulatory
materials. 
  

	 	2.3	Product Specifications; Modifications 

 Product specifications for the Initial Products are attached
hereto as Appendix 2.3. FMI will develop product specifications for all other Products during development of each such Product. FMI will provide a copy of draft product specifications to the JOC for all other Products as such specifications are
substantially completed. FMI will provide a copy of any material modifications to any Product specifications to the JOC no less than [...***...] prior to anticipated locking of the design file, unless such changes are reasonably required to be
implemented on an expedited basis, for example, to maintain compliance with Applicable Laws or the requirements of any Regulatory Authority, in which case FMI shall provide such specifications to the JOC as far in advance of implementation as is
reasonably practicable. FMI shall consider in good faith any and all comments or concerns timely raised by Roche in connection with its review of such draft specifications or such modifications. FMI has final authority to adopt specifications for
the Products and modifications thereto, [...***...]. 
  

	3.	Right to Include Future Products 

 During the Agreement Term, Roche shall have a first right to negotiate
with FMI to include in the Territory future clinical diagnostic testing commercial products Controlled by FMI (excluding (i) in vitro diagnostics kit products, (ii) any companion diagnostic assay products developed by FMI for a
Third Party, and (iii) any standalone data or molecular information products (i.e. other than clinical diagnostic testing commercial products)), as a Product to market, distribute and sell in the Territory, on terms to be mutually agreed upon
by the Parties. If FMI plans to Commercially Launch a clinical diagnostic testing commercial product in the Territory or grant such product rights to a Third Party, then FMI shall provide Roche with written notice of such plan and a copy of draft
specifications for such Product. [...***...]. 
  

	4.	Governance 

  

	 	4.1	Joint Management Committee 

 The roles and responsibilities of the JMC are set forth in the Collaboration
Agreement. 
  

	 	4.2	Joint Operational Committee 

 The JOC serves to oversee all activities under this Agreement. The JOC will
strive to reach consensus on any matters within its authority with each Party having one (1) vote. The JOC will reasonably consider all information, proposals and advice received from each Party in relation to the matters for which it has
responsibility. Unresolved disputes at the JOC will be escalated to the JMC using the procedures outlined in the Collaboration Agreement. 

  
 ***Confidential Treatment
Requested*** 
 - 11 - 

	 	4.3	Members 

 The JOC shall be composed of an equal number of persons from each Party
(“Members”). Roche and FMI each shall be entitled to appoint three (3) Members with appropriate seniority and functional expertise, unless otherwise agreed by the Parties. Each Party may replace any of its Members and appoint a
person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least [...***...] prior to the next scheduled meeting of the JOC. Both Parties shall use reasonable efforts to keep
an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part of or the whole JOC meeting with prior notification to the JOC. Members may be represented at any
meeting by another person designated by the absent Member. The JOC shall be chaired [...***...], and then alternating between the Parties on a [...***...] basis thereafter (“Chairperson”). 

 

	 	4.4	Responsibilities of the JOC 

 The JOC shall have the responsibility and authority to: 

 

	(a)	create and approve a transition plan for Existing Third Party Rights; 

  

	(b)	review and recommend for approval by the JMC Tactical Plans and Post Approval Plans for Products that Roche intends to Commercially Launch or has Commercially Launched; 

 

	(c)	review and recommend for approval by the JMC any revisions to the Tactical Plans and Post Approval Plans; 

  

	(d)	review and oversee execution of the Tactical Plans and Post Approval Plans; 

  

	(e)	establish timelines for the Commercial Launch of any Products and the marketing, distribution and sale of such Products; 

  

	(f)	identify appropriate resources necessary to conduct the Tactical Plans and Post Approval Plans; 

  

	(g)	create, oversee or disband JOTs as deemed appropriate; 

  

	(h)	establish and set expectations and mandates for JOTs, if applicable; 

  

	(i)	resolve disputes of the ESWG (as such term is defined in the US Education Collaboration Agreement) in accordance with Section 2.2.3 of the US Education Collaboration Agreement; 

 

	(j)	monitor and implement plans to ensure adequate Product supply in the Territory; 

  

	(k)	review and approve product and corporate level branding for Products subject to Section 12.2 (Trademarks & Labeling); 

  

	(l)	[...***...]; 

  

	(m)	review and recommend for approval by the JMC promotional materials outside of FMI’s approved guidelines; 

  

	(n)	review and recommend for approval by the JMC any clinical research for Products in the Territory; provided that the Parties may conduct clinical research without approval of the JMC in accordance with Section 6.2
(Clinical Trials); 

  

	(o)	[...***...]; 

  
 ***Confidential Treatment
Requested*** 
 - 12 - 

	(p)	recommend action items to its respective decision making bodies; 

  

	(q)	review Quality Standards and modifications thereto in accordance with Section 2.3 (Product Specifications and Modifications); 

  

	(r)	review customer service practices and performance in accordance with Section 7.5.2.3 (Customer Service); 

  

	(s)	review strategies for reimbursement approvals in accordance with Section 6.4 (Reimbursement); 

  

	(t)	review Average Delivery Time Metric in accordance with Section 7.5.2.4; and 

  

	(u)	attempt in good faith to resolve any disputes between the Parties. 

 The JOC shall have no responsibility and
authority other than that expressly set forth in this Section, in the Related Agreements or as otherwise agreed to in writing by both Parties. 
  

	 	4.5	Meetings 

 The Chairperson or his/her delegate will be responsible for sending invitations and agendas
for all JOC meetings to all Members at least [...***...] before the next scheduled meeting of the JOC. The venue for the meetings shall be agreed by the JOC. The JOC shall hold meetings at least [...***...], either in person or by
tele-/video-conference, and in any case as frequently as the Members of the JOC may agree shall be necessary, but not less than [...***...]. The Alliance Director of each Party may attend the JOC meetings as a permanent participant. 

 

	 	4.6	Minutes 

 The Chairperson will be responsible for designating a Member to record in reasonable detail and
circulate draft minutes of JOC meetings to all members of the JOC for comment and review within [...***...] after the relevant meeting. The Members of the JOC shall have [...***...] to provide comments. The Party preparing the minutes
shall incorporate timely received comments and distribute finalized minutes to all Members of the JOC within [...***...] of the relevant meeting. The Chairperson approves the final version of the minutes before its distribution. 

 

	 	4.7	Decisions 

  

	4.7.1	Decision Making Authority 

 The JOC shall decide matters within its responsibilities set forth in
Section 4.4. 
  

	4.7.2	Consensus; Good Faith 

 The Members of the JOC shall act in good faith to cooperate with one another and seek
agreement with respect to issues to be decided by the JOC. The Parties shall endeavor to make decisions by consensus with each Party having one (1) vote. 
  

	4.7.3	Failure to Reach Consensus 

 If the JOC is unable to decide a matter requiring JOC approval by consensus, then
the matter shall be escalated to the [...***...]. 

  
 ***Confidential Treatment
Requested*** 
 - 13 - 

	 	4.8	Information Exchange 

 FMI and Roche shall exchange the information in relation to its activities under
this Agreement through the JOC. FMI and Roche may ask reasonable questions in relation to the above information and offer advice in relation thereto and each Party shall give due consideration to the other Party’s input. The JOC may determine
other routes of information exchange. Notwithstanding anything to the contrary in this Agreement, if FMI, FMI’s Affiliates or sublicensees have sales forces in a country/Region outside of the FMI Territory for a product after the Business
Planning Period, then Roche shall have the right to redact competitively sensitive information, including within the Tactical Plans or Post Approval Plans provided to FMI for any Product in such country/Region. 

 

	 	4.9	Joint Operational Teams 

 The JOC shall have the right to establish joint operational teams
(“JOT”), which shall have the authority granted to them by the JOC and shall be comprised of members from both Parties. 
  

	 	4.10	Alliance Director 

 Each Party shall appoint one person to be its point of contact with responsibility
for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall be permanent participants of the JOC meetings (but not members of the JOC). The Alliance Directors
shall facilitate resolution of potential and pending issues and potential disputes to enable the JOC to reach consensus and avert escalation of such issues or potential disputes. 

 

	 	4.11	Limitations of Authority 

 The JOC shall have no authority to amend or waive any terms of this Agreement.

  

	 	4.12	Expenses 

 Each Party shall be responsible for its own expenses including travel and accommodation costs
incurred in connection with the JOC. 
  

	 	4.13	Lifetime 

 The JOC shall exist during the Agreement Term. 

 

	5.	Supply 

 Subject to Section 7.5.2.4, FMI shall be solely and exclusively responsible
[...***...] for the commercial supply of Products for sale in the Territory by or on behalf of Roche, and FMI shall use Commercially Reasonable Efforts to provide Products and Service Activities in the amounts requested by Roche meeting the
Quality Standards and Average Delivery Time Metric. 
 For a given Product, if FMI fails to complete the Service Activities associated with such Product in
a manner that meets such Product’s Quality Standards for at least [...***...] of the Qualified Samples received from Roche in the Territory in a given Calendar Quarter (a “Quarterly Quality Standards Failure”) and such
failure exists for [...***...], then prior to the end of such [...***...], the JOC shall prepare a plan for improving such performance, which plan will be implemented in the [...***...]. The JOC will monitor the implementation and
effectiveness of such plan with a goal of achieving and maintaining compliance on a consistent basis for such Quality Standards. If, following the implementation of a plan by the JOC to improve such performance, FMI is unable to improve performance,
and there is a Quarterly Quality Standards Failure for [...***...] (a “Material Performance Standards Failure”), then this shall be considered a material breach of this Agreement by FMI. 

  
 ***Confidential Treatment
Requested*** 
 - 14 - 

 [...***...]. Roche shall have the right, during normal business hours and upon reasonable advanced notice,
to audit any Third Party used by FMI or its Affiliates in the supply of Products and services related to Products to the extent permitted in any existing agreements with such Third Party contractors and in accordance with the terms and conditions of
such agreements. Any new agreements entered into by FMI with respect to commercial supply of Products for sale in the Territory by or on behalf of Roche, shall provide Roche with the right to audit. 

 

	6.	Regulatory 

  

	 	6.1	Responsibility 

 Except as otherwise agreed to by the Parties, FMI, [...***...], shall be
responsible for, in consultation with Roche, and shall use Commercially Reasonable Efforts in the preparation of applications for Regulatory Approvals, as well as all governmental approvals required to market, import, have imported, sell and have
sold Products in the Territory. FMI shall be responsible for pursuing and compiling all regulatory filing documentation, and Roche shall reasonably assist FMI in preparing and submitting such regulatory filing documentation and interacting with
Regulatory Authorities, for Products in the Territory. FMI or its Affiliates shall use Commercially Reasonable Efforts to prepare, or have prepared for it, all regulatory filings and Regulatory Approvals for all Products that are required to be
submitted in each country of the Territory where Roche intends to Commercially Launch a Product or has Commercially Launched a Product. Roche shall reasonably assist FMI in submitting all such regulatory filings and Regulatory Approvals in
FMI’s name, unless prohibited by Applicable Law, in which case, to the extent required under Applicable Law, Roche shall file such regulatory filings and Regulatory Approvals in Roche’s name. Each Party shall promptly supply the other
Party with a copy of all material communications related to a Product to or from any Regulatory Authority in the Territory, including (i) communications with respect to any visits by any governmental authority or Regulatory Authority to any
facilities at which any Product is manufactured or sold in the Territory and (ii) any written or oral inquiries about, any procedures in connection with any Product in the Territory. 

 

	 	6.2	Clinical Trials 

 The Parties shall discuss at the JOC and consider any clinical research (including,
without limitation, any investigator sponsored studies and studies with key opinion leaders) to be conducted for the Products during the Agreement Term that may be necessary or reasonably useful in furtherance of market development and access for
Products in the Territory. Except as otherwise agreed to by the Parties, Roche shall have the right to conduct local clinical studies (including investigator sponsored studies and clinical studies with key opinion leaders) where such clinical
research is for such local country or Region, provided that Roche shall consult with FMI through the JOC and consider in good faith any comments provided by FMI with respect to such strategy and conduct of such local clinical studies,
[...***...] in a given country in the Territory during the Agreement Term. Except as otherwise agreed to by the Parties, with respect to any global clinical studies, FMI shall have the right to conduct, [...***...], and shall be
responsible for the strategy and conduct of such global clinical studies, provided that FMI shall consult with Roche through the JOC and consider in good faith any comments provided by Roche with respect to such strategy and conduct of such global
clinical studies. If the Parties do not mutually agree to conduct additional global clinical research for the Territory, FMI shall have the right, but not the obligation, to pursue such global clinical research in its sole discretion and shall be
responsible for [...***...]. 

  
 ***Confidential Treatment
Requested*** 
 - 15 - 

	 	6.3	Reporting Adverse Events 

 If the development or commercialization or a given Product mandates the mutual
reporting of adverse events, the Parties will establish procedures for tracking and informing each other concerning such adverse advents as required by law, and shall maintain such databases and execute such agreements as needed for this purpose.

  

	 	6.4	Reimbursement 

 Roche will be responsible, [...***...], in cooperation with FMI, for all activities
related to reimbursement approval for Products in the Territory. Prior to submission, Roche shall discuss its proposed filings for reimbursement approval of Products at the JOC and shall consider in good faith any comments provided by FMI with
respect to such filings. After those materials have been submitted to the appropriate pricing authority, Roche shall permit FMI to obtain copies of such materials, including in electronic format, at reasonable times. However, if FMI, FMI’s
Affiliates, or sublicensees have sales forces in a country/Region outside of the FMI Territory for a FMI clinical diagnostic product after the Business Planning Period, then Roche shall have the right to redact from such filings competitively
sensitive information on reimbursement approvals to FMI for any Product in such country/Region. Roche shall use Commercially Reasonable Efforts to file submissions for reimbursement approval in each country where it intends to, or has, Commercially
Launched a Product. For clarity, submissions for reimbursement approval in the Territory shall be consistent with the [...***...] agreed upon by the Parties. 
  

	7.	Commercialization 

  

	 	7.1	Business Planning Period 

 The Parties will use the first [...***...] of the Initial Term (such
[...***...] period the “Business Planning Period”) to explore and develop a plan for the commercialization of the Initial Products by Roche in the Territory. 

During the Business Planning Period, the Parties will focus on an analysis of the market, prioritization of countries and Regions within the Territory with
respect to market access and market development, and in the formation of strategies related to obtaining Regulatory Approval and reimbursement for Products in said prioritized countries and Regions. 

Following the Business Planning Period, the Parties will implement on the strategies agreed to at the JOC and JMC, in a staged approach and according to
detailed Tactical Plans and Post-Approval Plans for each country/Region. Unless otherwise agreed by the Parties, following the Business Planning Period, Roche shall have the exclusive right (even as to FMI) to market, distribute and sell Products in
the Territory in accordance with the terms of this Agreement. Notwithstanding this exclusive right, the JOC shall consider utilizing FMI to conduct certain medical educational and/or medical affairs activities in connection with a Tactical Plan.

  

	 	7.2	Reduction in Scope of Territory 

 During the Business Planning Period, Roche shall have the right to
exclude countries or Regions from the Territory with immediate effect by providing written notice to FMI. Upon delivery of such written notice, the Territory shall be revised to remove such country or Region from the Territory and upon such country
or Region shall be deemed to be included in the FMI Territory. For clarity, 

  
 ***Confidential Treatment
Requested*** 
 - 16 - 

 
upon exclusion of any country or Region by Roche pursuant to this Section 7.2, the licenses and rights granted under this Agreement to Roche with respect to such country or Region, as
applicable, shall automatically terminate and FMI shall have the sole right and discretion with respect to Products in such excluded country or Region. 
  

	 	7.3	Sales 

 Except as otherwise expressly agreed between the Parties, after the Business Planning Period:

  

	 	(a)	Subject to the Existing Third Party Rights, Roche will book all sales of Products in the Territory. 

  

	 	(b)	Subject to the Existing Third Party Rights, Roche will be responsible for billing and collections of Products in the Territory. 

  

	 	7.4	Territory, Initial Launch and Launch Delay Fee 

 Following the Business Planning Period, and subject to
FMI having fulfilled its obligations under this Agreement, if Roche fails to Commercially Launch the Initial Products in a given Region in the Territory in accordance with the schedule below, then Roche shall have the right to pay FMI a Launch Delay
Fee [...***...] (the “Extended Period”). If Roche does not pay the Launch Delay Fee or thereafter Commercially Launch the Initial Products within the Extended Period, then FMI may, in its sole discretion, elect to
(i) convert the licenses under Section 2.1 to non-exclusive, or (ii) terminate the licenses under Section 2.1 and remove the Regions from the Roche Territory (and upon such election such Region shall be deemed to be included in the
FMI Territory) in each case (i) and (ii) other than in any country in such Region where Roche has already Commercially Launched prior to the end of the applicable period or Extended Period): 

[...***...]. 
 Notwithstanding the foregoing, Roche shall
not be required to pay any Launch Delay Fee if such failure to Commercially Launch is a result of FMI failing to meet its responsibilities under this Agreement, including providing [...***...], and, Roche shall have an automatic extension of
the deadline for the amount of time equal to the period in which FMI has not cured such failure before which Roche is required to launch in a Region. For clarity, upon FMI’s cure of such failure, if Roche fails to meet the extended deadline for
Commercial Launch, then Roche shall have the right to pay the Launch Delay Fee and obtain the extension or such Regions (other than any country in such Regions where Roche has already Commercial Launched) shall be deemed to be included in the FMI
Territory. 
  

	 	7.5	Responsibility 

  

	7.5.1	Roche Responsibilities 

  

	7.5.1.1	Funding Commitment 

 Subject to FMI meeting its obligations under this Agreement, during the [...***...]
of the Initial Term, Roche will commit at least [...***...] in Roche FTE resources (based on Roche’s standard FTE rates as consistently applied). and out-of-pocket expenditures for the activities under this Agreement. FMI may audit Roche
in accordance with Article 11 to ensure compliance with this Section. Notwithstanding the above, if there is a reduction in the scope of the Territory pursuant to Section 7.2, then FMI and Roche shall negotiate in good faith an adjustment to
the [...***...] commitment to equitably reflect the reduction in the market value of the Territory. 

  
 ***Confidential Treatment
Requested*** 
 - 17 - 

	7.5.1.2	Minimum Revenue Requirement 

 Commencing in [...***...], in connection with the review of the
Tactical Plan, [...***...] (the “Minimum Revenue Requirements”). If the Initial Product specifications are modified pursuant to Section 2.3, the JOC may establish new Minimum Revenue Requirements for such Initial Product
for the year in which such modification occurs. Roche will [...***...]. If Roche fails to meet the Minimum Revenue Requirements for an Initial Product in any country in the Territory for [...***...], then FMI will have the right, in its
sole discretion, to either (i) remove such country from the Territory (and upon such election such country shall be deemed to be included in the FMI Territory) or (ii) convert the license for such country to non-exclusive.  

 

	7.5.1.3	Commercial Activities 

 During the Business Planning Period, Roche’s activities shall focus
[...***...]. 
 Throughout the Agreement Term, Roche will be responsible for the preparation of country-or Region-specific Tactical Plans and
Post-Approval Plans for Products in the Territory, which shall be updated [...***...] and submitted to the JOC for review and comment. All activities under this Agreement will be conducted in accordance with country- or Region-specific
Tactical Plans and Post-Approval Plans to be developed by Roche, working in cooperation with FMI, subject to review and approval by the JMC. 
 Roche will
use Commercially Reasonable Efforts to initiate and pursue market development and Commercially Launch Products in the Territory in accordance with the Tactical Plans, Post Approval Plans and the terms of this Agreement. 

 

	7.5.1.4	Equitable Adjustments 

 Where either Roche or FMI has an obligation under this Agreement (each such a
“Dependent Obligation”) that can only reasonably be fulfilled if the other Party first performs one or more of its specific contractual obligations hereunder (each a “Precedent Obligation”), then, any deadline for
the performance by Roche or FMI, as applicable, of such Dependent Obligation shall be tolled (i.e., the deadline shall be extended) for a period of time equal to the delay in the performance by such other Party of the relevant Precedent Obligation.
For avoidance of doubt, each such deadline shall be similarly tolled to the extent achievement of an obligation under this Agreement is prevented by an event of force majeure as and to the extent provided in Section 19.16. 

 

	7.5.2	FMI Responsibilities 

  

	7.5.2.1	Product Training 

 FMI will provide Roche with NGS and Product training using Commercially Reasonable Efforts,
including samples of each related training material used by FMI in the FMI Territory throughout the Term. Such training will be provided in the locations and on the schedule agreed to in the Tactical Plans. Each Party shall be responsible for their
respective costs in relation thereto. For clarity, FMI trainers will provide this training at no charge to Roche. 

  
 ***Confidential Treatment
Requested*** 
 - 18 - 

	7.5.2.2	Materials 

 [...***...], or more frequently when available throughout the Term, FMI will provide Roche
with copies of its then current Product marketing material, and will share with Roche any Product brand, promotional, or similar plans, any market research plans and results, any educational materials or other information or analysis prepared by or
for FMI related to the Products in the FMI Territory or in the Territory. 
 Unless otherwise agreed between the Parties, after the Business Planning
Period, FMI will be responsible for Product sequencing, analysis and reporting services in accordance with the NGS Sequencing, Analysis and Reporting section below. 
  

	7.5.2.3	Customer Service 

 During the Business Planning Period, the JOC shall discuss and determine the reasonable
levels of customer service assistance in addressing sales and technical support issues, customer inquiries, defective product and service replacements to be provided by the Parties in each country in the Territory consistent with the Tactical Plans,
including in which local country languages and manner such customer service shall be provided. [...***...]. FMI shall provide Roche with [...***...] reports summarizing customer service assistance requests and inquiries (including a
breakdown by percentage of the general issues or complaints raised by customers for each country). 
  

	7.5.2.4	NGS Sequencing and Supply of Products and Service Activities 

 FMI shall use Commercially Reasonable Efforts to
provide Roche with the Service Activities (including NGS sequencing) necessary for Roche to implement the Tactical Plan and to meet the commercial need for Products sold by Roche in the Territory. Such Service Activities will meet the Quality
Standards and the Average Delivery Time Metric. In the event of a shortfall/limited capacity of Products or Service Activities needed by both FMI and Roche, such available capacity shall be distributed [...***...] with respect to the
then-current volume used by each Party. 
 For each Product, FMI will provide the JOC with the average time between receipt by FMI of a processable sample
meeting minimum tissue or other specimen requirements as set forth in FMI’s standard operating procedures (such sample, a “Qualified Sample”) and delivery by FMI of the results of testing for such Product (the “Average
Delivery Time Metric”). Such Average Delivery Time Metric will initially be [...***...] days for FoundationOne® and [...***...] days for FoundationOne® Heme. After the Business Planning Period and periodically
thereafter, the Average Delivery Time Metric may be revised by mutual written agreement of the Parties for differences in logistical, regulatory and other relevant factors. For a given Product, if FMI fails to achieve the Average Delivery Time
Metric for at least [...***...] of the Qualified Samples received from Roche in the Territory in [...***...] Calendar Quarter (a “Quarterly Average Delivery Time Failure”) and such failure exists [...***...], then
prior to the end of such [...***...], the JOC shall prepare a plan for improving such performance, which plan will be implemented in the [...***...]. The JOC will monitor the implementation and effectiveness of such plan with a goal of
achieving and maintaining compliance on a consistent basis for such Average Delivery Time Metric. If, following the implementation of a plan by the JOC to improve such performance, FMI is unable to improve performance, and there is a Quarterly
Average Delivery Time Failure for an additional [...***...] (a “Material Average Delivery Time Failure”), then this shall be considered a material breach of this Agreement by FMI. 

  
 ***Confidential Treatment
Requested*** 
 - 19 - 

 To the extent feasible and permitted by Applicable Law and regulatory guidelines of applicable Regulatory
Authorities, the initial sequencing will be conducted by FMI at FMI’s laboratory and facilities in the US. 
 FMI shall use Commercially Reasonable
Efforts to conduct or have conducted genomic sequencing locally for its Initial Products [...***...] after the Business Planning Period ends. FMI shall provide Roche with a written plan for the set-up of such [...***...] laboratories,
and shall consider Roche’s reasonable comments thereto. FMI shall update Roche on the progress of the establishment of [...***...] testing. Such [...***...] activities shall be provided in at least the same quality and standards as
the [...***...] testing in effect as of the Effective Date. To the extent that local Third Party costs are passed through to Roche, such costs shall be negotiated in good faith and at arms’ length with no benefits being given to FMI to
the advantage or FMI, its Affiliates, sublicensees or customers that cause a disadvantage or do not similarly benefit the Roche Group and its customers. 

FMI will be solely responsible, [...***...], for the establishment of such laboratories and all Regulatory Approvals necessary for the establishment and
operation of such laboratory(ies). Without limiting the foregoing, the Parties expressly acknowledge that FMI may choose to work with [...***...]. 

Unless otherwise expressly agreed by the Parties, data and final analysis, including medical curation and report generation will be conducted by FMI. Final
reports will be provided from FMI in English or in the local language, to the extent requested by Roche and agreed to by FMI. If FMI is unable to provide local sequencing on the timeline set forth in this Section 7.5.2.4, or if FMI is unable to
provide the NGS sequencing necessary to meet Roche’s commercial requirements for a period of [...***...], then the JOC shall meet to determine a plan for improving such performance and the JOC will monitor the implementation and
effectiveness of such plan, and FMI will provide reasonable support, with a goal of ensuring ongoing access to sufficient local sequencing, which may include Roche (itself or with or through a Third Party acceptable to FMI) performing such local
sequencing in a manner approved by FMI that meets FMI’s requirements for performing subsequent Service Activities. 
  

	 	7.6	Branding and Pricing 

 Product branding and corporate-level branding will be discussed and agreed to at
the JOC. The Parties will discuss at the JOC a [...***...] in the Territory (the “[...***...]”). Unless otherwise expressly agreed by the Parties, the list price for each Product in the Territory will be equal to or greater
than the [...***...] for such Product. 
  

	 	7.7	Product Promotional Materials 

 The Parties will collaborate and coordinate around development of any
promotional or educational materials to be utilized for Products in the Territory leveraging FMI’s existing materials. 
 After the Business Planning
Period, Roche shall be responsible for the preparation of all product promotional material for use with the Products by Roche in the Territory. All such Product promotional material shall be consistent with reasonable brand and Product guidelines
provided to Roche by FMI. Any Product promotional materials not consistent with such approved 

  
 ***Confidential Treatment
Requested*** 
 - 20 - 

 
guidelines shall be subject to review and approval by FMI. Notwithstanding the foregoing, any Product promotional guidelines and materials approved by FMI to be used by Roche will be subject to
final review and approval by Roche. 
  

	8.	Payment 

  

	 	8.1	General 

 Except as otherwise expressly provided for in this Agreement, each Party shall bear its own
costs for its activities under this Agreement, including without limitation, in connection with the Tactical Plans. 
  

	 	8.2	Costs of Services 

  

	8.2.1	FMI Service Costs 

 For each Product sold in the Territory, if FMI provides Service Activities for such Product,
at FMI’s laboratories and facilities in the United States, Roche will pay FMI [...***...] (collectively the “Global Cost”) [...***...] (collectively, the “Global Test Fixed Fee”). The Global Test
Fixed Fee for a Product will be calculated on a trailing [...***...] basis, and the Global Test Fixed Fee and calculation shall be provided to Roche within [...***...] after each [...***...] in the Agreement Term, based on the
Global Test Fixed Fee as determined from the preceding [...***...] and [...***...], subject to audit by Roche in accordance with Article 11. 

For each Product sold in the Territory if FMI provides initial sequencing in laboratories and facilities outside of the US, Roche will pay FMI
[...***...] (collectively, the “Local Cost”), plus [...***...] and [...***...] (collectively, the “US Cost”), [...***...] collectively, the “Local Test Fixed Fee”). The Local
Test Fixed Fee for a Product will be calculated on a trailing [...***...] basis, and the Local Test Fixed Fee and calculation shall be provided to Roche within [...***...] after each [...***...] in the Agreement Term, based on the
Local Test Fixed Fee as determined from the preceding [...***...] and fixed for such Calendar Quarter during the Agreement Term, subject to audit by Roche in accordance with Article 11. 

FMI will submit invoices on a [...***...] basis and Roche shall pay all Global Test Fixed Fees and Local Test Fixed Fees within [...***...]
following Roche’s receipt of an invoice for such fees. 
  

	8.2.2	Third Party Service Costs 

 FMI may have all or part of the Service Activities for Products in the Territory
performed by a Third Party subject to the terms and conditions for Third Parties set forth in Section 7.5.2.4 or as otherwise agreed to in writing by Roche. In the event that all or part of the Service Activities are performed by a Third Party,
Roche shall reimburse FMI [...***...] (the “Third Party Test Fee”), provided that (i) such Third Party Test Fees are negotiated in good faith and at arms’ length with no benefits being given to FMI to the advantage
or FMI, its Affiliates, sublicensees or customers that cause a disadvantage or do not similarly benefit the Roche Group and its customers, and (ii) [...***...]. 

Roche shall pay all Third Party Test Fees within [...***...] following Roche’s receipt of an invoice for such fees. 

  
 ***Confidential Treatment
Requested*** 
 - 21 - 

	 	8.3	Royalty Payments and Sales Milestones 

  

	8.3.1	Royalty Term 

 Royalties shall be payable by Roche on [...***...] of Initial Products on an aggregated
basis for all Initial Products commencing on the first commercial sale of an Initial Product and continuing for so long as Roche is selling any Initial Product (“Royalty Term”). 

 

	8.3.2	Royalty Rates 

 The following royalty rates shall apply to the respective tiers of aggregate [...***...]
of Initial Products in the Territory, on an incremental basis, as follows: [...***...]. 
 For example, if [...***...] of an Initial Product in
the Territory, for the first [...***...] in a given [...***...], is [...***...]. 
 If then in the second [...***...] of such
[...***...], the [...***...] of an Initial Product in the Territory is also [...***...] for such [...***...] thus far, [...***...]. 

For the purpose of calculating royalties of a Product, [...***...] and the royalty rates shall be subject to the following adjustments, as applicable:

  

	8.3.3	Third Party Payments 

 In the event that it is necessary for Roche to obtain a license from a Third Party for
Third Party intellectual property rights to use or sell the Product in the Territory following the Effective Date, Roche shall have the right to deduct [...***...] of any consideration actually paid to such Third Party for such license from
the royalties otherwise due and payable by Roche to FMI under this Section 8.3; provided, however, that in no case shall such reduction lower the amount of royalties otherwise payable under this Section 8.3 by more than [...***...].

  

	8.3.4	Sales Milestones 

 Roche will pay [...***...]. 

 

	8.3.5	Collaboration Products 

 The financial terms for any Product that is a Collaboration Product (including royalty
rates and sales milestone payments) and the diligence obligations for any such Product (including Commercial Launch obligations and Minimum Revenue Requirements) must be mutually agreed to in writing by the Parties, taking into consideration the
relative contributions made by each Party to the development of such Product, before such Product is included in this Agreement. Following FMI’s decision to Commercially Launch a Collaboration Product in the Territory, FMI shall provide written
notice to Roche, and if the Parties cannot agree to terms and conditions for the inclusion of such Collaboration Product as a Product in this Agreement within [...***...] (the “Initial Discussion Period”), then the Parties
shall each select an independent Third Party expert who is neutral, disinterested and impartial, and has significant relevant experience in the development and commercialization of pharmaceutical products (the “Expert”). Each
Expert will within [...***...] select a [...***...] Expert to form a panel of [...***...] Experts (“Panel”). The date on which such Panel is in place will be the “Arbitration Commencement
Date.” Each Party shall within [...***...] following the Arbitration Commencement Date prepare and deliver to both the Panel and the other Party its proposed financial terms (including royalty rates and sales

  
 ***Confidential Treatment
Requested*** 
 - 22 - 

 
milestone payments) and diligence obligations (including initial launch and minimum revenue requirements) (collectively, the “Arbitration Offer”) to resolve the disputed matter
for such Product and a memorandum (the “Supporting Memorandum”) in support thereof; provided that such Arbitration Offer shall be on the same or substantially similar terms as the last offer made by such Party to the other Party
during the Initial Discussion Period. The Panel will also be provided with a copy of this Agreement. Within [...***...] after receipt of the other Party’s Supporting Memorandum, each Party may submit to the Panel (with a copy to
the other Party) a rebuttal to the other Party’s Supporting Memorandum (a “Rebuttal”), which may include a revision, marked to show changes, of either Party’s proposed terms. Neither Party may have communications
(either written or oral) with the Panel other than for the sole purpose of engaging the Panel or as expressly permitted in this Section 8.3.5. Within [...***...] after the Panel’s receipt of each Party’s Rebuttal (or the
expiration of the period for the Parties to submit a Rebuttal, if earlier), the Panel will select, between the proposals provided by the Parties, the proposal that the Panel believes most accurately reflects an equitable result for FMI and Roche
(the “Selected Agreement”). The Panel shall not have the authority to modify a proposal initially submitted by a Party. The decision of the Panel shall be the sole, exclusive and binding remedy and the Selected Agreement
shall become a binding and enforceable agreement between the Parties. The Panel will have reasonable discretion to request additional information, hold a hearing, and extend the time frame for reaching a decision regarding the dispute at
issue. The Experts’ fees and expenses will be paid by the Party whose proposal is not selected by the Panel. Each Party will bear and pay its own expenses incurred in connection with any proceedings under this Section 8.3.5. 

 

	 	8.4	Disclosure of Payments 

 Each Party acknowledges that the other Party may be obligated to disclose this
financial arrangement, including all fees, payments and transfers of value, as may be advisable or required under Applicable Law. 
  

	9.	Accounting and Reporting 

  

	 	9.1	Timing of Payments 

 Roche shall calculate royalties [...***...] (each being the last day of an
“Accounting Period”) and shall pay royalties on Net Sales within [...***...] after the end of each Accounting Period in which such Net Sales occur. 
  

	 	9.2	Late Payment 

 Any payment under this Agreement that is not paid on or before the date such payment is
due shall bear interest, to the extent permitted by Applicable Law, at [...***...] points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such
payment is overdue. 
  

	 	9.3	Method of Payment 

 Royalties on Net Sales and all other amounts payable by Roche hereunder shall be paid
by Roche in US Dollars (the “Payment Currency”) to account(s) designated by FMI. 

  
 ***Confidential Treatment
Requested*** 
 - 23 - 

	 	9.4	Currency Conversion 

 When calculating the Sales of any royalty-bearing Product that occur in currencies
other than the Payment Currency, Roche shall convert the amount of such sales into [...***...] and then into the Payment Currency using [...***...]. 
  

	 	9.5	Reporting 

 With each payment Roche shall provide FMI in writing for the relevant [...***...] on an
aggregated basis for all Initial Products, and thereafter on a Product-by-Product basis, the following information: 
 [...***...]. 

 

	10.	Taxes 

 FMI shall pay all sales, turnover, income, revenue, value added, and other taxes levied on
account of any payments accruing or made to FMI under this Agreement. 
 If provision is made in law or regulation of any country for withholding of taxes
of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to FMI, then Roche shall promptly pay such tax, levy or charge for and on behalf of FMI to the proper governmental authority, and shall
promptly furnish FMI with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due FMI or be promptly reimbursed by FMI if no further payments are due to FMI. Each Party
agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or
deducted. 
  

	11.	Auditing 

  

	 	11.1	Right to Audit 

 Each Party shall keep, and shall require its Affiliates and sublicensees/Sublicensees to
keep, full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all amounts payable under this Agreement, such as with respect to royalties in the case of Roche and Cost of Services in
the case of FMI. Such books of accounts shall be kept at their principal place of business. At the expense of the auditing Party, the auditing Party shall have the right to engage an independent public accountant from a major, internationally
recognized accounting firm, to perform, on behalf of the auditing Party an audit of such books and records of the audited Party and its Affiliates, its licensees and sublicensees/Sublicensees, that are deemed necessary by the auditing Party’s
independent public accountant for the period or periods requested by auditing Party and the correctness of any financial report or payments made under this Agreement. 

Upon timely request and at least [...***...] prior written notice from the auditing Party, such audit shall be conducted in the countries specifically
requested by the auditing Party, during regular business hours in such a manner as to not unnecessarily interfere with the audited Party’s normal business activities, and shall be limited to results in the [...***...] prior to audit
notification. 

  
 ***Confidential Treatment
Requested*** 
 - 24 - 

 Such audit shall not be performed more frequently than [...***...] nor more frequently than
[...***...] with respect to records covering any specific period of time. 
 All information, data documents and abstracts herein referred to shall be
used only for the purpose of verifying statements, shall be treated as the audited Party’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than [...***...] after completion of an
audit hereof, if an audit has been requested; nor more than [...***...] from the end of the [...***...] to which each shall pertain; nor more than [...***...] after the date of termination of this Agreement. 

 

	 	11.2	Audit Reports 

 The auditors shall only state factual findings in the audit reports and shall not
interpret the Agreement. The auditors shall share all draft audit reports with the audited Party before the draft report is shared with the auditing Party and before the final document is issued. The final audit report, if any, shall be shared with
the audited Party at the same time it is shared with the auditing Party. 
  

	 	11.3	Over-or Underpayment 

 If the audit reveals an overpayment, such overpayment shall be credited against
future payments owed by Roche for the amount of the overpayment or, if no further payments are owed by Roche, then FMI shall reimburse Roche for the amount of the overpayment within [...***...]. If the audit reveals an underpayment, Roche
shall make up such underpayment with the next payment or, if no further payments are owed by Roche, Roche shall reimburse FMI for the amount of the underpayment within [...***...]. The audited Party shall pay for the audit costs if the
underpayment/over receipt of the audited Party exceeds [...***...] of the aggregate amount of payments owed with regard to the statements subject of the audit. Section 9.2 shall apply to this Section 11.3. 

 

	 	11.4	Duration of Audit Rights 

 The failure of FMI to request verification of any royalty calculation within
the period during which corresponding records must be maintained under this Article 11 will be deemed to be acceptance of the royalty payments and reports. 
  

	12.	Intellectual Property 

  

	 	12.1	Ownership of Inventions 

 Ownership of Inventions shall be as set forth in the Collaboration Agreement.

  

	 	12.2	Trademarks and Labeling 

 The Parties shall attempt to use a uniform global trademark and logo for the
Product; provided, that each Party may use its own trademarks and housemarks as it selects to promote the sale of the Product in the FMI Territory, with respect to FMI, and the Territory, with respect to Roche (collectively, excluding the
housemarks, the “Product Trademarks”). The Parties shall agree on at least [...***...] Product Trademarks for each Product, with [...***...] of the trademarks being the global trademark and the other(s) being trademarks
to be held in reserve in case the global trademark cannot be used in [...***...] or more countries. The placement and size of a Party’s housemarks relative to Product Trademarks shall be approved by the JOC. Excluding the Roche
housemarks, FMI shall own any global Product Trademarks used on or in connection with Products in the Territory, and shall, at its sole cost, be responsible for procurement, maintenance, enforcement and defense of such global Product Trademarks.

  
 ***Confidential Treatment
Requested*** 
 - 25 - 

 Roche shall own its trademarks, including the Roche trademark and hexagon, and may use the Roche trademarks in
connection with the Product as set forth in this Section. FMI shall not file any identical registrations or other filings in respect of any such housemarks owned by Roche. FMI shall own its housemark and any trademark it selects to promote the sale
of the Product in the FMI Territory. Roche shall not file any identical registrations or other filings in respect of any such trademarks and housemarks owned by FMI. 

Each Party shall maintain all registrations of such Product Trademarks owned by it and the other Party shall not file any registrations or other filings in
respect of any of such Product Trademark owned by the Product Trademark owning Party without the Product Trademark owning Party’s prior written consent. FMI shall use Commercially Reasonable Efforts to obtain and maintain Product Trademarks and
to take reasonable measures to enforce oppositions and litigations in relation to the Product Trademarks. 
 Each Party shall use the Product Trademarks in
accordance with sound trademark and trade name usage principles and in accordance with all Applicable Law as reasonably necessary to maintain the validity and enforceability of the Product Trademarks. Each Party recognizes that the trademarks owned
by the other Party represents a valuable asset of such other Party, and that substantial recognition and goodwill are associated with such name, logo and trademarks. Each Party hereby agrees that, without prior written authorization of the other
Party or as specifically permitted in this Agreement, it shall not use such other Party’s trademarks for any purpose. 
 Each Party shall have the
right to police its own trademarks and enforce its own trademarks. Each Party shall have the right to audit the other Party, its Affiliates, sublicensees/Sublicensees and contractors to ensure the quality of the Products to which the trademark is
associated. 
 In the event either Party becomes aware of any infringement of any Product Trademark by a Third Party, such Party shall promptly notify the
other Party and the Parties shall consult with each other and jointly determine the best way to prevent such infringement. 
  

	 	12.3	Prosecution of Patent Rights 

 Patent Rights shall be prosecuted as set forth in the Collaboration
Agreement. 
  

	 	12.4	Patent Coordination Team 

 The JPT as defined in the Collaboration Agreement will address all issues
related to Patent Rights. 
  

	 	12.5	Infringement 

 Infringement shall be addressed as set forth in the Collaboration Agreement. However, if
Roche is commercializing a Product in a particular country in the Territory, then Roche shall have the first right to enforce Patent Rights in such country in the Territory. 
  

	 	12.6	Defense 

 If an action for infringement is commenced against either Party, its licensees or its
sublicensees/Sublicensees, the provisions of the Collaboration Agreement shall apply. 

  
 - 26 - 

	 	12.7	Common Interest Disclosures 

 With regard to any information or opinions disclosed pursuant to this
Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property
rights may affect the conduct of the activities under this Agreement. Accordingly, the provisions of the Collaboration Agreement shall apply in this regard. 
  

	13.	Representations and Warranties 

  

	 	13.1	FMI Representations and Warranties 

  

	13.1.1	Safety Data 

 FMI warrants and represents that it has, and covenants that it will, continue to disclose to Roche
as soon as possible during the Term (i) the results of all preclinical testing and human clinical testing Controlled by FMI relating to any Product and (ii) all information in its Control concerning side effects, injury, toxicity or
sensitivity reaction and incidents or severity thereof with respect to any Product. 
  

	13.1.2	Third Party Patent Rights 

 FMI warrants and represents that, as of the Effective Date, it has no knowledge of
the existence of any patent or patent application owned by or licensed to any Third Party that could prevent Roche from making, having made, using, offering for sale, selling or importing Product in the Territory. 

 

	13.1.3	Ownership of Patent Rights 

 With respect to each Product, FMI shall provide Roche with a list of all FMI Patent
Rights in the Territory that could potentially be asserted with respect to the use, sale, offer for sale, import or export of such Product in the Territory. FMI shall then warrant and represent that it is the exclusive owner of all right, title and
interest in, or is the exclusive licensee of, such FMI Patent Rights. 
  

	13.1.4	Ownership of Trademarks 

 FMI warrants and represents that it is the exclusive owner of all right, title and
interest in, or is the exclusive licensee of the trademarks for the Initial Products in the Territory. 
  

	13.1.5	Inventors 

 FMI warrants and represents that for the inventors of the inventions disclosed and/or claimed in the
disclosed FMI Patent Rights, FMI has obtained the assignment of, or a license under, all interest and all rights or licenses thereunder with respect to the FMI Patent Rights necessary to grant the licenses granted hereunder. All of FMI’s
employees, officers and consultants have executed agreements requiring assignment to FMI of all Inventions made by such individuals during the course of and as a result of their association with FMI. 

 

	13.1.6	Grants 

 FMI warrants and represents that to the best of FMI’s knowledge and belief, FMI has the lawful
right to grant Roche and its Affiliates the rights and licenses described in this Agreement. 

  
 - 27 - 

	13.1.7	Valid Claims 

 As of the Effective Date, FMI warrants and represents that it is not in possession of any
information that would, in its reasonable opinion, render invalid and/or unenforceable any claims in any issued patent licensed pursuant to this Agreement. FMI has no knowledge of any inventorship disputes concerning any FMI Patent Rights. 

 

	13.1.8	Ownership and Validity of Know-How 

 As of the Effective Date, FMI warrants and represents that FMI’s
Know-How relating to Products and Service Activities is legitimately in the possession of FMI and has not been misappropriated from any Third Party, and FMI has taken reasonable measures to protect the confidentiality of its Know-How. 

 

	 	13.2	Mutual Representations of the Parties 

  

	13.2.1	Authorization 

 As of the Effective Date, each Party warrants and represents to the other Party that the
execution, delivery and performance of this Agreement by such Party and all instruments and documents to be delivered by such Party hereunder: (i) are within the corporate power of such Party; (ii) have been duly authorized by all
necessary or proper corporate action; (iii) are not in contravention of any provision of the certificate of formation or limited liability company agreement of such Party; (iv) to the knowledge of such Party, will not violate any law or
regulation or any order or decree of any court of governmental instrumentality; (v) will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which such Party is a party or by which such
Party or any of its property is bound, which violation would have a material adverse effect on the financial condition of such Party or on the ability of such Party to perform its obligations hereunder; and (vi) do not require any filing or
registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than approvals required under the HSR Act, Regulatory Approvals required for the
sale of Products and filings with Regulatory Authorities required in connection with Products). 
  

	13.2.2	No Claims 

 As of the Effective Date, each Party warrants and represents to the other Party that there are no
claims or investigations (other than with respect to the Parties’ HSR filings), pending or threatened against such Party or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters
contemplated under this Agreement or that would materially adversely affect such Party’s ability to perform its obligations hereunder. 
  

	13.2.3	No Conflict 

 Each Party warrants and represents that neither it nor any of its Affiliates is or will be under
any obligation to any person, contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of such Party’s obligations hereunder. 

  
 - 28 - 

	13.2.4	Activities 

 Each Party will perform all activities under this Agreement (i) in a professional manner,
(ii) in conformance with the level or care and skill ordinarily exercised by other professional institutions in similar circumstances, and (iii) in compliance with Applicable Law. 

 

	14.	Indemnification 

  

	 	14.1	Indemnification by Roche 

 Roche shall indemnify, hold harmless and defend FMI and its Affiliates, and
their respective directors, officers, employees, independent contractors, and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and
amounts paid in settlement) and any amounts FMI becomes legally obligated to pay because of any claim or claims brought by a Third Party against it to the extent that such claim or claims arise out of any member of the Roche Group’s action or
inactions in connection with activities under this Agreement, except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of FMI. 

 

	 	14.2	Indemnification by FMI 

 FMI shall indemnify, hold harmless and defend Roche and its Affiliates, and
their respective directors, officers, employees, independent contractors and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and
amounts paid in settlement) and any amounts Roche becomes legally obligated to pay because of any claim or claims brought by a Third Party against it to the extent that such claim or claims arise out of FMI’s and its Affiliates’ actions or
inactions in connection with activities under this Agreement, except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of Roche. 

 

	 	14.3	Procedure 

 In the event of a claim by a Third Party against a Party entitled to indemnification under
this Agreement (“Indemnified Party”), the Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and solely manage and
control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its
choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such
settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 
  

	15.	Liability 

  

	 	15.1	Disclaimer 

 EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY PROVIDE ANY WARRANTIES,
WHETHER WRITTEN OR ORAL, EXPRESS OR IMPLIED. FMI AND ROCHE DISCLAIM ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION 

  
 - 29 - 

 
EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL
VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. EXCEPT IN THE CASE OF A BREACH OF ARTICLE 16, AND WITHOUT LIMITING THE PARTIES’ OBLIGATIONS UNDER ARTICLE 14, IN NO EVENT SHALL EITHER
FMI OR ROCHE BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY. 
  

	16.	Obligation Not to Disclose Confidential Information 

  

	 	16.1	Non-Use and Non-Disclosure 

 During the Agreement Term and for [...***...] years thereafter, a
Receiving Party shall (i) treat Confidential Information provided by Disclosing Party as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third
Parties, without the Disclosing Party’s prior written consent, and (iii) not use such Confidential Information other than for fulfilling its obligations under this Agreement. If any Confidential Information is required to be disclosed by
the Receiving Party or its Affiliates to comply with a court or administrative order, the Receiving Party or its Affiliates will provide prompt notice to the Disclosing Party to enable the Disclosing Party to resist such disclosure. 

 

	 	16.2	Permitted Disclosure 

 Notwithstanding the obligation of non-use and non-disclosure set forth in
Section 16.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations. 

 

	 	16.3	Press Releases 

 Each Party shall provide the other with a copy of any draft press release related to the
activities contemplated by this Agreement at least [...***...] prior to its intended publication for such other Party’s review. The reviewing Party may provide the releasing Party with suggested modification to the draft press release.
The releasing Party shall consider, and shall not unreasonably disregard, the reviewing Party’s suggestions in issuing its press release. 
  

	 	16.4	Publications 

 During the Agreement Term, the following restrictions shall apply with respect to
disclosure by any Party of Confidential Information relating to the Product in any publication or presentation: 
  

	a)	Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and published in accordance with their internal guidelines. The Parties shall have the right to jointly publish all
studies, clinical trials and results conducted or generated in accordance with this Agreement to the extent both Parties have jointly participated in or collaborated in such clinical study or trial. To the extent any study or clinical trial is
conducted solely by Roche with no participation by FMI, Roche, in accordance with its internal policies and procedures, shall have the right to publish all such studies, clinical trials and results thereof on the clinical trial registries that are
maintained by or on behalf of Roche, and FMI shall not publish any such studies, clinical trials or results thereof on its clinical trial registry, provided however, the Roche’s clinical trial registry can be accessed via a link from FMI’s
clinical trial registry. 

  
 ***Confidential Treatment
Requested*** 
 - 30 - 

	b)	A Party (“Publishing Party”) shall provide the other Party with a copy of any proposed publication or presentation at least [...***...] prior to submission for publication so as to provide such
other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this
Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies (“Publishing Notice”) the Publishing Party in writing, within [...***...] after receipt of the copy
of the proposed publication or presentation, that such publication or presentation in its reasonable judgment (i) contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other Party
reasonably desires to obtain patent protection or (ii) could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall
prevent such publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such
invention, and in no event less than [...***...] from the date of the Publishing Notice. 

  

	 	16.5	Commercial Considerations 

 Nothing in this Agreement shall prevent a Party or its Affiliates from
disclosing Confidential Information of the other Party to (i) governmental agencies to the extent required or desirable to secure government approval for the manufacture or sale of Product in the Territory, and (ii) Third Parties acting on
behalf of Roche, to the extent reasonably necessary to conduct the activities contemplated by this Agreement, provided such Third Parties are bound by confidentiality and non-use obligations with respect to such information that are no less
stringent than those included in this Agreement. The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information is required to be disclosed by the Receiving Party to comply with
Applicable Law, to defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, takes reasonable
and lawful actions to minimize the degree of such disclosure 
  

	17.	Term and Termination 

  

	 	17.1	Commencement and Term 

 This Agreement shall commence upon the Effective Date and continue for the
Agreement Term. 
  

	 	17.2	Termination 

  

	17.2.1	Automatic Termination 

 This Agreement shall terminate automatically, without any notice or other action by any
Party, upon the first to occur of (i) termination of the Transaction Agreement in accordance with its terms and (ii) the mutual written consent of the Parties. 
  

	17.2.2	Termination for Breach 

 A Party (“Non-Breaching Party”) shall have the right to
terminate this Agreement in its entirety or on a country-by-country or Product-by-Product basis in the event the other Party (“Breaching 

  
 ***Confidential Treatment
Requested*** 
 - 31 - 

 
Party”) is in breach of any of its material obligations under this Agreement. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify
the breach and, if applicable, the affected countries in which, and the affected Products with respect to which, the Non-Breaching Party intends to have this Agreement terminate. The Breaching Party shall have a period of [...***...] after
such written notice is provided (“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a dispute as to whether such breach occurred or has been cured, it will so notify the Non-Breaching Party, and the
expiration of the Peremptory Notice Period shall be tolled until the Parties agree or the arbitrators have determined in accordance with Section 19.3 that this Agreement was materially breached. It is understood and acknowledged that, during
the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations under this Agreement. Upon such agreement or determination of
material breach or failure to cure, the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching
Party’s request for termination, this Agreement shall terminate in accordance with the written notice provided by the Non-Breaching Party and such termination shall be effective as of the expiration of the Peremptory Notice Period. For clarity,
Roche may terminate this Agreement under this Section 17.2.2 if there is a material diminution in the Quality Standards, except as permitted under Section 2.3, or if FMI is unwilling or unable to fulfill its obligations under
Section 7.5.2, and FMI may terminate this Agreement under this Section 17.2.2 if Roche is unwilling or unable to fulfill its obligations under Section 7.5.1. Notwithstanding the foregoing, Roche may terminate this Agreement under this
Section 17.2.2 if a Material Average Delivery Time Failure or Material Performance Standards Failure occurs by providing written notice to FMI within [...***...] of such Material Average Delivery Time Failure or Material Performance
Standards Failure, and no cure period as provided under this Section 17.2.2 shall be applicable for such termination. 
  

	17.2.3	Insolvency 

 A Party shall have the right to terminate this Agreement, if the other Party incurs an Insolvency
Event; provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not
dismissed within [...***...] after the filing thereof. 
  

	17.2.4	Termination by Roche without a Cause 

 Roche shall have the right to terminate this Agreement at any time after
the Initial Term on a Product-by-Product and/or country-by-country basis upon [...***...] prior written notice. The effective date of termination under this Section 17.2.4 shall be the date [...***...] after Roche provides such written
notice to FMI. 
  

	 	17.3	Consequences of Termination and Expiration 

  

	17.3.1	Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term. 

 Upon
any termination under Section 17.2.1, FMI for breach by Roche in accordance with Section 17.2.2, termination by Roche under Section 17.2.4, or upon expiration of the Agreement Term, the following shall apply: 

 

	a)	The rights and licenses granted by FMI to Roche under this Agreement shall terminate in their entirety or on a country-by-country basis, as applicable, on the effective date of termination. 

  
 ***Confidential Treatment
Requested*** 
 - 32 - 

	b)	After the effective date of termination Roche shall, to the extent Roche has the right to do so, assign and transfer to FMI all regulatory filings and Regulatory Approvals, all final pre-clinical and clinical study
reports and clinical study protocols, and all data, including clinical data, in Roche’s possession and control related to Product(s) in the country necessary for FMI to continue to commercialize the Product(s). All data shall be transferred in
the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to
FMI. 

  

	c)	Roche shall assign all clinical trial agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment
of any such agreement. 

  

	d)	FMI shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the sale of
Product(s) in the country, (ii) Third Parties acting on behalf of FMI, its Affiliates or licensees, to the extent reasonably necessary for the sale of Product(s) in the country, and (iii) Third Parties to the extent reasonably necessary to
market Product(s) in the country. 

  

	17.3.2	Termination by Roche for Breach by FMI or FMI Insolvency 

 Upon a material breach of a material obligation under
this Agreement by FMI pursuant to Section 17.2.1 or FMI’s Insolvency pursuant to Section 17.2.2, at Roche’s option, (i) Roche may seek damages via arbitration under Section 19.3 or (ii) as Roche’s exclusive remedy
(other than for breach of confidentiality under Section 16) FMI shall pay to Roche either a one-time payment reflecting the value of the terminated Product(s) or a royalty on sales of such terminated Product(s) based on the royalty that Roche
would have paid to FMI had the Agreement not terminated, the amount of which will be agreed to by the Parties negotiating in good faith. If the Parties cannot agree on the amount in clause (ii) above, then the determination of such amount shall
be referred to a Panel in a manner analogous to that found in Section 8.3.5. 
 Upon any termination by Roche for breach by FMI in accordance with
Section 17.2.1 or for FMI’s insolvency in accordance with Section 17.2.2, the following shall apply: 
  

	 	a)	the rights and licenses granted by FMI to Roche under this Agreement shall terminate in their entirety or on a country-by-country and Product-by-Product basis, as applicable, on the effective date of termination.

  

	 	b)	After the effective date of termination Roche shall, to the extent Roche has the right to do so, assign and transfer to FMI all regulatory filings and Regulatory Approvals, all final pre-clinical and clinical study
reports and clinical study protocols, and all data, including clinical data, in Roche’s possession and control related to Product(s) in the country necessary for FMI to continue to commercialize the Product(s). All data shall be transferred in
the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to
FMI. 

  
 - 33 - 

	 	c)	Roche shall assign all clinical trial agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment
of any such agreement. 

  

	 	d)	FMI shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the sale of
Product(s) in the country, (ii) Third Parties acting on behalf of FMI, its Affiliates or licensees, to the extent reasonably necessary for the sale of Product(s) in the country, and (iii) Third Parties to the extent reasonably necessary to
market Product(s) in the country. 

  

	17.3.3	Direct License 

 Upon termination of this Agreement pursuant to Sections 17.2.2 or 17.2.3, with respect to any
existing, permitted sublicense granted by Roche under Section 2.1.2(ii) of this Agreement (and any further sublicenses thereunder) upon the written request of Roche, (i) if the sublicense was consented to by FMI or is to Chugai, then the
sublicense shall survive termination provided such Sublicensee (a) is not then in breach of its sublicense agreement and (b) such Sublicensee agrees to be bound to FMI under the terms and conditions of such sublicense agreement, and
(ii) if the sublicense was not consented to by FMI, then FMI shall negotiate in good faith with the applicable Sublicensee the terms under which such sublicense shall survive such termination, provided that (a) such Sublicensee is not then
in breach of its sublicense agreement (and, in the case of termination by FMI for breach by Roche, that such Sublicensee and any further sublicensees did not cause the breach that gave rise to the termination by FMI); and (b) such Sublicensee
agrees to be bound to FMI under the terms and conditions of such sublicense agreement. 
  

	17.3.4	Other Obligations 

  

	17.3.4.1	Obligations Related to Ongoing Activities 

 Upon the effective date of termination of this Agreement, each Party
(a) shall have the right to cancel all ongoing obligations as of the effective date of termination and (b) shall complete all non-cancellable obligations at its own expense. 

From the date of notice of termination until the effective date of termination, Roche and FMI shall each continue their activities, including preparatory
activities, ongoing as of the date of notice of termination. However, neither Party shall be obliged to initiate any new activities not ongoing at the date of notice of termination. 

After the effective date of termination, neither Party shall have an obligation to perform and/or complete any activities or to make any payments for
performing or completing any activities after such effective date of termination under this Agreement, except as expressly stated herein. 

  
 - 34 - 

 Notwithstanding the foregoing, (a) in case of termination by FMI under Section 17.2.2 or 17.2.3 or by
Roche under Section 17.2.4, upon the request of FMI, Roche shall complete any clinical studies related to the Product(s) that are being conducted by Roche for the Product(s) and are ongoing as of the effective date of termination, and (b) in
case of termination by Roche under Section 17.2.2 or 17.2.3, upon the request of Roche, FMI shall complete any clinical studies related to the Product(s) that are being conducted by FMI for the Product(s) and are ongoing as of the effective
date of termination; provided, however, that 
  

	(i)	both FMI and Roche in their reasonable judgment have concluded that completing any such clinical studies does not present an unreasonable risk to patient safety; 

 

	(ii)	neither Party shall have an obligation to recruit or enroll any additional patients after the effective date of termination; and 

  

	(iii)	FMI agrees to reimburse Roche for all of its development costs that incurred by or on behalf of Roche after the effective date of termination in completing such clinical studies as per subsection (a) above and
Roche agrees to reimburse FMI for all of its development costs that incurred by or on behalf of Roche after the effective date of termination in completing such clinical studies as per subsection (b) above. 

 

	17.3.4.2	Ancillary Agreements 

 Unless otherwise agreed by the Parties, the termination of this Agreement shall cause the
automatic termination of all ancillary agreements related hereto, including but not limited to supply or quality agreements, if any, but shall not cause the termination of the Related Agreements unless specifically stated in such Related Agreement.

  

	17.3.4.3	Limitations on Grant-Backs; Transfer Expenses 

 For purposes of clarity, irrespective of anything to the
contrary in this Agreement: 
  

	a)	All transfers and licenses from Roche to FMI or other obligations of Roche under Section 17.3 are solely with respect to Product(s). 

 

	b)	In connection with clinical trials, Roche may have collected human samples and related clinical information for additional limited research and development programs (“Samples”). Legal and contractual
restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. FMI acknowledges and accepts that notwithstanding anything herein, Roche shall not be obliged to transfer any such Samples to FMI.

  

	c)	Nothing in this Agreement shall be construed as granting FMI any license under the intellectual property of Roche or its Affiliates in existence as of the Effective Date. 

 

	d)	 Except with respect to termination by FMI for Roche’s breach pursuant to Section 17.2.2, FMI shall promptly reimburse Roche for all
reasonable out-of-pocket costs and expenses (including FTE charges based on Roche’s standard FTE rates) incurred by or on behalf of Roche for transfer of documents and materials as requested by FMI under this Article 17; however transfer
activities corresponding to the return of material remains, data, reports, 

  
 - 35 - 

	 	
records, documents, Regulatory Filings and Regulatory Approvals originally provided by FMI to Roche (“FMI-Originated Transfer Activities”) shall be at no expense to FMI. If FMI
desires Roche Transfer Activities other than FMI-Originated Transfer Activities, FMI shall make a payment to Roche of [...***...] (“Minimum Transfer Payment”). The Minimum Transfer Payment shall be non-refundable, but shall be
fully creditable against FMI’s reimbursement for the Roche Transfer Activities. Roche shall be under no obligation to provide Roche Transfer Activities (beyond the FMI-Originated Transfer Activities) prior to receipt of the Minimum Transfer
Payment. 

  

	17.3.5	Royalty and Payment Obligations 

 Termination of this Agreement by a Party, for any reason, shall not release
Roche from any obligation to pay royalties or make any payments to FMI that are payable for sales of Product prior to the effective date of termination. Termination of this Agreement by a Party, for any reason, will release Roche from any obligation
to pay royalties or make any payments to FMI that would otherwise become payable on or after the effective date of termination. 
  

	 	17.4	Survival 

 Article 1 (Definitions, to the extent necessary to interpret the Agreement), Article 10
(Taxes) Article 11 (Auditing), Article 12 (Intellectual Property, to the extent relating to intellectual property existing at the time of termination), Article 14 (Indemnification, to the extent relating to claims existing at the time or
termination), Article 16 (Obligation Not to Disclose Confidential Information), Section 17.3 (Consequences of Termination and Expiration, to the extent applicable), Section 17.4 (Survival), Section 19.1 (Governing Law) and
Section 19.3 (Arbitration) shall survive any expiration or termination of this Agreement for any reason. Notwithstanding the foregoing, any provision of this Agreement that is intended by its very nature to survive expiration or termination of
this Agreement shall also survive. 
  

	18.	Bankruptcy 

 All licenses (and to the extent applicable rights) granted under or pursuant to this
Agreement by FMI to Roche are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under
Section 101(60) of the Bankruptcy Code. Unless Roche elects to terminate this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and
elections under the Bankruptcy Code, subject to the continued performance of its obligations under this Agreement. 
  

	19.	Miscellaneous 

  

	 	19.1	Governing Law 

 This Agreement shall be governed by and construed in accordance with the laws of New
York, US, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

 

	 	19.2	Disputes 

 Unless otherwise set forth in this Agreement, in the event of any dispute in connection with
this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows:

  

			
	For FMI:	  	CEO
	For Roche:	  	Head of Roche Partnering or the CEO of the Roche Group in the case of Minimum Revenue Requirements.

  
 ***Confidential Treatment
Requested*** 
 - 36 - 

	 	19.3	Arbitration 

 Should the Parties fail to agree within [...***...] after such dispute has first
arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association (“AAA”) as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. The place
of arbitration shall be New York, New York, US. The language to be used shall be English. 
  

	19.3.1	Arbitrators 

 Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the
request for arbitration within [...***...] of being requested to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within [...***...] of being requested to do so, the other
Party shall request the AAA to make such appointment. 
 The arbitrators nominated by the Parties shall, within [...***...] from the appointment of
the arbitrator nominated in the answer to the request for arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the Arbitral Tribunal. Should such procedure not result in an
appointment within the [...***...] time limit, either Party shall be free to request the AAA to appoint the third arbitrator. 
 Where there is more
than one claimant and/or more than one respondent, the multiple claimants or respondents shall jointly appoint one arbitrator. 
 Any Party-appointed
arbitrator or the third arbitrator resigns or ceases to be able to act, a replacement shall be appointed in accordance with the arrangements provided for in this clause. 

The language of the arbitration shall be English. Documents submitted in the arbitration (the originals of which are not in English) shall be submitted
together with an English translation. 
  

	19.3.2	Decisions; Timing of Decisions 

 The arbitrators shall render a written opinion setting forth findings of fact
and conclusions of law with the reason therefor stated, within no later than [...***...] from the date on which the arbitrators were appointed to the dispute. A transcript of the evidence adduced at the arbitration hearing shall be made and,
upon request, shall be made available to each Party. 
 The time periods set forth in the AAA Arbitration Rules shall be followed; provided however that the
arbitrators may modify such time periods as reasonably necessary to render a written opinion in accordance with this Section 19.3.2. 
 The Arbitrator
is empowered to award any remedy allowed by law, including money damages, prejudgment interest and attorneys’ fees, and to grant final, complete, interim, or interlocutory relief, including injunctive relief. 

  
 ***Confidential Treatment
Requested*** 
 - 37 - 

 This arbitration agreement does not preclude either Party seeking conservatory or interim measures from any court
of competent jurisdiction including, without limitation, the courts having jurisdiction by reason of either Party’s domicile. Conservatory or interim measures sought by either Party in any one or more jurisdictions shall not preclude the
Arbitral Tribunal granting conservatory or interim measures. Conservatory or interim measures sought by either Party before the Arbitral Tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim measures. 

In the event that any issue shall arise which is not clearly provided for in this Section 19.3, the matter shall be resolved in accordance with the AAA
Arbitration Rules. 
 Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard
each Party’s Confidential Information. Except as required by law, neither Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written
consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise
required by Applicable Law. 
 Notwithstanding anything to the contrary in this Agreement, any and all issues regarding the scope, construction, validity
and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent Rights in question. 

Notwithstanding anything to the contrary in this Agreement, any and all issues regarding a breach or alleged breach of a Party’s obligations under
Article 16 (Obligation Not to Disclose Confidential Information) shall be determined in a court of competent jurisdiction under the laws of New York, with express exclusion of its conflict of laws principles. 

 

	 	19.4	Assignment 

 Neither Party shall have the right to assign the present Agreement or any part thereof to
any Third Party other than Affiliates without the prior written approval of the other Party. 
  

	 	19.5	Compliance with Applicable Law 

 Each Party shall comply with Applicable Law in conducting activities and
carrying out responsibilities under this Agreement[, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, (collectively hereinafter the “FCPA”) and anti-bribery laws in the countries in the Territory where Roche has
its principal place of business and where it conducts activities under this Agreement. 
  

	 	19.6	Debarment 

 Each Party represents and warrants that it has never been debarred under 21 U.S.C.
§335a, disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or
debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a Party receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the
above-referenced statutes, such Party shall [...***...]. 

  
 ***Confidential Treatment
Requested*** 
 - 38 - 

 Each Party agrees that, to the best of its knowledge, none of its employees or agents conducting activities on
its behalf under the Agreement is currently or will be during the term of this Agreement, debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42
U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a
Party learns that any such employee or agent becomes so debarred, sanctioned, suspended, excluded or declared ineligible or is the subject of proceedings that may result in such debarment, sanction, suspension, exclusion or ineligibility, it will
promptly so notify the other Party and will no longer allow such employee or agent to conduct activities under this Agreement. 
  

	 	19.7	Independent Contractor 

 No employee or representative of either Party shall have any authority to bind
or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and not-
withstanding any other provision of this Agreement to the contrary, FMI legal relationship to Roche under this Agreement shall be that of independent contractor. 
  

	 	19.8	Unenforceable Provisions and Severability 

 If any of the provisions of this Agreement are held to be
void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement
will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 

 

	 	19.9	Waiver 

 The failure by either Party to require strict performance and/or observance of any obligation,
term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any
obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
  

	 	19.10	Appendices 

 All Appendices to this Agreement shall form an integral part to this Agreement. 

 

	 	19.11	Entire Understanding 

 This Agreement contains the entire understanding between the Parties hereto with
respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral. 

  
 - 39 - 

	 	19.12	Amendments 

 No amendments of the terms and conditions of this Agreement shall be binding upon either
Party hereto unless in writing and signed by both Parties. 
  

	 	19.13	Invoices 

 All invoices that are required or permitted hereunder shall be in writing and sent by FMI to
Roche at the following address or other address as Roche may later provide: 
 F. Hoffmann-La Roche Ltd 

Kreditorenbuchhaltung 
 4070
Basel 
 Switzerland 
  

	 	19.14	Notice 

 All notices that are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: 
  

			
	if to FMI, to:		 Foundation Medicine, Inc.
 150 Second Street

Cambridge, MA 02141
 Attn: Legal Department

Facsimile No.: (617) 418-2201

		
	if to Roche, to:		 F. Hoffmann-La Roche Ltd
 Grenzacherstrasse
124
 4070 Basel
 Switzerland

Attn: Legal Department
 Facsimile No.: +41 61 688 13
96

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. The effective date of any notice shall be: (a) the date of the addressee’s receipt, if delivered personally, by courier, or by registered or certified mail; or (b) the date of receipt if received by 5:00 p.m.
local time on a business day or, if not, the first business day after receipt, if sent by facsimile. 
  

	 	19.15	Subcontractors 

 Subject to Section 2.1.2, either Party may perform any of its obligations under this
Agreement, including under the Tactical Plans and Post Approval Plans, through one or more subcontractors or consultants; provided that (i) such Party remains responsible for the work allocated to, and payment to, such subcontractors and
consultants to the same extent it would if it had done such work itself, and such Party shall be liable for any act or omission of such subcontractor and consultant that is a breach of any of such Party’s obligations under this Agreement as
though the same were a breach by such Party, and the other Party shall have the right to proceed directly 

  
 - 40 - 

 
against such Party without any obligation to first proceed against such subcontractor or consultant; (ii) the subcontractor or consultant undertakes in writing commercially reasonable
obligations of confidentiality and non-use regarding Confidential Information, that are substantially the same as those undertaken by the Parties with respect to Confidential Information pursuant to Article 16 hereof; and (iii) the
subcontractor or consultant undertakes in writing to assign or exclusively license back (with the right to sublicense) all intellectual property with respect to Product developed in the course of performing any such work under the Tactical Plans and
Post Approval Plans to the subcontracting Party. Notwithstanding the above, if a the work to be done by the subcontractor or consultant is material to the performance of a Party under this Agreement, then the Party engaging such subcontractor or
consultant shall seek the consent of the other Party, which consent shall not be unreasonably withheld. 
  

	 	19.16	Force Majeure 

 Both Parties shall be excused from the performance of their obligations under this
Agreement to the extent that such performance is prevented or delayed by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting
force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure means conditions beyond the reasonable control of the Parties, including an act of God, war, civil
commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, and failure of plant or
machinery (provided that such failure could not have been prevented by the exercise of skill, diligence, and prudence that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of undertaking
under the same or similar circumstances). Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party. 

[Signature Page Follows] 

  
 - 41 - 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

			
	Foundation Medicine, Inc.
	
	 /s/ Stefan J. Kafka

		
	Name:		Steven J. Kafka
		
	Title:		Chief Operating Officer

  

									
	F. Hoffmann-La Roche Ltd						
			
	 /s/ Jason Coloma
				 /s/ Stefan Arnold

					
	Name:		Jason Coloma 				Name:		Stefan Arnold
					
	Title:		Global Head of Venture & Innovation, Roche Partnering				Title:		Head Legal Pharma

  

 Appendix 1.19 

Existing Third Party Rights 

[...***...]. 

  
 ***Confidential Treatment
Requested*** 

 Appendix 2.3 

Product Specifications 
 [...***...].

  
 ***Confidential Treatment
Requested***

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]